The role of the hormone relaxin in human reproduction by MacLennan, Alastair Harvey
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
THE ROLE OF THE HORMONE RELAXIN 
IN HUMAN REPRODUCTION
A THESIS SUBMITTED BY
ALASTAIR HARVEY MACLENNAN 
M.B.Ch.B., F.R.C.O.G., F.R.A.C.O.G.
for the degree of 
Doctor of Medicine 
at the
University of Glasgow, Scotland.
The research described in this thesis was conducted at 
The Department of Obstetrics and Gynaecology,
The University of Adelaide, South Australia.
Thesis submitted March 1985
ProQuest Number: 10907124
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10907124
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
2.
TABLE OF CONTENTS
Page
Title Page i  m
Table of Contents 2.
List of Tables 9.
List of Illustrations 13.
Acknowledgements 17.
Summary of Thesis 20.
List of Publications from this Thesis 24.
Chapter 1: Introduction 27.
.1,1 The aim of the thesis 28.
1.2 Historical review 29.
1.3 The isolation and purification of relaxin 30.
1.4 Biochemical structure 31.
1.5 Assays 33.
1.5.1 Bioassays 33.
1.5.2 Radioimmunoassays 33.
1.6 Distribution and sites of synthesis 35.
1.7 Serum levels 36.
1.8 Receptor sites 38.
1.9 Target organs and biological effects 39.
1.9.1 Pubic symphysis/formation of the pubic ligaments 39.
3.
1.9.2 Myometrium/inhibition of activity during pregnancy 39.
1.9.3 Uterine connective tissue/pregnancy accommodation 42.
1.9.4 Endometrium/preparation for implantation 42.
1.9.5 Cervix/cervical ripening 43.
1.9.6 Mammary glands/lactation 45..
1.9.7 Semen/sperm mo tility 45.
1.9.8 Skin/collagen disorders 46.
1.10 Mechanism of action 47.
1.11 Controlling mechanisms 48.
1.12 Speculation on the roles of relaxin in the human 50.
Chapter 2: The Purification of Porcine Relaxin 53.
2.1 Introduction 54.
2.2 Collection of ovarian tissue 55.
2.3 Purification process 56.
2.4 The quality control of porcine relaxin purification 58.
Chapter 3: The Bioassay of Porcine Relaxin 60.
3.1 Introduction 61.
3.2 The inhibition of spontaneous activity in rat myometrium 62.
3.3 The inhibition of KCl-induced contractility in rat 63.
-
myometrium
Chapter 4: The Radioimmunoassay of Relaxin 64.
4.1 Introduction 65.
4.2 Reagents * 66.
4.3 Procedures 67.
4.4 Details and validation of assay 69.
4,
Chapter 5: Serum Relaxin Levels in Normal Human Pregnancy 70.
5.1 Summary 71.
5.2 Introduction 72.
5.3 Patients and methods 73.
5.4 Results 74.
5.5 Discussion 76.
Chapter 6: The Relationship of the Hormone Relaxin to Pelvic
Pain and Joint-Laxity in Human Pregnancy 79.
6.1 Summary 80.
6.2 Introduction 81.
6.3 Patients and methods 83.
6.4 Results 85.
6.5 Discussion 86.
Chapter 7: Relaxin Levels in Multiple Pregnancy, Premature
Labour, Pre^eclampsia, Normal Neonates and Neonates
with Congenital Dislocation of the Hip 88.
7.1 Summary 89.
7.2 Introduction 90.
7.3 Methods and results 92.
7.4 Discussion 97.
Chapter 8: Effects of Relaxin on the Intrauterine Distribution
and Antimesometrial Positioning and Orientation of
Rat Blastocysts Prior to Implantation 100.
8.1 Summary 101.
8.2 Introduction 102.
8.3 Materials and methods 103.
8.4 Results 105.
8.5 Discussion 108.
5.
Chapter 9: The Effect of Porcine Relaxin Vaginally Applied at
Human Embryo Transfer in an In Vitro Fertilisation 
Programme 110.
9.1 Summary 111.
9.2 Introduction 112.
9.3 Patients and methods 114.
9.4 Results 116.
9.5 Discussion 119.
Chapter 10: The.^Effect of Porcine Relaxin and Progesterone on Rat,
Pig and Human Myometrial Activity In Vitro 121.
10.1 Summary 122.
10.2 Introduction 123.
10.3 Methods 125.
10.4 Results 128.
10.5 Discussion 132.
Chapter 11: Ripening of the Human Cervix and Induction of Labour
with Purified Porcine Relaxin 136.
11.1 Summary 137.
11.2 Introduction 138.
I
11.3 Patients and methods 139.
11.4 Results 142.
11.5 Discussion 149.
Chapter 12: Cervical Ripening with Combinations of Vaginal
Prostaglandin Fpq, Estradiol and Relaxin 152.
12.1 Summary 153.
12.2 'Introduction 154.
12.3 Patients and methods 155.
12.4 Results
12.5 Discussion
158.
161.
Chapter 13: Ripening of the Human Cervix and Induction of Labour
with Intracervical Purified Porcine Relaxin 163.
13.1 Summary 164.
13.2 Introduction 165.
13.3 Patients and methods 166.
13.4 Results 169.
13.5 Discussion 174.
Chapter 14: The Morphology of Cervical Ripening Induced by the
Hormones Relaxin and Prostaglandin F?a in a Rabbit 
Model 177.
14.1 Summary 178.
14.2 Introduction 179.
14.3 Materials and methods 180.
14.4 Results 181.
14.4.1 Control rabbits 181.
14.4.2 Prostaglandin and relaxin treated rabbits 182.
14.4.3 Giant cells 182.
14.5 Discussion 185.
Chapter 15: The Absorption of Porcine Relaxin from the Human
Vagina and Cervical Canal 188.
15.1 Summary 189.
15.2 Introduction 190.
15.3 Patients and methods 191.
15.4 Results 192.
15.5 Discussion 193.
7,
Chapter 16: Follow Up Studies on Patients Involved in Clinical
Trials of Porcine Relaxin 195.
16.1 Summary 196.
16.2 Introduction r 197.
16.3 Methods 199.
16.4 Results 200.
16.5 Discussion 202.
Chapter 17: Final Discussion 203.
17.1 General 204.
17.2 Hypothesis - Relaxin’s role in the prevention and 
initiation of labour 207.
17.3 Future relaxin research 209.
Appendix 1 ; Cervical Ripening and Induction of Labour with
Intravaginal Prostaglandin F?q 211.
A1.1 Summary 212.
A1.2 Introduction 213.
A1.3 Patients and methods 214.
A1.4 Results 216.
A1.5 Discussion 223.
Appendix 2: A Double Blind Dose Trial of Intravaginal Prosta­
glandin F?q for Cervical Ripening and Induction 
of Labour 225.
A2.1 Summary 226.
A2.2 Introduction *  .. ■ 227.
A2.3 Patients and methods 228.
A2.4 Results 230.
A2.5 Discussion 237.
8Appendix 3 : The Effect of Intravaginal Prostaglandin F9 a on
Labour After Spontaneous and Artificial Rupture 
of the Membranes 239
A3.1 Summary 240
A3.2 Introduction 241
A3.3 Patients and methods 242
A3.4 Results 245
A3.5 Discussion 248
References 250
9.
Table 1
Table 2
Table 3
Table 4
Table 5
Table 6
Table 7
Table 8
Table 9
LIST OF TABLES
The possible biological roles of relaxin in mammals.
Individual serum relaxin concentrations in 11 multiple 
pregnancies.
Individual serum relaxin concentrations in 14 pregnancies 
with pre-eclampsia.
Individual serum relaxin concentrations in 8 patients in 
premature labour.
Blastocyst positioning and orientation after treatment 
with relaxin.
Pregnancy outcome after embryo transfer in relaxin and 
placebo treated patients.
Pregnancy rate in treatment and placebo groups according 
to number of embryos transferred.
The inhibitory effect of porcine relaxin on myometrial 
contractility in the non-pregnant and pregnant rat, pig 
and human.
Comparison of treatment and control groups in the first 
cervical ripening trial.
Table 10 Outcome of first cervical ripening trial.
10.
Table
Table
Table
Table
Table-
Table
Table
Table
Table
11 Outcome of labour in control and relaxin-treated groups.
12 Analysis of results of intravaginal relaxin pretreatment 
by initial cervical score after treatment.
13 Analysis of results of intravaginal relaxin pretreatment 
by parity.
14 Analysis of results of intravaginal relaxin pretreatment 
by gestation.
1.15 Comparison of treatment groups in preliminary combination
trial of cervical ripening agents.
16 Outcome of pretreatment with relaxin and prostaglandin
F201 given individually and in combination.
17 Outcome of cervical pretreatment in the preliminary
combination trial of cervical ripening agents.
18 Comparison of the treatment and control groups in the
intracervical relaxin pretreatment trial.
19 Outcome of pretreatment with intracervical placebo or
relaxin.
Table 20 Analysis of results of intracervical pretreatment by 
initial cervical score.
XL,
Table
Table
Table
Table
Table
Table
Table
Table
Table
Table
21 Analysis of results of intracervical pretreatment by 
parity.
22 Outcome of labour in intracervical pretreatment trial.
23 Results of percentage bound I125 relaxin in study and
control patients being investigated for formation of 
porcine relaxin antibodies.
A 1 Patient matching in treatment and control groups.
A 2 Outcome of cervical pretreatment on the morning of
proposed surgical induction.
A 3 Outcome of labour in control and prostaglandin treated
groups.
A 4 Gestation and mean change in cervical score 15 h after
pretreatment.
A 5 Parity and mean change in cervical score 15 h after pre­
treatment.
A 6 Initial cervical score and mean change in cervical score
15 h after pretreatment.
A 7 Patient matching in control and pretreatment groups.
Table A 8 Outcome of cervical pretreatment.
Table A 9 Outcome of labour in control and treatment groups.
Table A10 Initial and post-treatment cervical scores.
Table All Parity and mean change in cervical score.
Table A12 Gestation and mean change in cervical score.
Table A13 Matching of treatment groups.
Table A14 Outcome of labour after intravaginal PGF2 C1 and intravenous
oxytocin following A.R.M.
Table A15 Outcome of labour after intravaginal PGF201 and intravenous
oxytocin following S.R.O.M.
13.
Figure .1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
LIST OF ILLUSTRATIONS
The carboxymethyl cellulose purification of porcine 
relaxin.
The comparison of the amino acid sequences of porcine 
relaxin- and human relaxin.
Serum relaxin levels during human pregnancy.
The hormones in the human which may promote or inhibit 
cervical ripening and uterine contractility.
Possible mechanism of action of relaxin in target tissues.
Summary of the biochemical steps in the purification of 
porcine relaxin.
Porcine relaxin elution profile on a Sephadex G-50 (fine) 
column.
Porcine relaxin elution profile on a carboxymethyl 
cellulose column.
Comparison of the concentration response curves of the 
reference and study porcine relaxins in the bioassay.
Comparison of the concentration response curves of the 
reference and study porcine relaxins in the porcine 
relaxin radioimmunoassay.
Figure 11
Figure 12
Figure 13
Figure 14
Figure 15
Figure 16
Figure 17
Figure 18
Figure 19
Figure 20
14.
Double electrophoresis of the study porcine relaxin.
Bioassay for the presence of relaxin-like activity involv­
ing the inhibition of spontaneous myometrial activity in 
the oestrogen primed non-pregnant rat.
Bioassay of St. Louis (1981) for relaxin-like activity 
involving the inhibition of KCl-induced tetanic rat 
myometrial contractions.
A standard curve obtained during the radioimmunoassay of 
porcine relaxin.
Mean immunoreactive relaxin levels in the serum of women 
during pregnancy.
Individual serum relaxin concentrations in patients who 
spontaneously laboured within 7 days of sampling.
Serum relaxin concentrations in patients with pelvic joint 
pain and laxity.
Serum relaxin concentrations in patients with a multiple 
pregnancy.
Serum relaxin concentrations in patients in premature 
labour.
Implantation sites in the uterine horns of a control and 
relaxin-treated rat.
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
Figure
15
21 Histological sections of implantation sites from control 
and relaxin-treated rats.
22 Myometrial contractility tracings from a non-pregnant and
a pregnant rat.
23 KC1 bioassay comparing the response of non-pregnant rat
myometrium to porcine relaxin before and after pretteat- 
ment with progesterone.
24 Myometrial contractility tracings from a non-pregnant and
a pregnant sow.
25 KC1 bioassay comparing the response of non-pregnant pig
myometrium to porcine relaxin before and after pretreat­
ment with progesterone.
26  ^ Myometrial contractility tracings from a non-pregnant
and pregnant human uterus,
27 Histology of cervical tissue from non-pregnant and
pregnant control rabbits.
28 Histology of cervical tissue from prostaglandin and
relaxin-treated pregnant rabbits.
29 Histology of giant cells in rabbit cervical tissue.
30 The ultrastructure of a giant cell (x7,500).
16,
Figure
Figure
Figure
Figure
31 The ultrastructure of a giant cell (xl8,900).
32 Serum relaxin concentrations following the intracervical
application of 2 mg porcine relaxin.
33 Serum relaxin concentrations following the vaginal
application of 2 mg porcine relaxin.
34 Diagram of the possible role and relationship of relaxin
to other hormones involved with the initiation of 
parturition.
17,
ACKNOWLEDGEMENTS
Inspiration I wish to firstly thank Professor1s Fred and Gillian 
Greenwood for their, enthusiasm, expertise and support in establishing 
my interest and laboratories in this field when they visited Adelaide in 
1978 on their sabbatical leave from Hawaii. They have continued to 
support me and collaborate with me across the Pacific Ocean and I am 
indebted to them for their help and friendship.
Supervision Professor Lloyd Cox, Chairman, Department of Obstetrics
and Gynaecology, The University of Adelaide, has been the official 
supervisor of this thesis. I am very grateful to him for his encourage­
ment to write this thesis at this point in the relaxin story and for all 
the facilities of his department which he readily made available for 
this research. May thanks also to Dr. Robert Seamark, Reader in 
Reproductive Endocrinology, The University of Adelaide, who helped me 
through the initial technical problems in setting up the purification 
process for porcine relaxin and its radioimmunoassay.
Grants The majority of these studies was supported by a grant
from the National Health and Medical Research Council of Australia. 
Grants were also later gratefully received from The Queen Victoria 
Research Foundation and The Queen Victoria Hospital's Womenfs Auxiliary.
Co-authors Whilst the candidate was first and main author on 15 of 
the papers (published or in press) I wish to acknowledge the help of my 
co-authors, particularly Sister Ros Green (Research Sister, The Queen 
Victoria Hospital) who chaperoned me through all the clinical trials 
and was responsible for many of the blood collections, Mrs. Patricia 
Grant (Technical Assistant, The University of Adelaide) who latterly
inherited much of the labour involved in the purification of the relaxin 
and muscle experiments and Mrs. Ruth Nicolson (N.H. and M.R.C. Research 
Assistant) who helped establish and run the radioimmunoassay.
Donations I am indebited to Dr. Elizabeth 0fByrne, New York, for
supplying the R6 rabbit anti-porcine relaxin serum, and Dr. Christian 
Schwabe for donating the relaxin tracer. The relaxin standard was kindly 
supplied by the National Institutes of Health, U.S.A.
Advice Mr. Dietmar Ness, Research Officer, Department of
Obstetrics and Gynaecology, The University of Adelaide, provided expert 
statistical advice and Dr. Helen Chambers, Senior Pathologist, The Queen 
Victoria Hospital, kindly reviewed my morphological studies in Chapter
14.
Illustrations Mr. Kym Tank, Clinical Photographer, The Queen Victoria 
Hospital, expertly printed most of the illustrations and I thank Miss 
Mary Ciganovic for her help with the art work.
Typing This thesis was painstakingly typed and retyped without
complaint by Miss Carmel Sandercock and I thank her for sharing the work 
by compiling this thesis.
Support The doctors and nursing staff of The Queen Victoria
Hospital have always been most generous in allowing me access to their 
patients and without their help and the generosity of the patients them­
selves, this research would not have been possible. My special thanks 
to my wife Alice for her understanding as to why I did not come home at 
night and for her help in the proof reading. Finally, I thank my two 
daughters Suzanna and Lorna for access to their guinea-pig, Marmalade,
who did confirm that several days prior to parturition the pubic 
symphysis does indeed relax.
20.
SUMMARY OF THESIS
Relaxin is a polypeptide hormone, similar in structure to insulin, 
which was originally discovered 60 years ago as a hormone that relaxed 
the pubic symphysis of the guinea-pig prior to parturition. However, 
relaxin has only very recently been purified and characterized in the 
rat, pig and human. Its main source appears to be the corpus luteum 
of pregnancy but it is also produced by decidual tissue and the pros­
tate gland. Its main mechanism of action appears to be the facilitat­
ion of remodelling of connective tissue in target tissues to allow the 
necessary changes in organ structure during pregnancy and parturition. 
A secondary mode of action in some mammals may be to inhibit uterine 
contractility until near the end of pregnancy. Until recently the 
existence of relaxin in the human was debated and its role was unknown. 
Human relaxin is not yet available for laboratory or clinical trials 
but it is now possible to purify large quantities of pure porcine 
relaxin.
The aim of this thesis was to examine the possible roles of 
relaxin in human reproduction, specifically in the areas of implantat­
ion of the fertilised ovum, the maintenance of myometrial quiescence 
during pregnancy and the facilitation of cervical ripening and part­
urition. These studies involved the extensive purification of porcine 
relaxin for laboratory experiments and for the first clinical trials 
of a pure relaxin. A homologous porcine relaxin radioimmunoassay was 
also set up to measure peripheral serum relaxin-like immunoactivity.in 
nornjal and abnormal human pregnancy. Where possible human studies 
were performed but where this was not practically or ethically 
possible, in vitro or animal studies were performed to further 
elucidate relaxin*s possible role in reproduction.
In a cross sectional study of 330 normal singleton human
21.
pregnancies serum relaxin concentrations were found to be highest in 
early pregnancy and thereafter they gradually declined until term. 
Post-term patients had significantly lower relaxin concentrations and 
for the first time in the human a significant elevation in relaxin 
levels was described in early labour corresponding with such an 
elevation near parturition in most other animals studied. This 
pattern of relaxin secretion is in keeping with its postulated roles 
of maintaining uterine quiescence but with a waning influence until 
term and a cervical ripening action around parturition.
Serum relaxin levels were also measured in pathological 
pregnancies and for the first time a correlation has been made between 
pelvic joint pain and laxity in pregnancy and high relaxin concentrat­
ions. Relaxin levels were also high in late pregnancy in multiple 
gestations. However, low levels were found in patients in premature 
labour suggesting the possibility that such low levels might contribute 
to this pathology. Little maternal relaxin appears to cross into the 
fetal circulation and this assay could not detect high levels of 
relaxin in the umbilical cord blood of babies with congenital dis­
location of the hip. Relaxin levels were not altered in pre-eclampsia.
In a study of the effect of a continuous infusion of porcine 
relaxin in rats during the time of implantation normal spacing and 
orientation of the blastocysts was disturbed and implantation sites 
were found to be confined to the cranial half of each uterine horn.
In an attempt to utilise this effect to increase the pregnancy rate at 
human embryo transfer in an in vitro fertilisation programme pure 
porcine relaxin was given vaginally in a randomised controlled 
clinical trial. Such treatment did not improve or inhibit the 
pregnancy rate and a role for relaxin in implantation in the human 
could not be substantiated.
The in vitro effect of pure porcine relaxin on non-pregnant and 
pregnant myometrium before and after progesterone treatment was 
studied in the rat, pig and human. Porcine relaxin inhibited rat 
myometrial activity until mid pregnancy but had no effect in late 
pregnancy. Porcine relaxin inhibited pig myometrial activity through­
out pregnancy but in contrast had no significant effect on human myo­
metrial activity in the.pregnant or non-pregnant state. Progesterone 
was synergistic with relaxin in the rat and pig when the latter hormone 
exhibited an inhibitory effect. It is suggested that the*.lack of 
response of human myometrium to porcine relaxin is due to the differ­
ence in structure between porcine and human relaxin rather than there 
being a lack of relaxin receptors on human myometrium.
In a series of randomised controlled clinical trials pure porcine 
relaxin was shown for the first time to promote cervical ripening in 
patients near term and to induce labour in up to a third of those 
treated. Patients receiving porcine relaxin had a significantly 
shorter mean length of labour and less analgesic requirements. The 
clinical effects of vaginal and intracervically applied relaxin were 
similar to the effects of prostaglandin F2 Ct in other clinical trials 
of cervical ripening conducted by the candidate. Further clinical and 
morphological studies described in this thesis concluded that prost­
aglandin F201 and relaxin appear to activate the same collagenolytic 
system rather than acting in parallel to produce separate connective 
tissue changes. No side effects were detected following the use of 
pure porcine relaxin in any of the clinical trials and the induction 
of porcine relaxin antibodies was not detected. Porcine relaxin was 
shown to be systemically absorbed from the lower human genital tract 
and the association of both high endogenous and exogenous relaxin 
levels with cervical ripening and parturition suggests a role for 
relaxin in this aspect of human reproduction.
Finally a hypothesis is presented as to the role of relaxin and 
its controlling mechanisms in the maintenance of uterine quiescence 
during pregnancy and the facilitation of parturition at term. The 
synthesis of human relaxin is awaited to test this hypothesis and 
further substantiate the apparent important role of relaxin in human 
reproduction.
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C H A P T E R  1
INTRODUCTION
28,
1.1 THE AIM OF THE THESIS
The pdlypeptide hormone relaxin has only recently been confirmed 
to be present in the human and specific roles for it in the human 
have not been delineated. The main aim of this thesis is to examine 
possible roles for this hormone in the human specifically in the areas 
of implantation of the fertilised ovum, the maintenance of myometrial 
quiescence during pregnancy and the facilitation of cervical ripening 
at parturition. As human relaxin was not available at the beginning 
or during any of these studies, pure porcine relaxin and a porcine 
relaxin radioimmunoassay were used to investigate the likely role of 
relaxin in the human. These studies have involved newly developed 
methods to purify extensive amounts of pure porcine relaxin for lab­
oratory and clinical trials and the development of a homologous 
porcine relaxin radioimmunoassay for its heterologous application in 
measuring relaxin-like immunoactivity in the human. Where ethically 
and practically possible the studies were designed to investigate the 
role of the hormone relaxin in the human using human samples or by 
conducting clinical trials. However, where this was not possible, 
ainimal or in vitro studies have been performed to further define 
relaxinfs possible role in reproduction.
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1.2 HISTORICAL REVIEW The Discovery of Relaxin
The presence of a hormone causing separation of the pubic symph­
ysis of certain species of rodents before parturition was first 
detected by Frederick Hisaw in 1926 (Hisaw 1926) when he found that 
serum from pregnant guinea-pigs injected into virgin guinea-pigs 
caused relaxation of the pelvic ligaments. Such changes in the 
experimental animal could be induced only during oestrus or, as was 
later shown, after the animal was oestrogen-primed. Hisaw and his 
colleagues found that the corpus luteum of pregnancy was the main 
source of the factor causing relaxation of the public ligament (Fevold, 
Hisaw & Meyer 1930). From the corpora lutea of pregnant sows they 
obtained a fat-soluble extract and an aqueous extract. The fat- 
soluble extract induced progestational changes in the uterine endo­
metrium and this extract was named 1corporin1. Corporin was later 
found to be a combination of the hormones oestrogen and progesterone. 
The aqueous extract of the corpora lutea contained the relaxing 
properties firs£ noted by Hisaw, and it was proposed that the hormone 
in this extract be called 'relaxin*. As early as 1930, Fevold et al 
(1930) noted the similarity to insulin of relaxin's chemical features. 
However, for the next 30 years the purity of the relaxin extracts 
remained poor, approximately 90% of each preparation containing non- 
relaxin ovarian contaminants. These impure forms of relaxin were 
commercially produced under various commercial names, e.g. 'Releasin', 
''Lutrexin*, 'Cervilaxin'. The impurity of the hormone, together with 
difficulty in reproducing the bioassay (which used relaxin*s effect on 
the guinea-pig public ligament) led to confusing and contradictory 
reports about its biological effects for several decades until much 
improved methods for isolating relaxin in its pure form were published 
in 1974.
30.
1.3 THE ISOLATION AND PURIFICATION OF RELAXIN
Improvements in the purification of porcine relaxin began, .in the 
1960s (Cohen 1963; Frieden 1963; Griss et al 1967) and in 1974 
Sherwood and 0*Byrne reported its biochemical characterization and 
purification, revealing three continuous peaks on elution from a 
carboxymethyl cellulose column. The relaxin preparations obtained 
from these peaks were called CMB, CMa and CMA, respectively. All 
three were shown to have similar biological potency in the mouse 
intrapubic ligament assay. It has since been possible to increase the 
yields of porcine relaxin from pregnant sow ovaries by inhibiting its 
degradation during purification by adding protease inhibitors to the 
ovarian extracts (Kwok, Bryant-Greenwood & Niall 1980). Recent 
studies (Walsh & Niall 1980) have shown that when proteolysis during 
purification is further dminished, CMa relaxin is thejpredominant 
relaxin found in vivo and that heterogeneity of the relaxin molecule 
appears to be due to loss of one or more amino acids: during purificat- 
ion in vitro (Fig. 1). Walsh and Niall suggest that the major stored 
form of porcine relaxin in vivo is B31 relaxin (i.e. where relaxin's 
B chain contains 31 amino acids), and that the other.molecular variants 
with shorter B chains are artefacts of the isolation procedures 
previously employed. Commercial production of relaxin using recombin­
ant DNA technology is feasible and will be an important source of pure 
relaxin in the near future.
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FIGURE 1 Carboxymethyl cellulose purification of porcine relaxin.
(a) Procedure of Sherwood and 0 ’Byrne giving three biologically active 
components, CMB, CMa and CMA, differing only in the length of their B chains 
(28-31 residues) due to proteolysis during purification. (b) Procedure of 
Walsh and Niall which markedly reduces proteolysis during the isolation 
process revealing only one relaxin peak which comprises mostly B31 relaxin 
(see text). Reproduced with permission from Walsh and Niall (1980).
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1.4 BIOCHEMICAL STRUCTURE
Relaxin is a polypeptide hormone with a molecular weight of 6300. 
It has a conformational homology with insulin (Bedarkar et al 1977); 
both molecules have A and B chains connected by disulphide cross links 
in similar positions and share a similar tertiary structure. Approx­
imately 25% of the amino acid sequences of insulin and porcine relaxin 
are identical (Niall 1979). Despite its similarity to insulin, no 
insulin-like biological activity has been described for relaxin 
(Schwabe & Harmon 1978). The complete structure of porcine relaxin 
was separately reported by Schwabe, McDonald & Steinetz (1976, 1977) 
and James et al (1977). These investigators published similar results 
for the A chain but there was disparity in the terminal sequence of 
the B chain. This disparity has now been resolved following the 
evidence by Walsh & Niall (1980) of the proteolysis during purificat­
ion which accounted for the shorter chain described by Schwabe et al 
(1977). There is now evidence that one or more forms of a pro-hormone 
Oprorelaxin1) occurs in vivo (Kwok, Chamley & Bryant-Greenwood 1979). 
Rat relaxin has recently been characterized (Sherwood 1979) and 
although similar in its tertiary structure, there are variations in 
its amino acid content.
The amino acid sequence of a human relaxin derived from the 
recent identification of a genomic clone for relaxin is now known 
(Hudson et al 1983). There is only approximately a 50% homology 
between porcine relaxin and this human relaxin (Fig. 2). The import­
ance of this difference with regard to cross reactivity in vivo and in 
vitro is as yet unknown but porcine and human relaxins share the same 
tertiary structure and some of the same amino acid sequences at bio­
logically active sites. At least one other relaxin-like gene may be 
present in the human (Hudson et al 1983). Absolute proof that the
Comparison of Human and Porcine Relaxin
A-chain
Human
ys I Lys fArgTArg » pro[ TyrrVai  J ^ l L e u  IPheT GlJ Lysjf Cys/Vys iLeu
Porcine
B-chain
A  A AlalAlaA LysATrP (LysJ AspiAsp X ValIll.eXl.ys SerlGln
Human
val lSer ITrpAGlyl ArgAThr 1 Alai LeuASer lLeu
Porcine
-FIGURE 2 Comparison of the amino acid sequences of porcine relaxin and 
human relaxin. (Adapted,from Hudson et al (1983)). Coloured circles 
denote amino acids in homologous positions and open circles represent 
dissimilar amino acids. S = Disulphide bonds.
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above human genomic clone represents an expressed relaxin gene awaits 
identification of its corresponding cDNA derived from a relaxin 
secreting tissue in the human. Such tissues cannot easily be collect­
ed in the human but occasionally corpora lutea of pregnancy can be 
ethically collected and such work is presently under way. Sufficient 
amounts of human relaxin have not yet been purified or produced by 
genetic engineering techniques for any in vitro or in vivo studies.
Finally, relaxin and insulin share structural similarity to both 
nerve growth factor and insulin-like growth factor (James et al 1977). 
Thus, it seems probable that these four hormones have evolved from the 
same region of a primitive genome and therefore their biological 
actions may bear some comparison.
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1.5 ASSAYS
1.5.1 Bioassays
During his early work, Hisaw simply classified samples as 
positive or negative for relaxin activity on the basis of their 
relaxational effect on the guinea-pig pubic symphysis. Abramow- 
itz et al (1944) quantitated this effect, but the reproduciblity 
of the test was poor. Subsequent work using more specific 
conditions improved the guinea-pig bioassay (Steinetz, Beach & 
Kroc 1969), but a mouse pubic symphysis assay has since been used 
with more success (Steinetz et al 1960). Nevertheless, bioassays 
remain laborious and are relatively insensitive. Although 
relaxin standards are available, the guinea-pig bioassay is not 
precise and the guinea-pig unit (GPU) has no precise quantitative 
meaning. Thus the biological activity of purified porcine 
relaxin (CM-A) can only be expressed as having a potency of 
approximately 2200 GPU/mg (Frieden et al 1980). More modem bio­
assays utilise the inhibitory effect of relaxin on oestrogen- 
primed ratomyometrial activity (St. Louis 1981). These methods 
have been utilised in this thesis because of their greater 
reproducibility than pubic symphysis assays. They are described 
in Chapter 3.1.
1.5.2 Radioimmunoassays
The first radioimmunoassay for relaxin was described for 
porcine relaxin by Bryant in 1972 and was used to measure relaxin 
levels in various species. This assay utilized the labelling of 
tyrosine on a fraction of an impure relaxin preparation. When 
the structure of porcine relaxin was later characterized 
(Sherwood & O'Byrne 1974), pure relaxin was found not to contain
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tyrosine. Thus, the first radioimmunoassay may have measured the 
prohormone or other relaxin-related compounds. Sherwood, Rosen- 
treter & Birkhimer (1975) labelled pure porcine relaxin by the 
addition of tyrosine to the relaxin molecule and then radioiodin- 
ated the resulting polytyrosyl relaxin. Other methods of labell­
ing relaxin for radioimmunoassay have since been described 
(Bryant-Greenwood & Greenwood 1979). Satisfactory correlation 
of radioimmunoactivity and biological activity has yet to be 
achieved. A specific radioimmunoassay for human relaxin has yet 
to be established and presently published data on human serum 
relaxin levels are based on the porcine assay. Details of such 
a porcine relaxin radioimmunoassay utilised in these studies are 
described in Chapter 3.2.
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1.6 DISTRIBUTION AND SITES OF SYNTHESIS
Relaxin has been found in the serum of all female mammals studied 
and in comparatively high quantities during pregnancy (Schwabe et al
1978). In the pig there are especially high levels in the corpus 
luteum of pregnancy and this has been a major source of relaxin. 
Relaxin has also been found in non-mammalian species (Steinetz, Beach 
& Kroc .1959), e.g. sharks, and has been isolated from the testes in 
the rooster and the armadillo. No relaxin has been found in human 
testes, but significant quantities have been found in human seminal 
plasma (Loumaye, Decooman & Thomas 1980); this has probably originat­
ed in the prostate (Kendall et al 1983).
The corpus luteum appears to be the main source of relaxin in 
women. Venous blood from the ovary containing the corpus luteum 
taken at Caesarean section contains several times as much relaxin as 
blood from the contralateral ovarian vein (Weiss, 0*Byrne & Steinetz 
1976). Luteectomy at Caesarean section leads to an abnormally rapid 
decline of the serum relaxin levels (Weiss et al 1977). Immunocyto- 
chemical techniques with antisera raised to a highly purified form of 
porcine relaxin (Kendall, Plopper & Bryant-Greenwood 1978) have 
localized relaxin to numerous small granules in the cytoplasm of the 
granulosa lutein cells in the pregnant sow. Recent detailed studies 
(Bigazzi 1981; Bryant-Greenwood 1981; Fields, Pardo & Larkin 1981) 
support older work by Zarrow & McClintock (1966) that human decidua is 
a source of active production. Recently there has been speculation 
that relaxin may be a neuropeptide as relaxin-like activity has been 
found in the pituitary gland.
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1.7 SERUM LEVELS
In many species studied, relaxin levels rise during pregnancy and 
peak prior to parturition, suggesting a role for relaxin at that time. 
However, in the human, serum relaxin levels,as measured by heterolog­
ous RIA methods using porcine antisera,are highest in early pregnancy 
(Quagliarello et al 1979) reaching approximately 2 ng porcine equival­
ents/ml (Fig. 3). Thereafter, levels decline to approximately 1 ng 
porcine equivalents/ml during the second trimester and remain fairly 
steady at this concentration for the rest of pregnancy. When the 
expansion of plasma volume in pregnancy is taken into account, total 
relaxin production rates may be relatively stable throughout human 
pregnancy. However, studies by Bryant's group (Atele et al 1979) 
indicate that relaxin is secreted in a pulsatile manner and is rapidly 
cleared from the circulation and very frequent blood sampling must be 
carriedT out in order to obtain meaningful relaxin profiles. Most 
human studies have not achieved such a frequency of sampling prior to 
parturition, and therefore, a transient rise at this time, has not 
been excluded. Von Maillot et al (1977) claimed that tissue levels 
are highest at this time, suggesting that relaxin may have a role to 
play in human parturition. Postnatally, serum levels quickly drop to 
pre-pregnant levels (Quagliarello et al 1979); lactation or its 
suppression makes no difference to the rapidity of the decline. The 
sensitivity of porcine RIA is such that only a small fraction of the 
bioactivity of human relaxin may be measured. Also, since relaxin 
may act mainly as a 'local hormone', serum levels may not accurately 
reflect its biological role even when a human relaxin RIA is 
available.
Accepting these limitations, human relaxin levels as reflected 
in porcine equivalents using a porcine relaxin radioimmunoassay, have
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FIGURE 3 Serum relaxin levels during human pregnancy detected by a 
heterologous radioimmunoassay using porcine antisera. Reproduced with 
permission from Quagliarello et al (1979).
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been reported in several obstetric pathologies (Szlachter et al 1982). 
Although relaxin levels were not higher during the third trimester df 
twin pregnancies they were significantly lower in post mature 
pregnancies and in patients who laboured prematurely. The authors 
speculate that lower relaxin levels in postmaturity might be associat­
ed with a delay in cervical ripening whilst lower relaxin levels in 
patients who laboured prematurely might decrease uterine quiescence 
and allow other factors to increase uterine activity. Evidence for 
relaxinfs role in these areas in the human is discussed later in this 
thesis.
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1.8 RECEPTOR SITES
The development of techniques to identify specific relaxin 
receptor sites is still in its infancy (Greenwood et al 1981).
Specific binding sites fulfilling the rigid criteria of receptor sites 
have been described only in the rat uterus CMercado, Bryant-Greenwood 
& Greenwood 1980). However, sites identified less rigorously have 
been reported in fibroblasts from mouse pubic symphysis and human skin 
(McMurty, Floershein & Bryant-Greenwood 1980) and in tissue from the 
cervix of the guinea-pig and the mammary gland of the rat (McMurty, 
Kwok & Bryant-Greenwood 1978).
In the rat, relaxin binding sites increase in direct relationship 
to the rise in plasma relaxin during pregnancy (Mercado et al 1980). 
However, at the time of the rat's prepartum surge in serum relaxin, an 
apparent reduction in relaxin receptor sites occurs. These sites may 
be under the control of oestrogen (Mercado et al 1980) or the oest­
rogen/progesterone ratio, although it is unlikely that such steroid 
levels are the only factors affecting the number of affinity of 
receptor sites. Lastly, direct correlation has yet to be made between 
specific relaxin receptor sites and biological response.
39.
1.9 TARGET ORGANS AND BIOLOGICAL EFFECTS
Apparent physiological responses to relaxin have been found in 
many tissues.
1.9.1 Pubic Symphysis/Formation of the Pubic Ligaments 
Relaxation of the pubic ligaments in response to relaxin
after oestrogen priming was first described during pregnancy and 
parturition in the guinea-pig and later in mice. The changes in 
the connective tissue of the pubic ligaments involve dissociation 
of the collagen bundles, a net increasejin total collagen, 
increased water uptake and a decrease in the viscosity of the 
ground substance which together lead to an increased flexibility 
and enlargement of the birth canal in these animals (Chihal & 
Epsey 1973). Pelvic ligament relaxation occurs to a much lesser 
degree in higher mammals and in human pregnancy changes in pelvic 
anatomy are comparatively minor, except in a few women who suffer 
from instability of their pelvic joints during pregnancy. No 
definite correlation of this clinical condition with relaxin has 
yet been published. However, data is presented in Chapter 6 
suggesting there is a relationship between high peripheral serum 
relaxin levels and pelvic joint pain and laxity during human 
pregnancy.
1.9.2 Myometrium/ Inhibition of Activity During Pregnancy 
The tocolytic properties of relatively impure porcine
relaxin on rat (Sawyer, Frieden & Martin 1953) and human (Kelly 
1959) myometrial contractility in vitro were later confirmed in 
studies on rat and human non-pregnant myometrium using purified 
porcine relaxin (Porter, Downing & Bradshaw 197.9; Szlachter et al
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1980). Clinical studies in the 1950s suggested that crude 
relaxin in adequate dosage inhibited premature labour (Abramson 
& Reid 1955; McCarthy, Er.ving & Lauffe 1957; Eichner et al 1958). 
However, most of these studies were poorly designed and lacked 
adequate control groups. No clinical study using purified 
relaxin has been attempted to date. Relaxin*s inhibitory effect 
on uterine contractions in vitro does not appear to be mediated 
through a beta-adrenergic mechanism (Porter, Downing & Bradshaw
1979). However, cyclic AMP concentrations are increased (Cheah & 
Sherwood 1980) and this is known to inhibit enzymes initiating 
smooth muscle contraction. Nevertheless, relaxin*s mechanism of 
action at the myometrial cellular level has yet to be clarified.
The inhibitory effect of relaxin on rat, pig and human myo­
metrial activity has not been comprehensively studied and such a 
study is described in Chapter 10 together with the synergistic 
role played by progesterone with relaxin during pregnancy. 
Relaxing effect on uterine muscle activity may change during 
pregnancy possibly in response to other hormonal changes, e.g. 
the oestrogen/progesterone ratio. Progesterone, oestrogen and 
relaxin appear to play a synergistic role in the inhibition of 
myometrial activity in early pregnancy. However, at the end 
pregnancy under different hormonal conditions, relaxin*s role 
may be to facilitate labour. In a recent randomized double blind 
clinical trial using purified relaxin by vaginal application 
(Chapter 11) one-third of patients near term laboured within 15 
h, whilst there was no such effect in placebo groups. Whether 
the initiation of labour was indirectly due to relaxin*s 
cervical ripening activity or whether relaxin has a direct effect 
on the myometrium is not clear but other studies described in 
this thesis suggest the former mechanism is more likely.
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In non-pregnant rats, guinea-pigs and sheep, both relaxin and 
oestrogen inhibit spontaneous and prostaglandin-driven myometrial 
activity, but;leave the uterus responsive to oxytocin (Porter 1979 
a). It is possible, in some animals at least, that progesterone 
may inhibit premature labour indirectly by inhibiting the form­
ation of cytoplasmic oestrogen receptor sites. A change in the 
oestrogen/progesterone ratio thus increases these receptor sites 
(Mercado et al 1980; Nissenson, Flouret & Hetchter 1978). Thus, 
withdrawal of progesterone is likely to enhance the oxytocin 
sensitivity Of the myometrium and subsequent oxytocin-driven myo­
metrial activity will not be inhibited by oestrogen or relaxin.
A brief pre-labour surge and subsequent withdrawal of relaxin in 
some species may facilitate the precise timing of the onset of 
labour.
Very recent work by Koay et al (1983) suggests that relaxin 
may play a part in rupture of the fetal membranes. They cultured 
human amnion and chorion in vitro and found that added relaxin 
caused a corresponding increase in collagenase and plasminogen 
activator over a 32 h period. This work suggests that the fetal 
membranes may also be a target tissue for relaxin and that by 
stimulating the release of collagenolytic enzymes relaxin may 
contribute to the weakening and eventual rupture of the fetal 
membranes. This may be a gradual process as the clinical trials 
(Chapter 13) in Adelaide with exogenous porcine relaxin placed in 
the cervical canal and against the fetal membranes suggest that 
over a 15 h period such an application does not precipitate 
membrane rupture.
1.9.3 Uterine Connective Tissue/Pregnancy Accommodation
There is extensive uterine collagen synthesis during preg­
nancy and rapid degradation postpartum. Relaxin may play a major 
role in collagen biosynthesis and be responsible for both the 
proliferation of the uterine collagenous framework and the 
increase in uterine distensibility during pregnancy. Postnatally 
relaxin may directly or indirectly play a part in aiding uterine 
involution. Studies on combinations of relaxin, oestradiol and 
progesterone given to ovariectomized rats show that the greatest 
increase in uterine connective tissue occurs when all three 
hormones are given together (Cullen & Harkness 1964). In the rat, 
relaxin significantly augments the distensibility of the uterus 
in pregnancy (Wiqvist 1959) and has protein and carbo­
hydrate anabolic effects on the uterus (Vasilenko, Frieden &
Adams 1980). Histological studies (Chapter 14) in our laborat­
ories have shown that in late pregnancy pure porcine relaxin 
applied vaginally is associated in the rabbit with an apparent 
dissolution on the cervical stromal connective tissue 18 h after 
application. The role of relaxin in uterine accommodation during 
human pregnancy awaits study.
1.9.4 Endometrium/Preparation for Implantation
In 1967, Hisaw et al showed that the development of full 
histological changes of the endometrium in early pregnancy in the 
rhesus monkey depended on the presence of the three hormones - 
oestrogen, progesterone and relaxin. Relaxin appears to augment 
the progestational changes. Large doses of oestrogen inhibit 
relaxin*s effect. Subcutaneous injections of relaxin in the non­
pregnant monkey also induce hyperplasia of the endothelium of 
maternal endometrial blood vessels (Hisaw et al 1967). Such
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endothelial changes are normally seen in early pregnancy. These 
effects suggest a possible role for relaxin in the preparation of 
the endometrium for implantation of the blastocyst.
A continuous infusion of relaxin during rat blastocyst 
implantation interferes with normal blastocyst spacing (Chapter 8). 
In these experiments we found that all implantation sites were 
confined to the upper half of each horn instead of being evenly 
spaced along the lumen and the orientation of the embryonic discs 
were also disrupted. Thus, exogenous relaxin appeared to inhibit 
normal distribution of the blastocysts possibly through decreas­
ing uterine muscle contractility or by a direct effect on the 
endometrium. Resulting crowding of the blastocysts may have been 
responsible for the atypical implantation sites around the' 
uterine lumen. Studies on the role of relaxin in human implant­
ation are described in Chapter 9.
1.9.5 Cervix/Cervical Ripening
In most species, including the human, the cervix undergoes 
marked changes in its structure prior to parturition. A soften­
ing, shortening and opening of the cervix is associated with 
histological changes in the cervical stroma as mentioned below. 
Although the precise mechanism of cervical ripening and the 
initiation of parturition is not known several hormones are known 
to influence these processes (Fig. 4).
There have been many studies in which relaxins of differing 
purity have been used showing that relaxin causes cervical ripen­
ing in a variety of animals (Zarrow et al 1956; Stone, Sedlis & 
Zuckerman 1959; Hollingsworth, Isherwood & Foster 1979; Kertiles 
& Anderson 1979). Some conflict in the results of these early 
studies was probably due to the impurity of the preparations
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used. However, a recent double blind randomized controlled trial 
in the human using purified porcine relaxin showed that vaginal 
application of relaxin to patients near term was associated with 
cervical ripening in 85% of patients so treated (Chapter 11). 
Animal studies CSteinetz, 0*Byrne & Kroc 1980) suggest that 
relaxin-induced cervical ripening is similar to that seen before 
parturition and that the connective tissue changes are similar to 
those seen in the pubic symphysis and uterus. In these connect­
ive tissues, the collagen fibres become loose and widely separat­
ed, whilst the viscosity of the ground substance decreases. A 
major increase in glycosaminoglycans, together with a slight 
increase in the water content of the cervix, contribute to a 
large increase in the volume of the ground substance. A rise in 
total cervical collagen also occurs, but the increase in ground 
substance is greater, leading to a relative dilution of the 
collagen within the cervical tissue (Steinetz et al 1980).
Evans et al (1983) have confirmed the cervical ripening 
effect of porcine relaxin near term by giving 2 mg porcine 
relaxin pessaries in the cervical canal. In their trial these 
relaxin treated patients had shorter induction/delivery intervals 
compared to the control group. This is in keeping with the 
clinical trial of MacLennan et al (1980) which used 2 mg of 
porcine relaxin in a vaginal gel 15 h prior to surgical induction 
of labour. In this latter trial the relaxin treated group had 
significantly shorter labours and less need for obstetric inter­
vention during labour and delivery. In a further trial (Chapter 
12) combinations of relaxin with other cervical ripening agents,
i.e. oestradiol and prostaglandin F2 <* did not enhance their 
individual effects suggesting that these hormones may act in 
sequence to produce the same cervical ripening effect rather than
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to act in concert to produce complementary effects.
1.9.6 Mammary Glands: Lactation
Early studies suggested that crude relaxin extracts promoted 
mammary gland connective tissue growth in rodents and that 
relaxin was synergistic with other steroid hormones in promoting 
breast tissue growth during pregnancy (Schwabe et al 1978). 
Relaxin binding sites have been described in rat mammary tissue 
(Zarrow & McClintock 1966; McMurty et al 1978). In the pig, 
plasma relaxin is increased by suckling (Atele et al 1979), but 
lactation in the sow can also be inhibited or reduced by inject­
ions of exogenous relaxin towards the end of pregnancy (Steinetz 
et al 1980). Although serum relaxin levels in the human rapidly 
delcine after parturition (Quagliarello et al 1979), detailed 
studies during suckling have not been carried out. Relaxin*s 
role, if any, in human breast growth and lactation has not been 
established.
1.9.7 Semen/Sperm Motility
Relaxin is present in human seminal plasma (Loumaye, Decoo- 
man & Thomas 1980). When purified porcine relaxin is added to 
washed human sperm from both semen samples with normal sperm 
motility and from subfertile specimens with reduced motility, 
relaxin attenuated the normal decline in sperm motility and 
forward progression Of the sperm (Essig et al 1982). Further 
support to a role for relaxin in enhancing sperm motility has 
been reported by Sarosi et al (1983), who found that anti-porcine 
relaxin antibody quickly and significantly impaired human sperm 
motility even when diluted to very low concentrations. They 
suggest a potential for anti-relaxin antibody as an adjuvant in
barrier contraception and also for such sperm immobilization to 
be used as a rapid screening procedure for anti-human relaxin 
antisera.
The exact role of relaxin in human seminal plasma has yet to 
be defined but clearly it is another factor that facilitates 
sperm motility. Other possible roles for seminal relaxin that 
require investigation are cervical mucus penetration, relaxation 
of the uterotubal sphincter and ovum penetration.
1.9.8 Skin: Collagen Disorders
The possibility that relaxin may exert an effect outside the 
reproductive tract has barely been explored. Certainly there are 
minor changes in skin connective tissue during pregnancy. 
McMurtryet al (1980) reported specific relaxin binding sites on 
fibroblasts from human skin. Their data also suggest that relaxin 
is mitogenic.to skin fibroblasts in vitro. However, the binding 
of purified relaxin to skin fibroblasts or to any other binding 
sites has yet to be shown to have any biological consequence. 
Casten & Boucek (.1958) reported an increase in the elasticity of 
the skin in patients with scleroderma when treated with crude 
extracts of relaxin. Simildr clinical studies have not yet been 
reported with purified relaxin. A specific role for relaxin in 
non-reproductive disease, in particular the collagen disorders 
and arthritis, warrants further investigation.
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1.10 MECHANISM OF ACTION
Relaxin appears to influence collagen metabolism in most target 
tissues. In vitro studies on the rat pubic symphysis suggest that 
relaxin activates the collagenolytic system by raising tissue levels 
of collagenase and collagen peptidase, an enzyme involved in the 
degradation of denatured collagen (Weib, Magelschmidt & Struck 1979). 
The mitogenic action of relaxin, on the other hand, appears to stim­
ulate fibroblast replication in the target tissue and concomitantly, 
the synthesis of new collagen. Thus., relaxin appears to stimulate 
collagen biosynthesis by increasing both collagen production and 
breakdown to allow remodelling of the target tissue, thereby giving it 
greater distensibility and pliability to accommodate the growth of the 
pregnancy. Cyclic AMP may serve as a second messenger in the target 
tissues to mediate other biological responses - e.g. the inhibition of 
uterine activity - since cyclic AMP levels are significantly elevated 
after relaxin administration in the uterine and cervical tissues 
(Cheah & jSherwood 1980) .
The net effect of relaxin1s action on protein and carbohydrate 
metabolism is anabolic (Vasilenko, Frieden & Adams 1980), collagen 
synthesis being greater than collagen degradation with a resultant 
increase in the total collagen content of the target tissues. Relaxin 
also effects: a decrease in the viscosity of the intercellular ground 
substance (Zarrow et al 1956; Leppi & Kinnison 1971) by increasing its 
water and glycosaminoglycan content. The resultant increase in volume 
of the ground substance is greater than the net increase in collagen 
and thus there is a relative decrease in the collagen concentration of 
the target tissues allowing increased extensibility and remodelling 
(Fig. 5). The evidence for the mechanisms of action of relaxin has 
mostly been derived from animal studies and clear evidence for such a 
role in the human remains to be presented.
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FIGURE 5 Possible mechanism of action of relaxin in target tissues.
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1.11 CONTROLLING MECHANISMS
Oestrogen priming is required before relaxin can exert its effect 
on the guinea-pig pubic symphysis (Hisaw 1926; Fevold et al 1930) and 
inhibition of steroid synthesis in the pregnant rat inhibits relaxin*s 
effect of cervical softening (Schwabe et al 1978). Oestrogen and 
progesterone are required for relaxin to exert its effect on the endo­
metrium (Hisaw et al 1967). In some animals, oestrogens may effect 
the release of relaxin (Porter 1979b) and recent work suggests that in 
the rat, oestrogen may also stimulate an increase in relaxin receptor 
sites (Mercado et al 1980). Thus, there is a close but not precisely 
defined relationship between oestrogen and relaxin and, as discussed 
earlier, it is possible that differing ratios of oestrogen and prog­
esterone may mediate in the changing of relaxin*s role in pregnancy.
Some aspects of the relationships of other pregnancy hormones to> 
relaxin have been studied. Whereas the prolactin level does not 
affect relaxin levels in the rat (Schwabe et al .1978) prostaglandins 
do influence the action of relaxin in this and other animals. Prost­
aglandin synthetase inhibitors block the cervical ripening effect of 
relaxin in rats, suggesting that this action may be mediated by prost­
aglandins (Kennedy 1976). Indeed, injection of PGF201 in the pregnant 
sow induces a rapid increase in relaxin levels (Sherwood et al 1976), 
and recent studies on the rat suggest that PGF2 C1 causes cervical 
ripening indirectly by acting on the ovary to release relaxin.
However, in a clinical study of seven patients given intravenous PGF201 
a rise in serum level of relaxin was not detected (Hochman et al 
1978). PGF201 and relaxin, separately, produced similar cervical 
ripening effects in the human when administered vaginally at term 
(MacLennanet .al 1980; MacLennan & Green 1980), but no significant 
additive, synergistic or inhibitory effect occurred when they were
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given in combination (MacLennan 1981).
Lastly, with regard to controlling mechanisms, it is probable 
that the corpus luteum of pregnancy secretes relaxin in response to a 
fetal-placental stimulus soon after conception. Human chorionic gon­
adotrophin, prolactin and placental lactogen apparently fail to 
stimulate increased relaxin formation in incubations of human term 
corpora lutea (Schwabe et al 1978). However, injections of HCG in 
non-pregnant women will stimulate relaxin production if injected from 
8-10 days after ovulation (Quagliarello et al 1980). No detectable 
serum levels of relaxin are found when HCG injections are given 2-3 
days after ovulation. Thus, the age of the corpus luteum is an 
important determinant in the relaxin response to HCG and HCG may be 
the stimulus to relaxin production in human pregnancy.
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1.12 SPECULATION ON THE ROLES OF RELAXIN IN THE HUMAN
The first human clinical trials using purified porcine relaxin are 
described in this thesis and examine relaxin*s role in facilitating 
implantation, cervical ripening and in initiating labour near term.
This latter effect may be in response to its cervical ripening action.
Other roles for relaxin in the human are more speculative, the 
evidence being indirect and derived from animal models, iri vitro 
stqdies of. human tissues and; from.iheterologoiis RIA methods as 
described in Chapters 5, 6 and 7. This indirect evidence suggests 
that during pregnancy relaxin alters collagen biosynthesis in the 
reproductive tract to facilitate remodelling of these tissues. 
Specifically, relaxin may play an important part in (i) implantation, 
facilitating invasion of the decidual connective tissue by the 
developing trophoblast, (ii) uterine growth, allowing accommodation 
of the growing pregnancy by promoting remodelling of the uterine conn­
ective tissue and (iii) in the inhibition of myometrial activity until 
late pregnancy. Direct evidence of these postulated roles in the 
human is needed. Relaxin may have other roles related to its effect on 
collagen metabolism in human reproduction, as there is at least 
suggestive evidence that it may facilitate rupture of the follicle at 
ovulation (Chihal & Epsey 1973), enhance sperm penetration (Essig et 
al 1982) and, like its structural relatives, insulin and nerve growth 
factor, it could possibly be a fetal growth factor (Hall & Sara 1978). 
Relaxin*s relatively established and more speculative roles in mammals 
are tabultaed in Table 1. Lastly, relaxin may not be solely a hormone 
of pregnancy, as it has been detected in non-pregnant women, and men.
A role for relaxin that is not pregnancy-related has not been 
identified, but it could play a part in the control of connective 
tissue dynamics.
ESTABLISHED IN SOME SPECIES
1. Relaxation of pelvic ligaments near parturition
2. Uterine stromal remodelling during pregnancy
3. Inhibition of myometrial activity during pregnancy
4. Cervical ripening and facilitation of parturition
5. Mammary growth during pregnancy
6 . Enhancement of sperm motility
SPECULATIVE
1. Facilitation of follicle rupture at ovulation
2. Facilitation of blastocyst implantation
3. Fetal growth factor
4. Facilitation of fetal membrane rupture
5. Factor influencing skin collagen metabolism and collagen disorders
TABLE 1 m Possible biological roles of relaxin in mammals
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This thesis describes some of the candidatel s  ongoing studies on 
the role of relaxin in human reproduction and specifically describes 
relaxin levels in normal and abnormal human pregnancy in vitro,studies 
on the effect of relaxin on myometrial activity and the 
first clinical trials with pure porcine relaxin in the .areas of human 
embryo implantation, cervical ripening at term and the induction of 
labour.
C H A P T E R  2
THE PURIFICATION OF PORCINE RELAXIN
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2.1 INTRODUCTION
In each of the studies described in this thesis porcine relaxin 
was purified by thd methods described in this chapter. The method­
ology is based on extraction process of Sherwood and 0*Byrne (1974). 
This process finally gives three bioactive relaxin peaks (CMB, CMa 
and CMa*) on elution from a carboxymethyl cellulose column (Fig. 1 
Chapter 1). The complete porcine relaxin polypeptide contains .31 
amino acids in its B chain and this form is the main constituent of 
the CMa and CMa* peaks. The contiguous peaks are due to molecular 
variants with shorter B chains, e.g. B29 relaxin and B30 are^artefacts of 
the isolation procedure due to proteolysis occuring during purificat­
ion (Walsh and Niall, 1980).
To minimise proteolysis and obtain a single peak of B31 relaxin 
the method of Sherwood and 0fByrne has been adapted according to the 
method of Walsh and Niall (1980) (with minor modifications) where 
octadecylsilica columns are used in the elution process. All steps 
in the purification process described below were performed in a cold 
room (4°C) to minimise proteolysis.
2.2 COLLECTION OF OVARIAN TISSUE
Pregnant sow ovaries were snap frozen in liquid nitrogen within
two minutes of slaughter at the South Australian Metropolitan
\
Abattoir. The ovaries used were only collected from pigs whose 
carcases had been certified by Commonwealth Health inspectors as being 
appropriate for human consumption. The ovarian tissue was stored at 
-8 Q°C until further processing.
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2.3 PURIFICATION PROCESS
This process is summarised in Figure 6 .
Cl) Approximately 1 Kg of frozen pregnant sow ovaries were used in 
each purification process having been cut into 20G pieces. These 
pieces were individually homogenised for two minutes using a Dorvall 
Orini Mixer Homogeniser.
(2) Five ml of extraction buffer C0°C) per gram of tissue was added 
to the semi frozen homogenate.
Extraction buffer : 15% trifluroacetic acid (v/v)
5% formic acid (v/v)
1 % sodium chloride (w/v)
1M hydrochloric acid
(3) The homogenate was then centrifuged at 2,600 r.p.m. at 4°C for 30 
minutes and the precipitate discarded.
(4) The supernatant was then filtered through Whatman filter paper
(No. 541) and thereafter through a 0.45 y millipore filter.
(5) Three small disposable octadecylsilica (0DS,618) columns (Sep-
Paks, Waters Associates) were connected in series and equilibrated by 
pumping 30 ml of an 80% (v/v) acetonitrile, 0.1% (v/v) trifluoroacetic 
acid solution through them using a Master-flex peristaltic pump at 5 
ml/minute. The system was then washed through in a similar manner 
with 30 ml distilled water.
The effluent from the octadecylsilica columns was collected and 
pumped through the columns for a second time. During this process the 
columns became yellow-brown in colour from absorbed protein. They 
were then washed with 30 ml of a 10% (v/v) acetonitrile, 0.1% (v/v) 
trifluoroacetic acid solution and the effluent discarded.
(6 ) Relaxin and other ovarian peptides were then eluted from the
columns with 40 ml of the 80% acetonitrile, 0 .1 % trifluoracetic acid
-FIGURE 6  
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solution. Duting this process the yellow-brown discolouration is 
removed from the columns.
(7) The eluant was lypholysed to near dryness by rotary film evapor­
ation at 38°C.
(8 ) The lypholysed compound was reconstituted with 1-2 ml 0.01M 
ammonium acetate, pH 5.0, and applied to a 1.5 x 100 cm column of G5D 
Superfine Sephadex equilibrated with the same buffer.
(9) The fractions were collected overnight and the relaxin (mol. wt. 
6,300) is eluted as a peak at optical density 280 nM (Fig. 7 - Peak A). 
The column was developed at a rate of 0.5 ml/minute using a peristal­
tic pump and 1 ml fractions were collected. The relaxin activity as 
measured by bioassay (Chapter 3) and by radioimmunoassay (Chapter 4) 
elutes as a symmetrical peak of optical density (280 nM) at a 
position corresponding to a molecular weight of approximately 6 , 0 0 0  
daltons.
(10) The eluted peak was pooled and pumped directly onto a 10 mm x 10 
cm carboxymethylcellulose column equilibrated with 0.01M 'ammonium 
acetate, j>H 5.0, conductivity 0.6 mS. This column was developed with 
a linear salt gradient of ammonium acetate, pH 5.0, to a final con­
ductivity 15 mS, at a flow rate of 0.5 ml/minute.
(11) The purified relaxin eluted, at about 14 mS, conductivity, as a 
single peak (Fig. 8 - Peak B) which was pooled and dialysed against 
double distilled water.
(12) The resulting pure porcine relaxin was then lypholysed as in 
step 7 and stored at -80°C.
Using this method approximately 90-100 mg of pure porcine relaxin 
was produced from 1 Kg of mid to late pregnant sow ovaries and approx­
imately 500 mg of pure porcine relaxin was produced for the in vitro, 
animal and clinical trials described in this thesis. All batches of 
relaxin were subjected to the quality control procedures described in 
Chapter 2 (2.4).
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FIGURE 7 Porcine relaxin elutes as peak A on a Sephadex G50 column
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FIGURE 8 Porcine relaxin elutes as a single peak (B) on a carboxymethyl 
cellulose column.
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2.4 QUALITY CONTROL OF PORCINE RELAXIN PURIFICATION
2.4.1 Bioassay
At the end of step 9 in the previously described methodol­
ogy for the purification of porcine relaxin and after the final 
step the product was tested for relaxin activity using the rat 
myometrial activity inhibition bioassay and quantitatively in 
the rat myometrial bioassay of St. Louis (1981) as described in 
Chapter 3. The biopotency was compared to the reference 
preparation (NIH-R-PI) and to the reference preparation (CMa) 
used for the analysis of the primary structure and sequence 
studies of porcine relaxin (James et al 1977) which was kindly 
supplied by Prof. F.C. Greenwood, University of Hawaii. All 
batches used in the studies were of comparable biopotency to the 
reference preparations (Fig. 9).
2.4.2 Radioimmunoassay
Each batch was assayed by radioimmunoassay as described in 
Chapter 4. The activity of the porcine relaxin produced in our 
laboratories closely matched that of the reference preparations 
(Fig. 10).
2.4.3 Double Electrophoresis
Each batch was also subjected to double electrophoresis to 
further test for contaminants (Fig. 11). No batch showed 
evidence of negatively or positively charged contaminants, a 
sipgle spot remaining on the solvent front after double electro­
phoresis.
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relaxin purified for these studies compared to the NIH standard porcine 
relaxin when measured by the bioassay of St. Louis (1981).
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FIGURE 11 Double electrophoresis of porcine relaxin purified for these 
studies showing a single spot remaining on the solvent front and a lack of 
negatively or positively charged contaminants.
2.4.4 Bacteriological Testing
The relaxin used in the clinical trials was prepared by the 
hospital pharmacist aseptically in a sterile laminar air flow 
area by diluting the required amounts ( 1  or 2 mg) of relaxin in 
sterile water. This was subjected to millipore filtering and the 
dissolved relaxin was stored at 4°C in sterile vials. These were 
subjected to random sampling for bacterial analysis following the 
pharmaceutical protocols of the Australian National Biological 
Standards Committee. No batches showed any sign of bacterial 
contamination.
C H A P T E R  3
THE BIOASSAY OF PORCINE RELAXIN
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;j3il INTRODUCTION
Two assays were used. The first was used as a qualitative test 
for the presence of relaxin-like activity. However, because the 
spontaneous activity of myometrium declines with time the second assay 
is a better and more reproducible quantitative assay.
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3.2 THE INHIBITION OF SPONTANEOUS ACTIVITY IN RAT MYOMETRIUM
This assay involves the inhibiton of spontaneous uterine motility 
in vitro in specimens taken from oestrogen-primed rats and is based on 
the method of Wiqvist and Paul (1958) with minor modifications.
Virgin rats (200-250G) were primed with a single injection of 0.2 mg 
oestradiol valerate 24 h prior to decapitation. The uterine horns 
were removed and cut into 0.5-1.0 cm segments. Each segment was 
suspended in Earle*s solution by a cotton thread in a 15 ml double­
jacketed chamber. The solution was corrected to a physiological pH. 
Temperature was maintained at 37°C and there was a constant flow of 
95% oxygen and 5% carbon dioxide. Isometric contraction of each 
uterine segment was recorded on a Gibson polygraph calibrated to a 
tension of 1G. After the spontaneous contraction of the uterine 
segment had been established the presence of relaxin bioactivity could 
be detected by the addition of the unknown sample in varying concen­
trations to the Earle's solution in the chamber and the subsequent 
inhibition or diminution in the frequency and amplitude of the con­
tractions (Fig. 12). Each sample was run in triplicate and the return 
of myometrial activity confirmed after washing of the muscle with 
Earle's solution. Comparison of the effects of known relaxin 
standards could be performed but more precise quantitation of effect 
was found with the assay described below.
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FIGURE 12 Bioassay for the presence of relaxin-like activity involving 
the inhibition of spontaneous myometrial activity in the oestrogen-primed 
non-pregnant rat.
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3.3 THE INHIBITION OF KC1-INDUCED CONTRACTILITY IN RAT MYOMETRIUM
This is the bioassay described by St. Louis (1981). it also uses 
oestrogen-primed rat myometrium set up in a similar manner to the 
description in the previous bioassay. However, the chamber contains 
a 20% KC1 solution in physiological saline. This induces a tetanic 
contraction of the myometrium giving a stable plateau on the poly­
graph recording (Fig- 13). The dose response effect of a relaxant 
can be measured as a percentage of the reduction in the height of the 
plateau and these responses can be titrated against known standard 
concentrations of pure relaxin.
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FIGURE 13 Bioassay of St. Louis (1981) for relaxin—like activity 
involving the inhibition of a KC1—induced tetanic contraction of oestrogen- 
primed rat myometria. The arrows pointing downwards represent the addition 
of increasing concentrations of the relaxin being studied, which quantit­
atively decreases the amplitude of the contraction.
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4.1 INTRODUCTION
As yet no homologous human relaxin radioimmunoassay has been 
developed due to the difficulties in obtaining sufficient amounts of 
human relaxin as described in the Introduction to this thesis and in 
the Final Discussion. However, a homologous porcine relaxin radio­
immunoassay which appears to recognise human relaxin has been 
described by 0*Byme and Steinetz (1976). This assay using the same 
antibody was set up in the author*s laboratory for the studies 
described in this thesis. The ratio of biological to immunological 
activity is 1.3-4.4 to 1 .(0*Byrne et al 1978).
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4.2 REAGENTS
(1) Assay Buffer 0.5 phosphate buffered saline, pH 7.4, with 5% 
bovine serum albumen.
(2) Standard Porcine Relaxin Pure porcine relaxin (B31) as
purified in Chapter 2 of this thesis.
(3) Control Plasma Ovariectomised female plasma from the same
species as the unknown samples. ■
(4) Antibody Rabbit anti-porcine relaxin serum (R6 as kindly 
supplied by Dr. E.M. O’Byme, New York). The cross-reactivity and 
specificity of this antibody for relaxin-like substances in the blood 
of various mammalian species including the pig and the human have 
been published (O'Byrne and Steinetz 1976 & O'Byrne et al 1978).
(5) Antibody Diluent Buffer 0.05M of ethylenedinitrilo-tetraacetic
acid, pH 7.4 with 2% normal rabbit serum.
(6 ) Relaxin Derivative for Radio-iodination N-a-formyl-tyrosyl- 
relaxin was kindly supplied by Dr. Christian Schwabe, U.S.A. As 
discussed in the Introduction, porcine relaxin does not have any iod- 
inatable amino: acid'residues and therefore an iodinatable relaxin 
derivative must be synthesised. N-ia-formyl-tyrosyl-relaxin has been 
found to be a reliable and reproducible tracer for relaxin radioimmuno­
assay (Schwabe 1983).
(7) Second Antibody Goat antibody to rabbit gamma-globulin (Cal- 
biochem) was used. 125 units were dissolved in 25 ml of assay buffer.
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4.3 PROCEDURES
(1) Radio-iodination of the Relaxin Derivative 1 milli Curie of 
Ii 2 5  was added to 5 yg of N-a-formyl-tyrosyl-relaxin per 5 yL of 
distilled water followed by freshly prepared chloramine T solution (50 
yg in 10 yL of 0.05M phosphate buffer, pH 7.5). After shaking for 10 
seconds, freshly prepared sodium metabisulfite (100 yg in 10 yL phos­
phate buffer) was added followed immediately by potassium iodide 
solution (1 mg in 100 yL phosphate buffer). Separation of the iodin- 
ated relaxin from the free Nali 2 5  was accomplished by gel filtration 
on a 0.5 x 20 cm column of Sephadex G-25 (medium) presaturated with 2% 
bovine gamma globulin in 0.05M phosphate buffer, pH 8 . 6  and eluted 
with phosphate buffer. Fractions of 0.5 ml were collected and the 
fractions with the highest binding as measured in the RIA were used.
(2) Radioimmunoassay Procedure All glassware used during the
procedure was siliconised to reduce any binding of relaxin to the
glass and all assays were performed in triplicate.
(.a)^  Standard porcine relaxin in quantities of 0, 1, 4, 16, 64,
256 and 1024 ng/ml diluted to 200 yL with assay buffer was added 
to the standard curve tubes.
(b) 200 yL of assay buffer alone was added to 100 yL of the
samples to be assayed and a similar amount of buffer was added
to non-specific binding control tubes which contained 200 yL of 
antibody diluent buffer.
(c) An equal volume (200 yL) of control plasma was added to the 
standard curve tubes and the non-specific binding control tubes.
(d) Antibody (R6 ) in quantities of 200 yL at a dilution of 1 in 
5,000 in diluent buffer was added to the standard curve tubes and 
unknown samples bring thd final volume in each tube to 600 yL.
(e) The solutions were mixed gently and incubated for 24 h at 4°C.
Cf) 100 yL of radio-iodinated relaxin (containing 25,000 counts 
per minute) was added to each tube in the assay, gently mixed and 
incubated for a further 24 h at 4°C.
(3 ) On the third day, 200 yL of second antibody was added to 
each tube, mixed and again incubated at 4°C for 24 h.
(h) Thereafter, the tubes were centrifuged at 2,500 r.p.m. at 
4°C. The supernatant was siphoned off and the remaining pellet 
was counted in a Beckman gamma-counter. The relaxin concentrat­
ion in the unknown samples were determined by interpolation from 
a least square regression line of logit (B/B0) versus log 
concentration of a standard relaxin according to the linear 
equation of Rodbard et al (1969).
Logit (B/B0) = b. log (X) + a 
where B is counts bound, B0  is counts bound for zero dose, X is 
the hormone concentration, a and b are constants. N (non­
specific counts) determined by the omission of the antibody to 
the non-specific binding control tubes were subtracted from the 
B and B0  before logit transformation.
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4.4 DETAILS AND VALIDATION OF ASSAY
A standard curve obtained during this radioimmunoassay is shown 
in Figure 14.
The dose-response curve was linear over the range of 1 to 64 ng/ 
ml. The mean slope of the dose-response curve was b = 2.25 (n - 10). 
The least detectable dose as defined by two standard deviations of 
percentage binding at the zero point was approximately 12.5 pg of 
relaxin. The between-assay and the within-assay coefficients of 
variation of the radioimmunoassay were 38.0% (n = 10) and 9.5% (n - 
10) respectively. Porcine and human insulin, prolactin, FSH, LH and 
TSH showed no cross-reactivity with this assay.
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FIGURE 14 A standard curve obtained during the radioimmunoassay of 
porcine relaxin used in these studies.
C H A P T E R  5
SERUM RELAXIN LEVELS IN 
NORMAL HUMAN PREGNANCY
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5.1 SUMMARY
In a cross sectional study of 330 normal singleton human pregnan­
cies the relaxin-like immunoactivity in peripheral serum was measured 
in a porcine relaxin radioimmunoassay. Serum relaxin concentrations 
were highest in early pregnancy and gradually declined until term. At 
term, patients in labour had a significantly higher mean relaxin con­
centration compared to patients who were not in labour. No significant 
rise in relaxin levels could be detected in patients sampled during the 
week prior to the spontaneous onset of labour. After term there was a 
continuing significant decline in relaxin concentrations in patients 
who were not in labour. By the third postnatal day relaxin concentrat­
ions had fallen almost to the level of the non-pregnant control group. 
This pattern of relaxin secretion is compatible with the postulated 
roles of relaxin during human pregnancy with regards the maintenance of 
myometrial quiescence, the facilitation of uterine stromal remodelling 
during uterine growth and the promotion of cervical ripening at the 
onset of parturition.
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5.2 INTRODUCTION
In mammals it is postulated that the polypeptide hormone relaxin 
promotes connective tissue remodelling during reproduction, inhibits 
myometrial contractility until late pregnancy and facilitates the 
progress of cervical ripening at the initiation of parturition (Mac- 
Lennan 1983). Relaxin is secreted from the human corpus luteum of 
pregnancy but may also be produced by the human decidua and the basal 
plate of the placenta (Larkin, Pardo & Renegar 1983). Human relaxin 
has recently been characterised but is not yet available for the 
development of a human relaxin radioimmunoassay. However, a homolog­
ous radioimmunoassay using porcine relaxin antisera has been establish­
ed (0*Byrne & Steinetz 1976). There have only been a few reports 
(O'Byrne et al 1978; Quagliarello et al 1979; Szlachter et al 1982; 
Scarselli et al 1983) of this assay’s application in the human. In 
most animals there is a rise in serum relaxin levels prior to or at 
the beginning of parturition but as yet this has not been described in 
the human.. The purpose of this study is to establish relaxin levels 
throughout normal human pregnancy as measured in a porcine relaxin 
radioimmunoassay and to compare these levels to those obtained in 
other human and animal studies using similar assays.
5.3 PATIENTS AND HETRODS
Permission for this study was obtained from the Research and 
Ethics Committee of The Queen Victoria Hospital, Adelaide and all 
samples were obtained with informed patient consent. Three hundred 
and thirty serum samples were collected throughout pregnancy from 6 to 
42 weeks gestation and on the third postnatal day. Eleven further 
control samples were collected from non-pregnant healthy premenopausal 
patients. The samples collected during pregnancy were grouped in 
weekly brackets and only samples from patients with a normal singleton 
pregnancy and a gestational age confirmed by early ultrasound were 
included in the study. The study was a cross sectional study and the 
number of samples per individual patient ranged from 1 to 4. Forty- 
four of the patients between 38 and 41 weeks laboured spontaneously and 
the timing between sampling and the onset of labour was calculated in 
these patients.
All samples consisted of 10 ml of clotted blood which was centri­
fuged and the serum frozen at -80°C for subsequent radioimmunoassay.
The antibody used was R6 rabbit antiporcine relaxin which has been used 
to measure immunoreactive relaxin in women CO*Byrne & Steinetz 1976), 
the tracer used was N-a-formyl-tyrosyl-relaxin (Schwabe 1983) and the 
second antibody was goat antibody to rabbit gammaglobulin (Calbiochem) . 
The sensitivity of the assay was 12.5 pg. The between-assay and the 
within-assay coefficients of variation of the radioimmunoassay were 38 
and 9.5 percent respectively. The data are expressed as nanogram per 
millilitre equivalents of porcine relaxin. The mean values for each 
gestation have been calculated + standard deviation of the mean.
Groups were compared by the Student (two tailed) t-test.
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5.4 RESULTS
Serum levels of relaxin during human pregnancy as measured in the 
porcine relaxin radioimmunoassay are shown in Figure 15. Relaxin levels 
(mean + S.D.) appeared to rise early in pregnancy and the levels were 
higher in the first half of pregnancy (6-20 weeks) (0.69 + 0.31 ng/ml) 
than in the second half of pregnancy (21-40 weeks) (0.48 + 0.18 ng/ml) 
(p<0.001). Patients who were not in labour at 41 and 42 weeks gestation 
had significantly lower mean serum relaxin levels (0.28 + 0 . 1 0  ng/ml) 
than the levels recorded during the second half of pregnancy (p<0 .0 Ql). 
Overall relaxin levels declined throughout pregnancy (6-40 weeks) and 
a line of regression with a significant negative correlation was 
obtained (r= -0.42) (pcO.OOl).
Patients in labour had a significantly higher mean + S.D. relaxin 
level (0.59 + 0.33 ng/ml) than either the mean relaxin level of 
patients in the second half of pregnancy (p<0.05) or patients at 40 
weeks gestation (0.39 + 0.13 ng/ml) (p<0.01). The highest relaxin 
levels during labour were recorded in patients in early labour.. Of 
the 44 patients sampled near term to determine relaxin levels close to 
spontaneous parturition, 24 spontaneously laboured within one week of 
the sampling and their individual levels are shown in Figure 16, plotted 
by days prior to parturition. The mean + S.D. relaxin level of this 
group was 0.36 + 0.14 ng/ml and was not significantly different from 
the mean of the remaining 2 0  patients who did not labour within one 
week of sampling (0.35 + 0.15 ng/ml). No significant t:rend was noted 
in the relaxin levels in the days prior to labour but only two samples 
were obtained within 24 h of the spontaneous onset of labour.
Samples obtained on the third postnatal day (mean + S.D. 0.19 + 
0.15 ng/ml) were significantly lower than during the second half of 
pregnancy (p<0 .0 0 1 ) as were the control samples from the non-gravid
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Figure 15 Mean immunoreactive relaxin levels (+ S.E.) in the serum
of women throughout the course of pregnancy until the third postnatal
day. The line of regression (r) has been plotted and mathematically 
expressed.
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Figure 16 Individual serum relaxin concentrations in patients who 
laboured within 7 days of sampling plotted by days prior to the onset 
of spontaneous labour.
patients (mean + S.D. 0.(38 + 0,1 ng/ml) (p<0.001).
No obstetric pathology or abnormal obstetric outcome could be 
correlated with the pregnancies in which high or low relaxin levels of 
relaxin were obtained.
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5.5 DISCUSSION
The pattern of peripheral relaxin levels in early and mid 
pregnancy in this study closely matches the two main published studies 
of O'Byrne et al (1978) and Quagliarello et al (1979) both of which 
used a similar porcine relaxin radioimmunoassay. The actual levels (in 
porcine equivalents) of relaxin in this study are very similar to those 
published by O'Byrne et al (1978). Quagliarello et al (1979) reported 
levels approximately two-fold higher than those in this study. Both 
these previous studies suggested that relaxin levels remained stable in 
the • third trimester after a drop in mid pregnancy, whereas the data in 
this study suggests there is a continuing slow decline in peripheral 
serum reldxin levels after a peak is reached early in the second tri­
mester. Serum relaxin levels dropped significantly further after term 
in this study and this finding is in keeping with thd report by 
Szlachter et al (.1982) who found a reduction in serum relaxin in 
pregnancies beyond 43 weeks gestation. The rapid drop in relaxin levels 
in the'postnatal period is consistent with the findings of other studies 
and was not affected by lactation.
A rise in peripheral relaxin levels has been described in almost 
every species studied prior to parturition but no previous human study 
has shown a rise in serum relaxin before or during labour. This is the 
first human study to show a significant rise in peripheral relaxin 
levels at parturition. However, this was a cross sectional study and 
the findings should be confirmed in a serial study. There are practical 
difficulties in anticipating spontaneous human parturition and obtaining 
frequent serial samples around this time. Ideally serial samples should 
be collected hourly rather than daily as the rise in serum relaxin may 
be very brief. The cross sectional study described in this paper failed 
to show any significant rise during the week prior to labour. Serial
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daily samples from 3 patients sampled one to four days prior to labour 
by Quagliarello et al (1979) also showed no rise in relaxin levels. In 
this study the highest levels were obtained in very early spontaneous 
labour and the results of adequate serial sampling in the human at 
this time have yet to be published.
The significantly higher relaxin levels found in the patients in 
early labour compared with their term non-labouring counterparts is in 
keeping with the pattern in other animals where there is a surge in 
relaxin immediately before or during early labour. This surge in 
relaxin correlates with an increase in cervical softening and dilatat­
ion in most animals and it is postulated that one of relaxin's main 
roles is to facilitate parturition by promoting connective tissue re­
modelling in the cervical tissues. In the human, exogenous porcine 
relaxin applied vaginally at term can induce such cervical ripening 
and in some instances initiate parturition (MacLennan et al 1980).
Further postulated roles for relaxin are that it may facilitate 
uterine stromal remodelling allowing growth and distension of the 
uterus and that along with progesterone, it may promote uterine 
quiescence during pregnancy by inhibiting myometrial contractility 
(Chapter 10). The pattern of its secretion as described in this paper 
would be compatible with such roles, the levels of relaxin being 
highest in early pregnancy and gradually declining until parturition.
In the-i.rat relaxin inhibits both spontaneous and prostaglandin induced 
myometrial contractility but does not inhibit oxytocin induced myo­
metrial contractility (Porter, Downing & Bradshaw 1979). The synthesis 
of human relaxin is awaited to see if this is also true in the human. 
Should a similar mechanism of action be shown, then a rise in relaxin 
levels at parturition facilitating cervical ripening would not inhibit 
myometrial contractility in a uterus responsive to oxytocin due to the 
induction of oxytocin receptors in the myometrium at term.
The significance of the findings in this study depends on the 
validity of the heterologous application of this homologous porcine 
radioimmunoassay and on whether peripheral serum levels truly reflect 
local activity at thd site of action. There is only approximately a 
50 percent homology in the .amino acid sequences between porcine and 
human relaxins (Hudson et al 1983). The synthesis of human relaxin and 
the development of a human relaxin radioimmunoassay is awaited.
However, until then, in trying to define the role of relaxin in human 
reproduction, it is useful to have an understanding of the possible 
pattern of relaxin secretion during normal pregnancy and to look for 
changes in these patterns in pathological pregnancies, e.g. premature 
labour.
C H A P T E R  6
THE RELATIONSHIP OF THE HORMONE RELAXIN TO 
PELVIC PAIN AND JOINT LAXITY IN HUMAN PREGNANCY
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6.1 SUMMARY
Peripheral serum relaxin levels were measured in a porcine relaxin 
radioimmunoassay in 17 patients with severe pelvic pain and pelvid .joint 
instability during late pregnancy. These results were compared to a 
control group of 330 samples obtained throughout pregnancy from normal 
singleton pregnancies. The majority of the serum relaxin concentrations 
of the study group were above but within 1 S.D. of the mean for the 
corresponding gestational age of the control group. The mean relaxin 
concentration (0.63 ng/ml) of the patients with pelvic symptoms was 
significantly higher than the mean relaxin concentration of the normal 
patients during the second half of pregnancy (0.48 ng/ml) (p<0.005). 
Three patients had relaxin concentrations more than 2 S.D. from the 
mean of the normal patients for the corresponding gestational age and 
these patients were amongst the most clinically disabled. The three 
highest levels of relaxin in the study group were higher than any in 
the 163 patients in the control group sampled during the second half of 
pregnancy.w This study suggests that in some patients higher than 
normal relaxin levels may be ^ associated with and be responsible for 
excessive pelvic joint laxity and pelvic pain in ldte pregnancy.
6.2 INTRODUCTION
A major degree of separation of the pubic rami due to increased 
compliance of the connective tissues in the pubic symphysis happens 
only in species such as Rodents where the ratio of the diameters of 
the maternal pelvis and the fetal head is too small to allow normal 
delivery without such a separation. In the human the ratio of thdse 
diameters is sufficiently large that separation of the pubic symphysis 
is not normally necessary. It has been estimated, using radiological 
techniques, that there is only a mean 7>'imm increase in vertical 
stretching and a mean 3 mm increase in lateral stretching of the 
hdman pubic symphysis during pregnancy (Farbrot 1952). However, a 
minority of women in pregnancy experience severe pelvic pain in both 
the pubic symphysis and the sacroiliac joints. A proportion of these 
patients have clinically apparent joint instability and laxity and 
they may be unable to walk during the end of pregnancy. There have 
been no specific studies on pelvic joint laxity in pregnancy and 
radiological studies are not now acceptable. However, increased peri­
pheral joint laxity has been reported in the third trimester of 
pregnancy with an increase in laxity associated with multiparity 
(Calguneri, Bird & Wright 1982).
In rodents such as the guinea-pig and the mouse there is a rise 
in serum relaxin prior to the onset of parturition which is associated 
with separation of the pubic symphysis (Hisaw 1926). This separation 
can also be induced by the injection of exogenous relaxin in the 
oestrogen-primed animal. However, no correlation has yet been pubr-.. 
lished between relaxin levels in the human and pubic symphysial pain 
and laxity. The aim of this study was to measure peripheral serum 
relaxin levels in patieilts with major degrees of pelvic joint pain aid 
laxity during late pregnancy and compare these results to the levels
found in normal pregnancy using the same porcine relaxin radioimmuno­
assay (Chapter 5).
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6.3 PATIENTS AND METHODS
Permission for this study was obtained from the Research and 
Ethics Committee of The Queen Victoria Hospital, Adelaide. Patients 
were included in the study only when their complaint of pelvic joint 
pain was sufficiently incapacitating to necessitate prolonged bed 
rest in hospital or at home. Most of these patients had major 
problems in walking and all cases were assessed by a physiotherapist 
who performed lateral flexion tests with the patient standing on 
alternate legs. During these tests pubic symphysial pain was repro­
duced or exacerbated and joint instability was Apparent. An accurate 
clinical scoring system to assess the degree of pelvic pain and joint 
instability could not be validated. However, only patients with 
severe incapacitating pelvic joint pain associated with clinically 
apparent joint instability have been included in the study. A single 
serum sample was obtained from 16 patients, and three antenatal 
samples were obtained from a further patient who appeared to be more 
severely^incapacitated than the other patients, in that she was 
hospitalised for the last 14 weeks of her pregnancy and was unable to 
walk during that time. Postnatal samples were obtained from three of 
the patients. Only the mean antenatal relaxin levels of the patient 
sampled more than once has been included in calculating the mean serum 
relaxin level of the total group. Students (two tailed) t-test was 
used to compare the mean relaxin level of the pelvic pain group to 
that in normal pregnancy as assayed in the same radioimmunoassay 
(Chapter 5). The assay used was a homologous porcine radioimmunoassay 
as described previously CChapter 4) using R6 rabbit antiporcine 
relaxin serum for the antibody (O'Byrne & Steinetz 1976), N-a-formyl- 
tyrosyl-relaxin as the tracer (Schwabe 1983) and goat antibody to 
antirabbit gammaglobulin (Calbiochem) as the second antibody. The
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within assay coefficient of variation was 9.5 percent and the sensit-. 
ivity of the assay was 12.5 pg. All samples from the patients with 
pelvic pain were measured in the same radioimmunoassay together with 
control samples from patients in the normal pregnancy group.
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6.4 RESULTS
The serum relaxin concentrations in patients with pelvic pain are 
shown in Figure 17 and are compared to the levels previously described 
in normal pregnancy (Chapter 5). The mean (+ S.D.) relaxin concen­
tration of the patients with pelvic joint pain was 0.63 + 0.25 ng/ml 
and was significantly higher than the mean concentrations of relaxin 
in normal patients during the second half of pregnancy (0.48 + 0.18 
ng/ml) (p<0.005). The relaxin concentration in only 1 pelvic pain 
patient was below the mean for the second half of pregnancy in the 
normal group. Three study patients had levels more than 2 S.D. above 
the corresponding mean of the control group. These three patients 
had relaxin levels higher than any of the 163 samples taken from 
normal singleton pregnant patients during the second half of pregnan­
cy. The patient who was thought clinically to have the greatest 
degree of pelvic joint pain and instability had the highest relaxin 
levels (1.15 to 1.39 ng/ml). In the three patients sampled postnat- 
ally relaxin concentrations had returned to normal non-pregnant levels.
Amongst the 163 samples obtained between 21 and. 40 weeks gestat­
ion from normal pregnancies only 5 samples had relaxin concentrations 
(range 6 6  bo 8 6  ng/ml) which were greater than 2 S.D. from the mean 
for that gestation. None of these patients complained of major 
degrees of pelvic pain and none required hospitalisation for pelvic 
problems.
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FIGURE 17 Serum relaxin concentrations in 17 patients with pelvic 
joint pain and laxity Co) plotted in comparison to the mean (+ S.E.) 
levels at each week of gestation found in normal patients (Chapter 5). 
Samples from the same patient are connected by dotted lines (red).
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6.5 DISCUSSION
Although the mean serum relaxin concentration in the patients 
with pelvic pain and joint laxity was significantly higher than the 
control group, only 3 patients had very high serum relaxin concent­
rations. However, only 1 patient in the study group had a relaxin 
concentration below the mean for the control group during the second 
half of pregnancy. Moderately high levels of relaxin, e.g. 6 6  to 8 6  
ng/ml in the control group were not associated with major evidence of 
pelvic symptoms, hospitalisation or incapacity on retrospective 
analysis of their obstetric history. Minor degrees of pelvic pain 
and joint laxity were not assessed in this study but clearly not all 
patients with higher than normal relaxin levels in pregnancy complain 
of pelvic joint instability and pain. Equally not all pregnant 
patients with pelvic pain have clinically apparent joint laxity and 
there are many other causes of such pain, e.g. nerve compression, 
urinary tract infection, etc. A difficulty experienced in this study 
was the quantification of pain and pelvic joint laxity and a quantit­
ative scoring system of these symptoms and signs could not be valid­
ated. Nevertheless, the patient with the highest relaxin levels 
required tfe longest hospitalisation and the other 2 patients with the 
very high serum relaxin levels required admission to hospital and 
were unable to walk at the end of their pregnancy. All gradually 
recovered postnatally. In the 3 patients sampled postnatally the 
relaxin levels had,fallen to levels below the sensitivity of the assay.
Peripheral serum relaxin levels may not be as relevant as 
relaxin receptor levels and it may be that some patients are more 
susceptible to circulating or local concentrations of relaxin if a 
high level of receptors have been induced in the connective tissue of 
the pubic symphysis and sacroiliac joints. This might explain why the
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patients in the control group who had moderately high relaxin levels 
did not have symptoms. No human studies have been performed on 
relaxin receptors in these tissues but relaxin receptors have been 
described in fibroblasts taken from the mouse pubic symphysis (Bryant- 
Greenwood 1982). The induction of relaxin receptors is thought to be 
under the influence of oestrogen. The increase in theiwidth of pubic 
symphysis in the mouse during pregnancy involves the erosion of 
cartilage and bone and the transformation of the hyaline cartilage caps 
to fibrous connective tissue. These morphological changes in the 
pubic symphysis can be experimentally reproduced by the injection of 
relaxin if tKemouse has been previously primed with oestrogen (O'Byme 
et al 1982).
This study shows that some patients with pelvic pain and laxity 
of their pelvic joints have much higher than normal peripheral serum 
relaxin levels as measured in a porcine radioimmunoassay during 
the second half of pregnancy and suggests that these high relaxin 
levels may be responsible for their excessive pelvic joint instability 
and pain^during the latter months of pregnancy. The validity of 
relaxin-like immunoactivity in human serum as measured in a porcine 
relaxin radioimmunoassay requires confirmation when a specific human 
relaxin radioimmunoassay is available. Thereafter, studies are 
required to determine why relaxin levels are high in patients with 
pelvic pain and excessive joint laxity and whether relaxin levels can 
be safely lowered, e.g. with antiprostaglandin agents, with clinical 
effect.
C H A P T E R 7
RELAXIN LEVELS IN MULTIPLE PREGNANCY., 
PREMATURE LABOUR, PRE-ECLAMPSIA, 
NORMAL NEONATES AND NEONATES WITH 
CONGENITAL DISLOCATION OF THE HIP.
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7.1 SUMMARY
Peripheral serum relaxin levels, as measured in a porcine relaxin 
radioimmunoassay, in normal singleton pregnancies were compared to 
relaxin concentrations in the serum from patients with multiple 
pregnancy, premature labour and pre-eclampsia and to serum relaxin 
concentrations from the umbilical cord of normal neonates and neonates 
with congenital dislocation of the hip. The mean relaxin concentrat­
ion (0.70 ng/ml) of 11 patients with a multiple pregnancy sampled in 
late pregnancy was significantly higher (p<0 .0 0 1 ) than the mean for 
normal singleton pregnancies at the same gestation (0.48 ng/ml).
Eight patients in premature labour had a significantly lower mean 
relaxin concentration (0.29 ng/ml) than the control group who were not 
in premature labour (p<0.005). The mean relaxin concentration of 14 
patients with moderate to severe pre-eclampsia was not statistically 
significant from the control group. Umbilical cord serum samples from 
both normal neonates and those with congenital dislocation of the hip 
were all measured as being below the sensitivity of the assay. This 
suggests that there is little transfer of maternal relaxin to the 
fetus and that an association between high fetal relaxin levels and 
congenital dislocation of the hip could not be substantiated.
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7.2 INTRODUCTION
There have been very few reports of relaxin concentrations in 
abnormal pregnancy. Szlachter et al (1982) reported that relaxin 
levels in third trimester multiple pregnancies and in pre-eclampsia 
were not different from normal pregnancy but were lower in patients in 
premature labour. Whilst it has been postulated that congenital dis­
location of the hip may be caused by high relaxin levels, relaxin 
levels have never been studied in this condition. In this study peri­
pheral serum relaxin concentrations were measured in four perinatal 
pathologies using the same homologous porcine relaxin radioimmuno­
assay and compared to the concentrations of relaxin found in normal 
singleton pregnancy as described in Chapter 5.
Relaxin levels were measured in the following circumstances:
(a) multiple pregnancy
(b) premature labour
(c) pre-eclampsia, and
(d) umbilical cord samples from normal neonates and neonates with 
congenital dislocation of the hip.
There has only been one report in the literature of the measure­
ment of relaxin in fetal blood (Weiss et al 1978). In that study, 
using a similar heterologous application of a porcine relaxin radio­
immunoassay, relaxin was only just detectable in 1 of 1 0  cord blood 
serums tested. The sensitivity of that assay was reported as 50-100 
pg. As the sensitivity of the radioimmunoassay reported in this study 
was lower (12.5 pg) 40 cord blood sera were studied in normal 
pregnancies with a normal neonatal outcome and 18 cord blood sera 
were examined in babies who were found to have unilateral or bilateral 
congenital dislocation of the hip in the neonatal period.
Although the aetiology of this latter condition is un-
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known there is suggestive evidence that hormonal factors during 
pregnancy may cause fetal hip joint laxity and interfere with the 
normal development and formation of the fetal hip joint (Wilkinson 
1963).
9 . 2 ,
7.3 METHODS AND RESULTS
Multiple pregnancy
One serum sample was obtained from each of ten twin pregnan­
cies and one triplet pregnancy between 30 and 38 weeks gestation. 
The results are shown in Table 2 and Figure 18. The mean .(+ S.D.) 
concentration of relaxin in these multiple pregnancies was 0.70 + 
0^ .21 ng/ml. This was significantly higher than the mean concent­
ration CO.48 + 0.18 ng/ml) of relaxin in normal singleton preg­
nancies during the second half of pregnancy (p<0 .0 0 1 ).
Premature labour
A single serum sample was obtained from 8  patients in pre­
mature labour. Premature labour was defined as regular contract­
ions, as recorded by an electronic abdominal pressure transducer, 
occuring every ten minutes or less associated with effacement and 
dilatation of the cervix before the completion of the 37th week 
of pregnancy. Other pregnancy complications frequently occur 
with this group of patients and they are recorded in Table 4 
along with the time of delivery in relation to the time the 
serum samples were obtained.
The serum relaxin concentrations of patients in premature 
labour are shown in Table 3 and they were all below the regress­
ion line for patients with normal ongoing pregnancies (Figure 19). 
The mean relaxin concentration (_+ S.D.) of the premature labour­
ing patients was 0.29 + 0.14 ng/ml. This was statistically 
significantly lower than the mean relaxin concentration for the 
control group during the second half of pregnancy (p<0.005).
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FIGURE 18 Serum relaxin concentrations in patients with a multiple 
pregnancy (red squares) plotted in comparison to the mean (+ S.E.) levels 
at each week of gestation found in normal singleton pregnancy (Chapter 5).
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FIGURE 19 Serum relaxin concentrations in patients in premature labour (blue) 
plotted in comparison to the mean (+ S.E.) levels at each week of 
gestation found in normal pregnancy (Chapter 5).
PREGNANCY GESTATION RELAXIN CONCENTRATION 
ng/ml x 1 0 0
Twin 30 75
Twin 32 62
Twin 32 50
Twin 34 1 1 2
Twin 36 45
Twin 37 57
Twin 37 79
Twin 37 75
Twin 37 103
Twin 38 52
Triplet 32 50
TABLE 2 Individual serum relaxin concentrations in 11 multiple 
pregnancies sampled during the third trimester
PREGNANCY COMPLICATIONS GESTATION RELAXIN CONCENTRATION
In relation to date of sampling At sampling ng/ml x 100
Intrauterine death approximate­
ly 2 days prior to sampling 2 2 2
Antepartum haemorrhage one week 
prior to sampling. Delivered 
live baby one day later. 25 37
Antepartum haemorrhage on day 
of sampling. Delivered still­
born child five days later. 25 31
Delivered live baby 6 hours 
after sampling. 30 19
Delivered by caesarean section 
2 hours after sampling. 32 39
Premature labour inhibited for 
3 further weeks. 32 46
Delivered a growth retarded 
baby 8 hours after-sampling. 35 38
Delivered 2 days later 36 2 0
TABLE 3 '; Individual serum relaxin concentrations in 8 patients 
defined as being in premature labour at the time of sampling.
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Pre-eclampsia
A single serum sample was obtained from 14 patients with 
moderate or severe pre-eclampsia between 29 and 38 weeks gestat­
ion, In this study pre-eclampsia was defined as pregnancy 
induced hypertension greater than 100 mm Hg diastolic blood 
pressure, associated with proteinuria and/or oedema. The results 
are shown in Table 4 . The mean (+ S.D.) concentration of relaxin 
in the pre-eclamptic patients was 0.56 + 0.16 and was not 
statistically different from the mean of the normal control 
patients in the second trimester.
Umbilical cord levels in normal neonates and neonates with con­
genital dislocation of the hip
Relaxin concentrations in both groups ranged from zero to
0 . 1 2  ng/ml and thus all the relaxin concentrations were below 
the sensitivity of the assay. The mean + S.D. for the normal 
babies was 0.048 + 0.041 ng/ml and the mean for the babies with 
congenital dislocation of the hip was 0.043 + 0.044 ng/ml. 
Statistical analysis was not performed as all the levels were 
below the sensitivity of the assay.
GESTATION RELAXIN CONCENTRATION
ng/ml x 1 0 0
29 56
31 59
32 67
32 6 8
32 60
33 38
34 36
34 70
35 69
36 „ 8 6
37 30
37 43
38 63
38 39
TABLE 4 Individual serum relaxin concentrations in 14 singleton 
pregnancies with moderate to severe pre-eclampsia
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7.4 DISCUSSION
Multiple pregnancy
In this study of third trimester multiple pregnancies 10 
the 1 1  patients had serum relaxin concentrations above the mean 
of the control singleton pregnancies at the same gestation. 
Although in the only other report of relaxin levels in multiple 
pregnancy Szlachter et al (1982) did not find a statistically 
significant rise in the relaxin concentration of twin pregnant, 
cies in the third trimester they did report high levels in 2  
triplet pregnancies and very high levels in one mid trimester 
pregnancy before the patient aborted 9 fetuses.
The results of the study reported in this thesis and the 
later data of Szlachter et al suggest that serum relaxin con­
centrations in the human are related to the amount of corpora 
luteal tissue present and possibly the amount of placental 
tissue present as this is another site of relaxin production. In 
the^sow, Martin et al (1979) has shown that serum relaxin con­
centrations are related to the number of corpora lutea present 
and the results in this human study are in keeping with the find­
ings in the pig. However, serial samples from early in multiple 
pregnancy would help to confirm or refute the data in this study.
Premature labour
As will be discussed in later chapters relaxin in conjunct­
ion with progesterone inhibits myometrial contractility during 
some or all of pregnancy in the rat and the pig. In these 
animals relaxin appears to play a major role in maintaining 
uterine quiescence during pregnancy. Access to human relaxin is 
awaited to test the hypothesis that relaxin in the human also
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inhibits myometrial contractility until late in pregnancy. It 
is, therefore, of interest to note that many of the serum relaxin 
concentrations in patients in premature labour were low and all 
were below the mean for the control group at similar gestations. 
This is in agreement with the findings of Szlachter et al (1982). 
Only 8  patients in premature labour have been sampled so far in 
this study as this is the beginning of a further 3 year study and 
baseline levels have had to be established for normal non-labour­
ing patients. The study of premature labour also presents major 
problems for the clinical researcher as firstly the definition of 
clearly established progressive premature Mbour can be difficult 
and secondly many patients with premature labour have other 
associated pathologies as can be seen in the patients sampled in 
this study. Therefore the collection of large numbers of 
patients for this study will take time. There will be merit in 
future studies in measuring the serum progesterone and oestrogen 
as well as serum relaxin to look'for correlations in the ratios 
of these hormones and premature labour. In particular,- a 
specific human relaxin radioimmunoassay will be helpful to 
validate any possible association with low relaxin levels and 
premature labour. However, these initial pilot studies using the 
homologous porcine radioimmunoassay suggest that there may be 
such, an association.
Pre-eclampsia
No difference was found in the mean relaxin concentration of 
patients with pre-eclampsia and normal patients. This is in 
keeping with the findings of the only other similar report by 
Szlachter et al (1982) and suggests that there is no apparent 
link between abnormal relaxin secretion and pre-eclampsia. It
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also suggests that the finding of lower relaxin levels in other 
abnormal obstetric conditions is likely to be specific to that 
condition rather than a non-specific effect of pre-eclampsia 
when that condition is coincidentally present.
Umbilical cord levels
In theonly other report of relaxin concentrations in the 
fetus at birth, relaxin could only just be detected in 1 out of 
10 cord samples and 1 out of 9 amniotic fluid samples (Weiss et 
al 1978). The results of this study of 40 normal neonates is in 
agreement with that study and suggests that very little maternal 
relaxin crosses into the fetal circulation. It also suggests 
that the fetus does not secrete relaxin unless it is a relaxin ' 
of different structure that is not recognised by the porcine 
relaxin radioimmunoassay.
Higher than normal levels of relaxin were not found in the 
cord serum of neonates diagnosed as having congenital dislocat­
ion of the hip. However, it should be noted that all levels 
recorded in both normal and abnormal neonates were below the 
sensitivity of the assay and no definite conclusion can be 
reached that relaxin does not influence the normal formation of 
the fetal hip joint. Only if relaxin levels in the affected 
neonates had been significantly above both the levels in the 
normal neonates and the sensitivity of the assay could a possible 
association have been postulated. However, further studies 
using a more sensitive and specific human radioimmunoassay are 
still warranted.
C H A P T E R  8
EFFECTS OF RELAXIN ON THE INTRAUTERINE DISTRIBUTION 
AND ANTIMESOMETRIAL POSITIONING AND ORIENTATION OF 
RAT BLASTOCYSTS PRIOR TO IMPLANTATION
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8.1 SUMMARY
An intravenous infusion of porcine relaxin was administered to rats 
from the afternoon of day 4 of pregnancy to the morning of day 6 , a time 
by which implantation has normally occurred. Over the same time period 
control rats received intravenous saline. At sacrifice, implantation 
sites in the control rats were evenly distributed throughout the length 
of each uterine horn on their antimesometrial borders. In the relaxin 
treated rats the implantation sites were irregularly distributed and 
confined to the cranial half of each uterine horn. Histological 
sections of uteri fixed by vascular perfusion with osmium tetroxide 
revealed that the blastocyst was no longer invariably positioned anti- 
mesometrially within the lumen and that embryonic disc orientation was 
often abnormal. A reduced decidual cell reaction was observed around 
several of the implanting blastocysts.
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8.2 INTRODUCTION
In the rat, implanting blastocysts are distributed more or less 
evenly along each uterine horn, with implantation always being initiated 
at the antimesometrial border of the uterine lumen and the embryonic 
disc within each blastocyst always orientated towards the mesometrium 
(Finn 1977). However, the mechanisms responsible for the distribution, 
positioning and orientation of blastocysts along each uterine horn are 
poorly understood. Migration of the embryonic disc within the tropho- 
blast has been discounted by Gardner (1975), while other workers have 
shown that differential uterine growth around each implantation site 
could be responsible for the more even spacing of such sites (see e.g. 
Finn 1968). Rogers, Murphy and Gannon (1982) demonstrated that such 
differential uterine movement may also be achieved by tissue hydration, 
resulting from the increase in endometrial capillary permeability which 
occurs at each implantation site. McLaren & Michie (1959) postulated 
that myometrial activity was responsible for the even distribution of 
the blastocysts, before implantation, from the utero-tubal junction 
along each horn. Evidence to support this theory comes from the work of 
Pusey et al (1980) who used an intravenous infusion of porcine relaxin 
(a potent inhibitor of myometrial activity in the rat) to disrupt normal 
distribution before implantation, resulting in the majority of the 
blastocysts being recovered from the cranial third of each uterine horn. 
The present work was undertaken as a preliminary study to determine 
whether the continuation of such a relaxin infusion would result in the 
majority of implantation sites being similarly confined to the cranial 
third of each uterine horn, and to examine the effects of relaxin on the 
normal antimesometrial positioning and orientation of the blastocysts at 
implantation.
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8.3 MATERIALS AND METHODS
Female Porton rats (262-327 g) showing a pro-oestrous vaginal smear 
were housed overnight with a male; spermatozoa in the smear the follow­
ing morning confirmed this day as day 1 of pregnancy. Each rat was 
fitted with an indwelling jugular vein cannula (Silastic tubing, i.d.
0.635 mm o.d. 1.194 mm; Dow Corning, Midland, Michigan, U.S.A.) under 
methohexitone anaestheisa (3.3 ml brietal sodium/Kg, 2% solution in 
water, i.p.; Eli Lilly (Australia), Sydney) on the morning of day 3 of 
pregnancy. The cannula was run s.c. to the top of the head and exter­
iorized via a dental cement headpiece held in place by 3 watchmakers 
screws fixed into the skull. Rats were housed individually in environ­
mentally controlled cages. The exteriorized cannula (polyethylene tube^
1.d. 0.86 mm, o.d. 1.52 mm; Dural Plastics, New South Wales 2158, 
Australia) was run up to the roof of the cage inside a protective 
coiled wire spring. At the point where the cannula passed through the 
roof of the cage a swivel was incorporated in the line to permit it to 
rotate without kinking. An infusion pump (IM-1, Narashige, Tokyo,
Japan) housed outside the cage, and calibrated to deliver 0.2 ml/h was 
connected to the end of the cannula.
Relaxin was obtained from the ovaries of pregnant sows and was 
purified by the method of Walsh & Niall (1980), giving highly purified 
B31 porcine relaxin, which had a biopotency of 1500 GPU/mg relative to 
the reference preparation NIH-R-PI (potency 442 GPU/mg). (Steinetz et 
al 1960).
Two rats were treated as controls, receiving a saline (9 g NaCl/L) 
infusion from 17:00 h on day 4 of pregnancy to 10:00 h on day 6 . 
Environmentally controlled cages were set for onset of light at 07:30 h 
and onset of darkness at 19:30 h. Six rats received relaxin infusions
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(6 . 6 6  yg/h) in saline water over the same time period).
At 15 min. before autopsy, the rats were given an intravenous 
injection of 1% Evans blue in saline, via the indwelling jugular 
cannula, to permit identification of implantation sites (Rogers et al
1982) . As soon as the relaxin infusion was completed the rats were 
anaesthetised with intravenous pentobarbarbitone sodium (40 mg Nembutal/ 
Kg; Abbot, Sydney), the descending thoracic aorta was rapidly cannulated 
and the renal arteries were approached through separate lateral abdom­
inal incisions and clamped shut with haemostats at points close to each 
kidney. Osmium tetroxide (50 ml of 1% aqueous solution) in 0.1 M- 
phosphate buffer pH 7.4 containing 9 g NaCl/L was infused via the 
thoracic cannula, the first 40 ml with a driving pressure of 150 mmHg 
and the last 10 ml at 50 mmHG. The primary osmium fixation took about 
10 min. This was followed by vascular washout of the osmium fixative 
with 50 ml 0.1 M-phosphate buffer pH 7.4 containing 9g NaCl/L at 100 mm 
Hg driving pressure, and finally with 50 ml 2.5% glutaraldehyde in 0.1 M 
phosphate buffer'pH 7.4 containing 9 g NaCl/L at 100 mmHg. The whole 
uterus was then carefully excised with a minimum of physical twisting 
or bending, and further fixed by immersion in 2.5% glutaraldehyde for 1 
h. The whole uterus was rinsed and then stored in 0.1 M-phosphate 
buffer pH 7.4, before being processed for routine light microscope 
histology.
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8.4 RESULTS
Implantation sites in the control rats were evenly distributed 
along the full length of each uterine horn (Fig. 20 (1)). However, in 
the rats that had received a relaxin infusion the implantation sites 
(as indicated by the bands of blue uterine tissue) were always confined 
to the cranial half of each uterine horn (Fig. 20 (2)). The number of 
sites per horn ranged from 2 to 6 (mean 4.5) and their distribution was 
variable, with blue bands appearing from almost continuous to well 
separated. In one instance, two implanting blastocysts were found with­
in 1 2 0  pm of each other, with the primary decidual reactions being 
continuous.
A histological section of a normal rat implantation site from the 
morning of day 6 of pregnancy, showing the antimesometrial positioning 
of the blastocyst, and the surrounding primary decidual reaction, is 
illustrated in Figure 21 (3). By comparison examples of implantation 
sites taken at the same stage of pregnancy, but after an intravenous 
infusion, of relaxin, are shown in Figure 21 (4-6). The details of 
blastocyst position and orientation from relaxin treated rats are summ­
arized in Table 5. Two of the treated rats could not be included in 
the experimental data because the uterine lumen opened during either 
fixation or histological processing, dislodging the blastocysts, and 
thus making it impossible to assess their luminal position or orient­
ation accurately.
Despite the apparently normal positioning of 11 of the blasto­
cysts near the antimesometrial border of the lumen, 5 of these 11 show­
ed abnormal embryonic disc orientation (Fig. 21 (4)). In most of these 
5 cases the embryonic disc was laterally rather than mesometrially 
directed, although in at least one blastocyst the disc was orientated 
fully towards the antimesometrial border. Each of the three blastocysts
Figure 20-1 Uterine horn from a control rat killed on the morning of Day 
6 of pregnancy 15 min after receiving an i.v. injection of Evans blue. 
Note the relatively even spacing of the implantation sites (I) 
(represented by the dark bands where Evans blue bound to serum albumin 
has accumulated in the tissues due to the locally increased endometrial 
vascular permeability around each implantation site) along the full 
length of the uterine horn. 0, ovary.
Figure 20-2 Uterine horn from a rat killed on the morning of Day 6 of 
pregnancy after receiving a continuous infusion of porcine relaxin from 
the afternoon of Day 4 untilthe time of death. Note how the implantation 
sites (I) are irregularly spaced and confined to the cranial half of the 
uterine horn. 0, ovary.
,* # N(vW V j i$ 'Uy* i »,. '*
>*».v>'fV
’l O O u m
Figure21-3 Histological section of a control implantation site taken on 
the morning of Day 6 of pregnancy. The blastocyst is positioned anti-" 
mesometrially within the uterine lumen with the embryonic disc (ED) 
orientated towards the mesometrium, while the surrounding stromal cells 
exhibit an early decidual .reaction. H & E. 6pm.
Figures-4-6 Histological sections of implantation sites from relaxin 
treated rats on Day 6 of pregnancy. The antimesometrial margin is at the 
bottom in all photographs. In each example the embryonic disc is not 
orientated towards the mesometrium, and in Figs 5&6 the blastocyst is not 
positioned at the antimesometrial border of the lumen. Note the reduced 
decidual reactions compared with that in Fig. 3, and the differences in 
epithelial thickness on the mesometrial compared with the an timesome trial 
side of the blastocyst in Fig. 5. H & E, 6ym.
F IMPLANT- DISTANCE OF IM­ DISTANCE FROM A- NO. OF BLASTO­
LASTOCYSTS PLANTATION SITE M BORDER AS % OF CYSTS IN EACH
FROM A-M BORDER TOTAL DISTANCE GROUP SHOWING
Cum) BETWEEN A-M AND NON-MESOMETR-
MESOMETRIAL IAL ORIENTAT­
LUMINAL BORDERS ION OF THE
EMBRYONIC DISC
1 1 0 - 1 0 0 0-9% 5
3 1 0 1 - 2 0 0 10-13% 0
1 260 2 1 % 1
1 700 44% 1
1 930 89% 1
1 1080 62% 1
TABLE 5 Data for blastocyst positioning and orientation relative to 
the antimesometrial (A-M) border of the uterine lumen on day 6 of 
pregnancy in 4 rats treated with relaxin.
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that had implanted 1 0 1 - 2 0 0  ym from the antimesometrial border showed 
normal embryonic disc orientation. The remaining 4 blastocysts had 
abnormal embryonic disc orientation.
The extent of the decidual reaction appeared markedly reduced in 
many of the implantation sites from relaxin treated rats compared with 
controls (e.g. compare Fig. 21 (3) with Fig. 21 (4-6)). However, the 
degree of decidualization shows large variability even in normal 
circumstances, and so due to the limited number of specimens available, 
quantitative studies of the size or extent of the decidual reaction in 
relaxin treated rats were not undertaken in this study.
In several of the implantation sites located up to 260 ym from the 
antimesometrial border, the luminal epithelium mesometrial to the 
blastocyst appeared different from that on the antimesometrial side 
(Fig. 21 (5)), the mesometrially located epithelium was thinner than 
that on the antimesometrial side of the blastocyst, with individual 
cells appearing cuboidal rather than columnar. No measurements of epi­
thelial thickness were taken in this study due to the limited numbers 
of specimens available.
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8.5 DISCUSSION
This work demonstrates that blastocysts are able to initiate 
implantation successfully under the influence of exogenous relaxin, and 
confirms that the distribution of the implantation sites on day 6 of 
pregnancy is similar to that of the preimplantation blastocysts under 
the influence of relaxin on day 5 of pregnancy, i.e. restricted to the 
cranial portion of each uterine horn. It also demonstrates that under 
the influence of relaxin, rat blastocysts do not invariably implant at 
the antimesometrial border of the uterine lumen, and also that the 
embryonic disc is not always orientated towards the mesometrium.
To our knowledge this is the first report of non-antimesometrial 
implantation and/or unusual embryonic disc orientation in the rat, and 
the technique is therefore useful to investigate further these complex 
and poorly understood phenomena.
That 11 of the 18 blastocysts sectioned from relaxin treated rats 
were positioned at or near the antimesometrial border of the lumen 
suggests that thenormal antimesometrial positioning mechanism may still 
have been at least partly effective. This may be due either to the 
relaxin dose being only marginally effective, or a more indirect effect. 
It is possible, for example, that the unusual crowding of all the 
blastocysts at the ovarian end of the uterine horn due to the effects 
of the relaxin on the myometrium (Pusey et al 1980), may disrupt the 
subsequent antimesometrial positioning mechanism. Of the 11 blasto­
cysts positioned antimesometrially, 5 had unusual embryonic disc 
orientation, suggesting that the mechanism responsible for orientation 
may be, in part at least, different from that responsible for anti­
mesometrial positioning. This would also explain the observation that 
3 of the blastocysts that did not achieve normal antimesometrial 
positioning did, however, show normal embryonic disc orientation. A
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minimum of three separate mechanisms may therefore he involved in 
normal blastocyst movement before implantation; the first in spacing 
the blastocysts along the uterine horn, which involves the myometrium, 
the second in moving the blastocysts to the antimesometrial border, 
and the third in orientating the blastocysts so that the embryonic disc 
points towards the mesometrium.
The 4 blastocysts that implanted a substantial distance f?*om the 
antimesometrial border all showed unusual embryonic disc orientation.
V
Despite this, these sites demonstrate that it is possible for implant-
\
ation to be initiated well away from the antimesometrial border, and\ 
that it is the blastocyst, and not the antimesometrial portion of the 
endometrium, which is responsible for initating decidualization.
The differences in epithelial thickness mesometrial to the blast­
ocyst compared with antimesometrially, as seen in some implantation 
sites (Fig. 21 (5)), may be an indication of one of the mechanisms 
responsible for blastocyst movement. It is possible that these morph­
ological differences seen histologically represent epithelial cell 
migration in the living tissue. Thus the epithelium may be involved 
in moving the blastocyst towards its "correct" position, even though it 
has already implanted, by migrating towards the antimesometrial border.
\
\
\
\
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C H A P T E R
THE EFFECT OF PORCINE RELAXIN VAGINALLY APPLIED AT HUMAN 
EMBRYO TRANSFER IN AN IN VITRO FERTILISATION PROGRAMME
1-11
. 9.1 SUMMARY
It has been suggested that the polypeptide hormone relaxin is an 
early pregnancy factor which facilitates implantation and pregnancy 
maintenance. To test this hypothesis a double blind randomised 
placebo controlled trial was conducted where 2 mg purified porcine 
relaxin or distilled water was given in a vaginal gel on the day of 
embryo transfer and again three days later in a human in vitro fert­
ilisation (IVF) programme. There were 96 patients in the randomised 
trial and 73 patients who were treated concurrently in the same IVF 
programme acted as a further control group. Of the 51 patients who 
received relaxin, 10 pregnancies were confirmed and 8 continued 
successfully. In the 45 patients treated with placebo 10 pregnancies 
were also confirmed and 6 continued successfully. Amongst the 73 
patients concurrently treated outside the trial 14 achieved a 
pregnancy and 10 continued to term. Thus, porcine relaxin given in 
these circumstances in a human IVF programme did not appear to improve 
or interfere with the pregnancy rate. Possible factors that affected 
the implantation rates in this trial are discussed.
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9.2 INTRODUCTION
The fertilised ovum spends 3 to 4 days in the fallopian tube 
prior toimplantation in the uterus about 7 days after ovulation.
During this time messages are transmitted from the human blastocyst 
to the host to prepare the endometrium for implantation (Psychoyos 
1973), to promote the secretion of uteroglobin (Beier 1982) and to 
facilitate an increase in the activity of the corpus luteum (Lenton et 
al 1982). The messages involved in the communication of the presence 
of a pregnancy are unknown but human chorionic gonadotrophin, human 
placental lactogen and schwangerschaftsprotein 1 may play such a role 
(Klopper 1983).
The polypeptide hormone relaxin can be detected soon after ovul­
ation (Thomas, Loumaye& Ferin 1980). Plasma levels of relaxin 
increase if conception occurs and are at their highest during early 
pregnancy (Quagliarello et al 1979). In 1967, Hisaw et al (1967) 
showed that in the monkey the development of the full histological 
changes of the endometrium in early pregnancy depended on the presence 
of three hormones in combination, i.e. oestrogen, progesterone and 
relaxin. Relaxin appeared to augment the progestational changes in 
the endometrium and induce hyperplasia of the endometrial blood vessel 
endothelium, a charactertistic of normal decidualisation. It has been 
postulated that relaxin may be another luteal factor facilitating 
early pregnancy maintenance and, in particular, implantation through 
its potential to induce connective tissue remodelling in target 
tissues (MacLennan 1981).
During the process of in vitro fertilistion there is no opportun­
ity for messengers of early embryonic origin to inform the mother or 
the corpus luteum of the successful fertilisation until the embryo is 
transferred directly into the uterus, usually some 40-72 hours after
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oyum pick up. Thus, should these messengers induce secretion of 
relaxin or other luteal factors for early pregnancy maintenance, there 
may be a delay in their production and such a mistiming might be 
responsible for the relatively low pregnancy rates of around 16-29 
percent (Edwards & Steptoe 1983) currently being achieved following 
human embryo transfer.
The continuous infusion of pure porcine relaxin in the rat over 
the time of implantation interferes with the normal distribution of 
the multiple blastocysts down the uterine horn and causes them to 
implant only in the cranial half (Pusey et al 1980; Rogers et al 1983). 
Such an effect of exogenously administered relaxin after the transfer 
of one or two human blastocysts to the upper uterine cavity might be 
potentially advantageous.
Since 1974 it has been possible to produce highly purified 
relaxin from porcine sources and this purified form of relaxin has 
been successfully used without side effects or antibody formation in 
clinical trials of cervical ripening near term (MacLennan et al 1980; 
MacLennap et al 1981; Evans et al 1983). In these trials the relaxin 
was given in a vaginal tylose gel and increasing peripheral blood 
levels of relaxin were detectable within one hour after application. 
Although there are many possible factors that influence the success­
ful outcome of pregnancy following the transfer of embryos arising 
from oocytes fertilised in vitro, the failure of approximately 80 per­
cent of apparently normal embryos to implant after embryo transfer 
warranted a clinical trial of the administration of exogenous relaxin 
at the time of embryo transfer to determine if this potential early 
pregnancy maintenance factor given vaginally could improve the 
pregnancy rate.
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9.3 PATIENTS AND METHODS
Relaxin was obtained from the ovaries of pregnant sows and was 
purified by the method of Sherwood and O’Byme (1974). The relaxin 
used in this study had a biopotency of 1500 guinea pig units (GPU) /mg 
relative to the reference preparation NIH-R-PI (potency 442 GPU/mg).
The purified relaxin used was equivalent to the CM-a1 peak described by 
Sherwood and 0fByrne (1974) and is the same as that used for the 
analysis of the primary structure and sequence studies of porcine 
relaxin (Janies et al 1977).
Permission for the clinical trials was obtained from the research 
and ethics committee of the Queen Elizabeth Hospital, Adelaide. A 
double blind randomised placebo controlled trial was proposed and the 
number of patients to be included in the trial was determined statis­
tically by calculating the number required to be 80 percent sure of 
seeing a significant (p<0.05) increase in the pregnancy rate. A doub­
ling of the pregnancy rate in the treatment group was sought over the 
pregnancy rate current at the beginning of the trial and a sample 
number of 96 was determined to be sufficiently large to have such a 
chance of showing this trend.
After obtaining informed patient consent the patients were 
randomly allocated, using a list of random numbers, on a double blind 
basis to receive either 2 mg purified porcine relaxin or a placebo 
(distilled water) mixed with 300 mg of water-soluble cellulose (Tylose) 
granules (Hoechst) to make a viscous gel. The appropriate gel was 
placed in the posterior vaginal fornix by means of a soft latex 
catheter and a syringe immediately after embryo transfer and again 
three days later. Pregnancies were confirmed initially with serum 
Beta HCG levels and later by ultrasound. Statistical analysis of the
t
results was performed using the x2 test.
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Ninety-six patients consented to be in the.double blind randomised 
trial which took place over a 15 month period. Throughout this time 
a further 73 patients were treated in the same in vitro fertilisation
programme and were only excluded from the trial for administrative 
reasons, e.g. the temporary absence of one of the research team or the 
non availability of relaxin. These 73 patients, who did not receive 
any form of vaginal gel, are included in the results as. a further 
control group.
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9.4 RESULTS
During the 15 months period of this trial there were a total of 
280 cycles tracked, 211 laparoscopies and 169 embryo transfers. The 
pregnancy outcomes of the treatment and control groups are shown in 
Table 6. The pregnancy rates in each group are not statistically 
significantly different from each other (p>0.05).
The pregnancy incidence and sequence of successful implantation 
in all groups during the trial was non uniform with pregnancies often 
occuring ;in groups between which there were lengthy sequences where no 
pregnancy was achieved. The clusters of pregnancies did not correlate 
with the relaxin treatment but statistical analysis suggests that such 
groupings of the pregnancies are unlikely to have happened by chance.
The number of embryos transferred also influenced the pregnancy 
rate. One to four embryos were transferred and the number of embryos 
transferred and the corresponding pregnancy rates for the relaxin and 
placebo treated groups are shown in Table ?.
There were 8 ongoing multiple pregnancies in the total of 24 
successful pregnancies achieved during the 15 month period studied. 
There were 4 sets of twins in the placebo group and 1 set of triplets 
in the relaxin treated group. Thus, in the relaxin and placebo groups, 
there were 7 and 2 ongoing singleton pregnancies respectively.
No side effects were noted in any of the 96 patients treated with 
either relaxin or placebo. One patient in the placebo group mis­
carried at 16 weeks in association with a uterine rupture through a 
previously scarred uterine horn.
OUTCOME RELAXIN PLACEBO CONCURRENT CONTROL
GROUP GROUP GROUP (outside study)
(n = 51) (n = 45) (n = 73)
Confirmed pregnancies
Pregnancies that 
miscarried
Number of continuing 
pregnancies (>20/52)
10 10 14
2 3 + 1  ectopic 4
8 6 10
TABLE 6 Pregnancy outcome after embryo transfer in relaxin and 
placebo treated patients.
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9.5 DISCUSSION
Porcine relaxin, given vaginally in 2 mg doses at human embryo 
transfer and three days later, does not appear to improve or interfere 
with the pregnancy rate following in vitro fertilisation and embryo 
transfer. Limitations on the availability of pure porcine relaxin 
and the numbers of patients in the IVF programme did not allow the 
number of patients in the trial to be large enough to detect possible 
more subtle influences on singleton pregnancy. It has already been 
shown that multiple embryo transfer is likely to be more successful 
than single embryo transfer (Kerin et al 1983) and it is possible that 
the endometrium and ovary recognise the multiple stimulus of several 
embryos more readily than one. Four of the six ongoing pregnancies in 
the placebo group were multiple gestations.
Human pregnancy is possible even in patients without ovaries 
(Lutjen et al 1983) and thus ovarian relaxin cannot be essential for 
pregnancy maintenance. However, there are other sources of relaxin 
in human^ pregnancy, e.g. the decidua (Bigazzi et al 1983) which could 
be a significant source of this hormone. Since this trial commenced 
the amino acid sequence of human relaxin has been deduced (Hudson et al
1983). There is only approximately a 50 percent homology between the 
amino acid sequences of human and porcine relaxin. Thus, although 
porcine relaxin has been shown to be moderately effective in inducing 
cervical ripening iii the human (MacLennan et al 1980; Evans et al 1983) 
it is possible that human relaxin receptor sites in the endometrium (as 
in human myometrium - see Chapter 10) may not fully recognise porcine 
relaxin. The dose of relaxin given in the trial and the timing of its 
administration were by necessity empirically chosen and are, therefore, 
other potential factors influencing the apparent lack of effect of 
relaxin in these circumstances. Finally, in all in vitro fertilisation
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programmes at present there are many clinical and laboratory variables 
which may influence the pregnancy outcome, such as the culture 
conditions prior to embryo transfer, the quality and numbers of the 
embryos transferred and the degree of synchrony of the endometrial 
changes at the time of implantation. The non-uniform distribution of 
pregnancies during the in vitro fertilisation programme suggests that 
unknown factors other than relaxin influenced the success of the 
programme from time to time. When these factors are better understood 
and controlled there may be justification to repeat a similar clinical 
trial using pure human relaxin, when this becomes available in the 
near future using genetic engineering techniques.
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C H A P T E R  10
THE EFFECT OF PORCINE RELAXIN AND PROGESTERONE 
ON RAT, PIG AND HUMAN MYOMETRIAL ACTIVITY IN VITRO
1 2 2 .
.10 a  SUMMARY
The in vitro effect of pure porcine relaxin on non-pregnant and 
pregnant myometrium before and after progesterone treatment was 
studied in the rat, pig and human. Myometrial strips from 45 rats, 30 
pigs and 64 humans were studied. Porcine relaxin inhibited myometrial 
activity in the non-pregnant and pregnant rat until mid pregnancy when 
the sensitvity to relaxin gradually decreased. By day 19 of rat 
pregnancy the myometrium was completely refractory to the inhibitory 
effect of porcine relaxin. Pretreatment of rat myometrial strips in 
vitro with progesterone increased their sensitivity to relaxin but did 
not overcome the refractory period in late pregnancy. In the pig myo­
metrial contractility was completely inhibited by porcine relaxin both 
in the non-pregnant state and throughout pregnancy (days 25-109). 
Progesterone was again synergistic with relaxin in the pig in inhibit­
ing myometrial contractility. However, porcine relaxin had little or 
no effect on human myometrial contractility either in the non­
pregnant state or during the gestations of pregnancy tested (28-42 
weeks). Pretreatment of human myometrium with progesterone could not 
induce a response to porcine relaxin. It is suggested that the lack 
of response of human myometrium to porcine relaxin may be due to the 
non-recognition of porcine relaxin by human myometrial relaxin 
receptors because of the large difference in structure between porcine 
and human relaxin.
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10.2 DISCUSSION
One of the principle actions of the polypeptide hormone relaxin 
is the inhibition of myometrial activity (Porter 1979b; MacLennan 
1983). This action was first described in oestrogen-primed guinea- 
pigs by Krantz et al in 1950 using very impure preparations of relaxin. 
These porcine preparations were less than 10 percent pure and did not 
inhibit human myometrial activity in vitro (Miller, Kisley & Murray 
1957). Despite the negative in vitro findings, clinical trials using 
such impure preparations of relaxin were conducted during the 1950s 
and gave inconclusive and conflicting results. Recent biochemical 
advances have allowed the complete purification of porcine relaxin 
(Sherwood & 0*Byrne 1974; Walsh & Niall 1980) and it has been possible 
to study the effect of porcine relaxin on myometrial activity without 
the influence of contaminants.
The effect of porcine relaxin on rat myometrium has been well 
described and is the basis of one of the bioassays for this hormone 
(Wiqvist 1959; St. Louis 1981). The non-pregnant rat has to be 
oestrogen-primed for relaxin to exert its inhibitory effect on myo-> 
metrial activity and in pregnancy its effect in vitro can only be 
found during the first half of pregnancy. Progesterone and porcine 
relaxin are synergistic in decreasing the amplitude of non-pregnant 
rat myometrial contractions in vitro (Sarosi et al 1983) and it has 
been postulated that these hormones in combination play an important 
part in maintaining uterine quiescence during pregnancy. However, a 
synergistic effect of these hormones during pregnancy in the rat has 
not yet been described.
There is no literature on the effect of pure porcine relaxin on 
human myometrium in either the pregnant or non-pregnant state, nor have 
there been such reports of the effect of pure porcine relaxin on pig
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myometrial actiyity where, of course, the relaxin would be species 
specific. Although extracts of human corpora lutea of pregnancy have 
been tested on human myometrial activity in vitro with an inhibitory
effect (Szlachter et al 1980; Beck et al 1982) human relaxin has not
yet been purified in sufficient quantities to examine its specific
myometrial effect in vivo or in vitro.
This study was designed to comprehensively study and clarify the 
effect of pure porcine relaxin on gravid and non-gravid myometrial 
activity in the rat, pig and human and examine its potential synergism 
with progesterone.
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10.3 METHODS 
Rat
Thirty-two Hooded Wistar non-pregnant oestrogen-primed 
female rats (weight 200-250 G) were studied. Each rat received 
0.2 mg of oestradiol valerate subcutaneously 20 hours prior to 
decapitation. Thirteen pregnant rats were also studied. One was 
sacrificed on day 10, 4 on day 14, 1 on day 17 and 7 on day 19 of 
pregnancy. One of the day 14 rats had a unilateral pregnancy and 
both the pregnant and non-pregnant uterine horns were studied.
Pig
Seven mature cycling female non-pregnant pigs and 23 
pregnant pigs at varying gestations (25-109 days) were studied.
Human
Permission for collection of human myometrium was granted by 
The Queen Victoria Hospital, Adelaide, Research and Ethics 
Committee. Forty-seven strips of myometrium were obtained at 
caesarean section (gestations 28-42 weeks) where after delivery 
of the baby a thin 2 cm long strip of myometrium was excised from 
the upper edge of the incision in the lower uterine segment. 
Similar pieces of myometrium were exicsed from 17 non-pregnant 
hysterectomy specimens obtained from both premenopausal and post­
menopausal patients.
Relaxin
Relaxin was obtained from the ovaries of pregnant sows and 
was purified by the method of Sherwood and 0*Byrne (1974) with 
the modifications of Walsh and Niall (1980). The relaxin used in
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this study had a biopotency of 1500 guinea-pig units (GPU) /mg 
relative to the reference preparation NIH-R-PI (potency 442 GPU/ 
mg). The purified relaxin used was equivalent to the CM-a* peak 
described by Sherwood and 0*Byrne (1974) and is the same as that 
used for the analysis of the primary structure and sequence 
studies of porcine relaxin (James et al 1977).
Experiment
After excision the uterine biopsies were placed in Earle*s 
medium. Myometrial strips 2 mm diameter x 2 cm long were 
prepared from the biopsies and immediately suspended by cotton 
thread in a 15 ml double jacketed organ bath, containing Earle*s 
medium. The lower end of the myometrial strip was attached to a 
clamp at the bottom of the bath and the other end was connected 
by the thread to a Transmed Isometric Force Transducer Model No. 
T-1030. The contractile activity was isometrically recorded with 
a Gilson polygraph, calibrated at an initial tension of 5G for 
pig and human myometrium and 1G for rat myometrium.
The composition of Earle*s medium used in these experiments
in millimoles per litre was CaCl2 , 1.4; glucose, 5.6; MgSO^, 0.4;
2
KC1, 5; NaCl, 117; NaE2P0I+ H20, 0.9. The organ bath was kept at 
a constant temperature of 37°C and a pH of 7.4 was maintained by 
a constant flow of 95 percent 02 and 5 percent C02. The organ 
bath was siliconised prior to use to reduce adhesion of relaxin 
to the glassware-.!. Porcine relaxin concentrations in the medium 
were confirmed by a porcine relaxin radioimmunoassay utilising 
rabbit anti-porcine relaxin serum R6 and i25I-labelled poly- 
tyrosyl-relaxin (0*Byrne & Steinetz 1976).
Spontaneous contractions were recorded without interference 
until both the strength and the rate of contractions were steady.
1 2 7 ,
Increasing doses of relaxin were then added to the organ bath to 
assess the effect on muscle contractility. To determine.whether 
the original activity of the muscle could be restored the.relaxin 
was washed out with fresh Earlefs medium. If this was not 
achieved the experiment was: discarded.
KCl-induced contractions were produced according to the bio­
assay of St. Louis (1981). A 20 percent KC1 substitution of the 
normal NaCl content in Earlefs medium, induces a tetanic contract­
ion of myometrium giving a stable plateau on the polygraph record­
ing. The quantitative effect of a relaxant can be measured as a 
percentage of the reduction in the height of the plateau. In all 
cases the effect of porcine relaxin was studied on spontaneous 
myometrial activity and using the KCl-bioassay of St. Louis (1981).
Progesterone
Two myometrial strips taken from the same uterine biopsy 
from rat, pig or human, were placed in separate organ baths. One 
strip was pretreated for 45 minutes with progesterone in propy­
lene glycol (15 yl) to give a final concentration of 1 yg/ml of 
progesterone in the organ bath. The other strip was pretreated 
for 45 minutes with propylene glycol (15 yl), acting as a control, 
to determine whether the contractile pattern altered over the 
time period in the absence of progesterone. Following the above 
period of pretreatment with progesterone or control solution 
relaxin was added in increasing doses until a complete inhibit­
ion of spontaneous activity was achieved and in the KCl-assay at 
least a 20 percent reduction in the tetanic contraction occurred.
Ii
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10.4 RESULTS 
Rat
Consistent results were obtained in 32 of the 33 oestrogen- 
primed non-pregnant rats. Porcine relaxin in doses as low as 10 
ng/ml inhibited both spontaneous myometrial activity and KC1- 
induced contractility (Figure 22). However, when 1 yg/ml prog­
esterone was added to the organ bath 45 minutes prior to the 
administration of relaxin, the subsequent inhibition of myomet­
rial contractility by porcine relaxin was either greater or could 
be achieved at a lower dose (as low as 2.4 ng/ml) than when 
relaxin was added alone. In 20 non-pregnant rats studied, the 
mean response to relaxin was significantly greater in the muscle 
pretreated with progesterone for concentrations of relaxin ^80 
ng/ml (Figure 23).
The relaxant effect of porcine relaxin on early pregnant rat 
(days 10-14) myometrium was less than in the non-pregnant rat and 
doses of 40-500 ng/ml had to be given to produce a greater than 
20 percent reduction in myometrial contractility in the KC1 bio­
assay (Figure 22). In the rat with a unilateral 14 day gestat­
ion the same dose of relaxin 600 ng/ml produced a 7 percent 
reduction in contractiliy in the pregnant horn and a 25 percent 
reduction in the non-pregnant horn. The myometrium was most 
sensitive to relaxin on day 10 of pregnancy and less so on day 14.
Rat myometrial strips from days 10 and 14 of pregnancy pre­
treated with progesterone required less porcine-relaxin to 
inhibit myometrial contractility. On day 10 of pregnancy the 
amount of relaxin required to produce a 20 percent reduction in 
myometrial contractility in the KC1 bioassay was 2 ng/ml for the 
progesterone treated muscle and 75 ng/ml for the control muscle.
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FIGURE 22 Myometrial contractility tracings from a non-pregnant and a 
pregnant rat. The first half of each tracing shows the inhibition of 
spontenaous contractility by pure porcine relaxin. The contractions 
returned after washing (w). The second half of each tracing shows the KC1 
induced tetanic contraction which can be proportionately reduced by adding 
increasing quantities of relaxin (arrows).
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FIGURE 23 KC1 bioassay comparing the response of non-pregnant rat myo­
metrium to porcine relaxin when pretreated with progesterone to control 
samples from the same rat. The mean + SEM is shown for 20 rats tested. 
*p<0.05, **p<0.02, ***p<0.005, ***p<0.001.
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On day 14 of pregnancy rat myometrium was less sensitive to 
relaxin and the synergistic action of relaxin and progesterone 
was reduced, the meanamount of relaxin being required to produce 
a 20 percent reduction in myometrial contractility being 200 ng/ 
ml in the progesterone treated muscle and 470 ng/ml in the 
control muscle.
By day 17 of pregnancy porcine relaxin had only a minimal 
effect on rat myometrium and by day 19 relaxin had no inhibitory 
effect on rat myometrium, either on spontaneous activity or in 
the KC1 system for any of the relaxin doses tested (up to 15 pg/ 
ml). Pretreatment with progesterone before the administration of 
relaxin also had no effect.
Porcine relaxin effectively inhibited spontaneous myometrial 
activity in all 7 of the non-pregnant pigs (Figure 24). The 
minimum effective doses of porcine relaxin to cause a 20 percent 
relaxation of the induced tetanic contraction of the non-pregnant 
pig myometrium ranged from 5-50 ng/ml.
Progesterone pretreatment of non-pregnant pig myometrium 
prior to the addition of porcine relaxin resulted in a greater 
percentage inhibition of the tetanic contraction in the KC1 bio­
assay (Figure 25). The mean effect of progesterone pretreatment 
was to approximately double the relaxant effect of porcine 
relaxin alone. The lowest effective relaxin dose on non-pregnant 
pig jmyometrium pretreated with progesterone ranged from 0.5-5 ng/ 
ml.
Porcine relaxin was effective in inhibiting KCl-induced 
uterine contractions in all of the 23 pregnant pigs studied. 
Gestations studied ranged from 25-109 days and there was no
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FIGURE 24 Myometrial contractility tracings from a non-pregnant and a 
pregnant sow. The first half of each tracing shows the inhibition of 
spontaneous contractility by pure porcine relaxin. The contractions return 
after washing (w). The second half of each tracing shows the KC1 induced 
tetanic contraction which was relaxed by the addition of porcine relaxin to 
the organ bath (arrow).
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FIGURE 25 KC1 bioassay showing approximately a doubling of the sensitivity 
of progesterone pretreated non-pregnant pig myometrium to increasing 
concentrations of porcine relaxin compared to a control strip of pig 
myometrium treated with porcine relaxin alone.
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reduction in the myometrial sensitivity to relaxin during this 
period. Progesterone pre treatment of the myometrial strips again 
enhanced the effect of porcine relaxin. The lowest effective 
doses of porcine relaxin to inhibit pregnant pig myometrial 
activity ranged from 10-100 ng/ml in control specimens and 0.5- 
10 ng/ml in specimens pretreated with progesterone.
Human
Porcine relaxin in doses up to 10 yg/ml failed to inhibit 
spontaneous myometrial activity or induce relaxation in the KC1 
bioassay in 14 of the 17 non-pregnant specimens and 43 of the 47 
myometrial strips obtained during pregnancy (Figure 26). Three 
non-pregnant and 3 pregnant human myometrial strips showed a 
minimal decrease in the amplitude of the spontaneous contract­
ions following the administration of 3 pg porcine relaxin/ml 
(Figure 26). All the strips that showed a possible reaction to 
porcine relaxin were inner circular myometrial strips and the 
corresponding outer longitudinal muscle strips did not react to 
relaxin. Progesterone pretreatment had no effect on these or any 
of the other human specimens subsequently given relaxin.
Table 8 summarises the effect of pure porcine relaxin on 
gravid and non-gravid myometrium in the rat, pig and human. In 
all species tested where relaxin had an inhibitory effect on 
uterine contractility washing of the specimens brought back 
normal myometrial contractility. The progesterone dose and the 
propylene glycol used for pretreatment of the myometrial strips 
were insufficient to produce mor.e:than a 10 percent relaxation in 
the KC1 bioassay.
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FIGURE 26 Myometrial contractility tracings from a non-pregnant and a 
pregnant human uterus. Porcine relaxin had no effect on spontaneous or KC1 
induced contractility in the human although on exceptional occasions as 
shown in the pregnant specimen slight inhibition of the amplitude of the 
spontaneous contractions did occur.
SUMMARY OF INHIBITION OF MYOMETRIAL
CONTRACTILITY BY PORCINE RELAXIN
RAT PIG HUMAN
NON PREGNANT + + ---
EARLY PREGNANCY ' + ■ +
MID PREGNANCY + + ---
LATE PREGNANCY --- + ---
TABLE 8 Summary of the inhibitory effect of porcine relaxin on myometrial 
contractility in the non-pregnant and pregnant rat, pig and human. An 
inhibitory effect is represented as + and no effect as -. Early human 
pregnant myometrium has not been tested.
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10.5 DISCUSSION
This study firstly confirms that pure porcine relaxin inhibits in 
vitro myometrial contractility in the oestrogen-primed non-pregnant 
rat and the pregnant rat except in late pregnancy. Rat myometrium 
appeared to be less sensitive to the effect of porcine relaxin as 
pregnancy progressed and was completely refractory to its effect by 
day 19 of pregnancy. The reason for the change in the myometrial 
response to porcine relaxin during pregnancy in the rat is not clear 
but may be due to a change in the status of the relaxin receptors in 
the myometrium. In a study by Mercado-Simmen et al (1982) the 
concentration of unoccupied relaxin receptors in rat myometrium 
decreased in late pregnancy in inverse relation to the increases in 
endogenous plasma relaxin at this time. The same study also showed 
that oestrogen enhances the binding activity of the rat uterus by 
increasing the concentration of myometrial relaxin receptors. High 
plasma levels of relaxin, on the other hand, diminished the sensitivity 
of continual relaxin exposure by markedly reducing the number of 
available myometrial receptors. The work of Mercado-Simmen et al
(1982) suggested that the relaxin receptor concentration in rat myo­
metrium is controlled through co-existing occupancy and down-regulation 
and by oestrogen through synthesis of new receptor sites. The 
possibility that other mechanisms and hormones might also modulate 
relaxin receptors was not excluded. Similar relaxin receptor studies 
have not yet been performed in the human.
This study also confirmed the recent report of Sarosi et al
(1983) that porcine relaxin and progesterone are synergistic in in­
hibiting in vitro myometrial contractility in the non-pregnant rat. 
Similar synergism in early and mid pregnancy, as reported in this 
study, has not previously been described in the rat. Progesterone
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treatment could not overcome the refractory state of late pregnant rat 
myometrium to porcine relaxin. The increased sensitivity of rat myo­
metrium to relaxin after progesterone pretreatment significantly 
improves this method of bioassay of relaxin allowing much smaller 
amounts of relaxin or relaxin-like activity to be detected in biolog­
ical fluids or tissue extracts during the monitoring of biological 
activity at the time of relaxin purification.
There has been no previous report in the literature of the in 
vitro effect of pure porcine relaxin on porcine myometrial contract­
ility either in the non-pregnant or pregnant state. Such a study is 
clearly important as the relaxin in such an experiment is species 
specific. In the pig, porcine relaxin effectively inhibited myometrial 
contractility before and throughout the period of pregnancy tested 
(days 25-109), i.e. even in late pregnancy. Progesterone was again 
synergistic with relaxin in the pig with regards tto its inhibitory effect 
on myometrial activity. The consistent effectiveness of this action 
of porcine relaxin on the pig was in marked contrast to its almost 
total lack of action in both non-pregnant and pregnant human myomet­
rial strips whether pretreated with progesterone or not. This 
suggests that either porcine relaxin is not recognised by human myo­
metrial relaxin receptors or that relaxin plays a different role in 
the human to that in the pig or rat and does not play a role in 
uterine quiescence, at least in this fashion.
The former argument is supported by the report of Hudson et al
(1983) that there is only approximately a 50 percent homology between 
the amino acid structure of the first human relaxin that has been 
characterised and porcine relaxin. Extracts of human corpora lutea, 
whilst not claimed to be pure preparations of human relaxin, are 
reported to inhibit the amplitude of spontaneous contractions of human 
uterine strips in vitro (Beck et al 1982) suggesting that when species
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specific relaxin is used relaxin plays a similar role in the human as 
in the pig with regards uterine quiescence. In the present study 
frequent washing of the human myometrial strips over several hours 
did not result in responsiveness to exogenous porcine relaxin suggest­
ing that the lack of response was unlikely to be due to total occupancy 
of the relaxin receptors by endogenous human relaxin.
However, in contrast to the ineffectiveness of porcine relaxin on 
human myometrium in vitro, it has recently been reported that porcine 
relaxin inhibits human cervical smooth muscle activity in 18 percent 
of non-pregnant specimens, 68 percent of early pregnant and 100 per­
cent of term pregnant specimens tested (Norstrum et al 1984).
Clinical trials also show that vaginally applied pure porcine relaxin 
is effective in most patients at term in producing varying degrees of 
cervical softening and dilatation without apparent myometrial stimul­
ation (MacLennan, Bryant-Greenwood & Greenwood 1983). Thus, relaxin 
receptors in the human cervix may differ from those in human myomet­
rium and appear to be able to recognise porcine relaxin, especially 
near tern. This suggests a mode of action and role for relaxin in 
the process of cervical ripening that is separate from its possible 
role in maintaining uterine quiescence earlier in pregnancy. The 
potential availability of genetically engineered human relaxin in the 
near future for similar in vitro trials should help clarify whether 
the differing species response to porcine relaxin is due to the _ 
specificity of human relaxin for human receptors. Access to human 
relaxin should also allow further study of the biological variations 
in the sensitivity of target organs to relaxin during pregnancy.
The mechanism of action of relaxin in inhibiting myometrial and 
cervical smooth muscle contractility in the human is not clearly 
established. In the rat, relaxin decreases the activity of myosin 
light-chain kinase resulting in a decrease in myosin phosphorylation
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and actin-activated adenosine triphosphatase activity (Nishikori et al 
1983)• Enzymatic phorphorylation and dephosphorylation of the myosin 
light-chains are the key elements in the regulation of smooth muscle 
contractility. Activation of myosin light-chain kinase by its phos­
phorylation facilitates the temporary combination of actin and myosin 
into actomyosin which in turn produces a contractile state in smooth 
muscle. Myosin light-chain kinase activity is increased by calmodulin 
and adequate cellular calcium levels and decreased by cAMP-mediated 
phosphorylation of the kinase. A preliminary report (Weiss 1984) 
suggests that relaxin inhibits calmodulin activity. Relaxin also 
increases cAMP activity (Cheah & Sherwood 1980). Thus, relaxin 
influences two of the three main regulatory systems which control 
myosin light-chain kinase activity. The third regulator of myosin 
light-chain kinase activity is calcium, the intracellular levels of 
which are lowered by progesterone. Thus, the rate of myosin light- 
chain phosphorylation appears to be under the influence of both 
relaxin and progesterone. They both seem to be inhibiting the same 
intracellular mechanism in smooth muscle but their precise interaction 
and synergism at a biochemical level deserves more study.
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C H A P T E R  1 1
RIPENING OF THE HUMAN CERVIX AND INDUCTION 
OF LABOUR WITH PURIFIED PORCINE RELAXIN
!|
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11.1 SUMMARY
In a randomised double blind trial 10 of 30 patients given 2 mg 
of intravaginal purified porcine relaxin on the evening before 
surgical induction of labour went into labour before the proposed 
induction. Of 30 control patients, none went into labour. Of the 30 
patients treated with relaxin, 25 had improved cervical scores after 
treatment and significantly fewer required agumentation in labour with 
intravenous oxytocin than the control group. Administration of 
relaxin was associated with very little increase in uterine activity 
and no side effects. The trial shows that exogenous relaxin causes 
cervical ripening and can initiate parturition. Endogenous relaxin 
may have a similar role.
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11.2 INTRODUCTION
Relaxin is a polypeptide hormone, structurally related to insulin, 
first extracted and prepared in an impure form by Hisaw in 1926. It 
has been found in all species tested. In women it has been detected 
only in the corpus luteum of pregnancy (Weiss et al 1978). In many 
species, relaxin plays a major part in cervical ripening before partur­
ition (Steinetz, O'Byrne & Kroc 1980). However, its role in human 
parturition has not been established. In most animals studied, serum 
relaxin levels are highest shortly before parturition. In women, 
serum levels of relaxin do not rise towards the end of pregnancy but 
cervical-tissue concentrations do rise (Von Maillot et al 1977). A 
rise in relaxin levels in early human labour has been described for 
the first time in Chapter 5. Early clinical studies with impure 
extracts of relaxin given parenterally or orally produced conflicting 
results but suggested overall that relaxin, or contaminants in the 
extract, produced cervical softening, and that in higher doses it 
inhibited uterine contractions (McCarthy, Ervine & Laufe 1957; Eichner 
et al 1958; Kupperman, Rosenberg & Cutler 1958).
Porcine relaxin can now be purified and its effects of the human 
cervix can be tested without the previous complication of possible 
active impurities in the ovarian extract. No clinical trial of purif­
ied relaxin in the human had yet been published prior to this paper. 
Recent work (Appendix 1) on prostaglandin F2 « (PGF2 C1) and cervical 
ripening has shown that administration by the intravaginal route 
achieves direct and rapid absorption of this hormone to the site of 
action without systemic side effects. Thus, this route has been 
chosen for an investigation of the effect of purified relaxin on 
cervical ripening and parturition.
139.
11.3 PATIENTS AND METHODS
Relaxin was obtained from the ovaries of pregnant sows and was 
purified by the method of Sherwood and 0*Byrne (1974) with minor 
modifications as described by Kwok et al (1980). The relaxin used in 
this study had a biopotency of 1500 GPU/mg relative to the reference 
preparation NIH-R-PI (potency 442 GPU/mg). The purified relaxin used 
coincided with the CM-a1 peak as described by Sherwood and O'Byrne 
(1974) in the characterisation and isolation of relaxin and was of the 
same homogenLcity as the relaxin used for the analysis of the primary 
structure and sequence studies of porcine relaxin (James et al 1977).
Permission for the clinical trials was obtained from the research 
and ethics committee of The Queen Victoria Hospital, Adelaide. In a 
dosage trial 16 patients were given relaxin vaginally 15 h before 
surgical induction of labour, each patient receiving 1, 2 or 4 mg 
of relaxin. The fetal heart, uterine activity, and clinical status of 
the patient were closely monitored. This preliminary trial suggested 
that both the 2 mg and 4 mg doses might be associated with a degree of 
cervical ripening without apparent side effects, and a 2 mg dose was 
chosen for the clinical trial now described.
A randomised double blind trial involving 60 patients was set up. 
Criteria for iriolusion in the trial were: singleton pregnancy, 
cephalic presentation, unscarred uterus, maternal height over 150 cm, 
and informed consent from the patient. The patients were randomly 
allocated to receive either 2 mg relaxin diluted in 10 ml water or a 
placebo (10 ml sterile water), the allocated constituent being mixed 
with 700 mg tylose granules (Hoechst) to make a viscous gel. Close 
matching of the groups was apparent by the end of the trial in all 
respects except that the mean initial cervical score (modified Bishop 
score) (Calder, Embrey & Tait 1977) of the relaxin group was 1.6
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VARIABLE PLACEBO GROUP 
Cn = 30)
RELAXIN GROUP 
(n = 30)
Mean maternal age (yr) 26.1 25.0
Mean gestation (wk) 40.0 40.4
Mean parity 0.6 0.6
Mean birth weight Ckg) 3.4 3.4
Mean cervical score at priming 4.3 5.9
TABLE 9 Comparison of treatment and control groups
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points higher than that of the.placebo group (Table 9).
A.H.M., unaware of the treatment allocation, assessed the cervic­
al score at 5 p.m. on the evening before proposed induction of labour. 
The gel was then placed in the posterior vaginal fornix, by means of 
a soft latex catheter and a syringe. No attempt in this trial was 
made to stretch the cervix of sweep the membranes. The patient was 
asked to remain in bed for an hour. Next morning at 8 a.m. the 
cervical score was reassessed by A.H.M. Thereafter, the labour was 
managed by obstetricians unaware of the constituents of the vaginal 
gel.
Statistical analysis of the results was done with Student*s (one­
tailed) t test, Fisher's exact test, and the x2 test.
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11.4 RESULTS
The effect of the placebo gel and the relaxin 15 h after vaginal 
application is shown in Table 10. Labour became established in 10 of 
the 30 patients receiving relaxin, whereas no patient in the control 
group went into labour (p<0.0005, Fisher's exact test). The mean 
improvement in the cervical score was 3.38 for the relaxin group and 
0.86 far the placebo group (p<0.0025, Student's t test). The improve­
ment in the cervical score of the relaxin group was still significant 
even among patients who did not go into labour (p<0.0025, Student's t 
test). The cervical score remained unchanged in only 5 patients 
receiving relaxin, whereas 18 patients receiving placebo showed no . 
evidence of improvement (p<0.0005,x2)•
Significantly fewer women in the group receiving relaxin needed 
augmentation of labour with intravenous oxytocin (p<0.005, x2 test) 
(Table 11). The relaxin group also had shorter labours (p<0.05, x2 
test). However, there was no significant difference between the two 
groups in mode of delivery, analgesic requirements, or Apgar score of 
the infant at delivery.
The cervical score in the relaxin group improved regardless of 
the initial cervical score (Table 12), parity (Table 13), or gestat­
ion (Table 14) . Eight of the 10 patients who laboured had a favour­
able cervical score (7-9), but there was no apparent relationship 
between parity or gestation and the onset of labour after treatment 
with relaxin.
No side effects were experienced by the patients receiving 
relaxin and no neonatal complications were recorded. Although mild 
uterine activity was sometimes noted electronically by means of an 
abdominal pressure transducer after vaginal examination and applicat­
ion of the relaxin, only those who laboured were aware of a change
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in their preyious pattern of uterine activity. In fact, where labour 
did not supervene it was not possible clinically to detect any differ­
ence between the two groups. No abnormal fetal heart pattern was 
recorded after application of the gel and before^labour started. Two 
babies from the relaxin group and 4 from the placebo group showed 
signs of mild respiratory depression at birth and required active 
resuscitation. One patient in the relaxin group had a caesarean 
section for cephalo-pelvic disporportion. There were 3 caesarean 
sections in the placebo group, the indications being cervical dystocia, 
failure to progress, and fetal distress.
OUTCOME PLACEBO GROUP RELAXIN GROUP
(n = 30) (n = 30)
Delivered at 15 h
Established in labour 0 3
Average change in cervical
score 0.86 3.38
Average change where labour
did not supervene 0.86 2.08
No. with no change 18 5
TABLE 10 Outcome on morning after treatment of cervix
OUTCOME PLACEBO GROUP 
(n = 30)
RELAXIN GROUP 
(n = 30)
No. augmented with oxytocin 23 13
ft
Length of labour (hr) 
(mean + SD) 8.2 (+ 3.2) 6.6 (+ 3.1)
Caesarean section 3 1
Instrumental delivery 15 14
Pethidine given (mean dose) 13 (115 mg) 15 (100 mg)
Epidural block (mean dose) 15 (31 ml) 12 (23 ml)
No analgesia in labour 4 8
Apgar score at 1 min. 8.1 8.1
Apgar score at 5 min. 9.0 9.0
TABLE II Outcome of labour in control and relaxin treated groups
ft
"Excluding Caesarean section
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INITIAL SCORE MEAN IMPROVEMENT IN CERVICAL SCORE
PLACEBO RELAXIN
0 - 3 0.9 (12) 2.8 (6)
4 - 6 0.9 (14) 2.8 (9)
7 - 9 0.5 (4) 4.0 (15)
TABLE 12 Initial cervical score and mean change in cervical score 
15 h after treatment.
No. of patients in parentheses
PARITY MEAN IMPROVEMENT IN CERVICAL SCORE
PLACEBO RELAXIN
0 0.9 (16) 2.8 (16)
1 0.7 (11) 4.3 (10)
2+ 1.3 (3) 3.9 (4)
TABLE 13 Parity and mean change in cervical score 15 h after 
treatment.
No. of patients in parentheses
GESTATION (wk) MEAN IMPROVEMENT IN CERVICAL SCORE
PLACEBO RELAXIN
38 - 39 0.8 (13) 2.2 (6)
40 - 41 1.0 (12) 3.7 (17)
41+ 0.6 (5) 3.7 (7)
TABLE 14 Gestation and mean change in cervical score 15 h after 
treatment.
No. of patients in parentheses
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11.5 DISCUSSION
The placebo and treatment groups were well matched except that 
the mean cervical score of the relaxin group was 1.6 points higher 
than that of the placebo group before treatment. In particular, more 
patients in the relaxin group had a favourable cervical score (Table 
12) and 8 of the 10 patients who went into labour were in this group. 
Thus, the apparent effectiveness of relaxin may have been biased by 
this chance difference between the two groups. However, in a similar 
trial (Appendix 1) of cervical ripening with PGF2a, there were 11 
patients in the placebo group with an initial cervical score between
7 and 9. However, only 1 of these 11 went into labour, compared with
8 of 15 patients with a similar cervical score in the relaxin group.
A statistically significant improvement in the cervical score was seen 
in the 20 patients treated with relaxin who did not labour and an 
improvement in the mean cervical score was noted whatever the initial 
score before treatment (Table 12). Thus the difference in the mean 
initial cervical scores between the two groups is unlikely to account 
for the effect of relaxin on cervical ripening and the initiation of 
parturition. However, the difference in the initial cervical score 
may account to some extent for the shorter labours in the relaxin 
group.
In a double blind dose trial (Appendix 2) which was identically 
structured to this trial, 25 mg of intravaginal PGF2a was associated 
with a mean improvement in the cervical score of 3.76, and labour 
started in 9 of the 30 patients treated. A higher dose (50 mg) of 
intravaginal PGF2a improved the cervical score by 4.63, and 10 of the 
30 patients went into labour. Thus, the effect of 2 mg of intra­
vaginal relaxin is comparable to these doses of intravaginal PGF2a*
The relationship between relaxin and prostaglandin in women is
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unknown, but both are probably necessary for cervical ripening. 
Injections of PGF2« in pregnant pigs on day 112 caused sharp rises in 
plasma relaxin concentrations (Sherwood et al 1976). However, in 7 
patients given intravenous PGF2<* to induce labour a statistically 
significant rise in serum relaxin levels was not seen (Hochman et al 
19.78). A prolonged rise in plasma relaxin in the pregnant sow after 
oestrogen administration (F. Amato, G. Warnes, M. Ralph, G.D. Bryant- 
Greenwood, F.C. Greenwood & R.F. Seamark, unpublished) and the post­
ulated relationship between oestrogen and prostaglandin suggests that 
the triad of hormones - oestrogen, prostaglandin and relaxin - 
requires study in man.
This trial suggests that endogenous relaxin might play an 
important part in the ripening of the human cervix and in the initiat­
ion of parturition. The mode of action of endogenous or exogenous 
relaxin is not clear. In this trial, unless labour supervened, the 
patient was not aware of any uterine activity after application of 
the relaxin. However, in some patients increased uterine activity was 
noted electronically by means of an abdominal pressure transducer, 
though this may have been due to a transient rise in endogenous 
prostaglandin levels caused by the vaginal examinations. Whether the 
relaxin caused cervical ripening by indirect stimulation of uterine 
contractions or by a direct effect on the cervix is not known.
Because bhe contractions were small and inconsistent, a direct effect 
seems more likely, and attempts are in progress to characterise 
relaxin receptors in the cervix.
The effects of intravaginal relaxin in women are similar to those 
of intramuscular relaxin given to pregnant luteectomised sows, in 
which premature cervical dilatation, premature labour and a reduction 
in the length of labour resulted (Kertiles & Anderson 1979). Lactat­
ion in those sows was severely reduced. However, almost all mothers
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in this trial breast-fed, and no reduction in lactation was detected.
Two mg relaxin appears to be at least as safe and effective as 25 
mg of intravaginal PGF2 0 , and in this trial labour was significantly 
shorter than in the control group. Further dose studies and an 
increased availability of porcine or human relaxin may eventually 
make it a useful alternative in the induction and management of 
labour. Meanwhile, the relationships between oestrogen, prostaglandin, 
and relaxin in their effects on cervical ripening and parturition may 
be studied empirically (Chapter 12).
The role of endogenous relaxin in human parturition needs further 
investigation. In this study exogenous purified porcine relaxin 
induced cervical changes in most patients and in some was associated 
with the initiation of parturition. If there are receptor sites for 
relaxin in the human cervix in late pregnancy, a role for the endo­
genous hormone would be suggested perhaps by a local action not 
reflected in significant changes in serum relaxin.
C H A P T E R  1 2
CERVICAL RIPENING WITH COMBINATIONS OF VAGINAL 
PROSTAGLANDIN F£a, OESTRADIOL AND RELAXIN.
-153 *
.12.1 SUMMARY
The first of a two part trial consisted of a double blind random­
ised pilot study in which 4 groups of 10 patients near term received 
one of the following hormonal combinations in a vaginal gel 15 h 
before surgical induction of labour: (1) prostaglandin F2 <* (PGF2 0O
and relaxin, (2) relaxin and oestradiol, (3) oestradiol and PGF201 , 
and (4) relaxin, oestradiol and PGF2 <*. In each group the mean 
cervical score improved after treatment; the relaxin/PGF2 a combination 
was associated with the greatest improvement in cervical score (4.8). 
The highest incidence of subsequent labour was also seen in the 
relaxin/PGF2 a group (40%). However, with the exception of the latter 
group, the clinical effects of these hormonal combinations were 
neither greater nor smaller than the previously published effects of 
these hormones used individually in similar circumstances. The second 
part of the study further explored the possibility of an additive 
effect of relaxin and PGF201 in combination as suggested by the pilot 
study, and an additional 40 patients were given this combination. 
Analysis of these larger numbers showed no additive effect when these 
hormones were used in combination compared with when they were used 
individually. Thus, in the circumstances described, there is no 
clinical advantage to the concurrent administration of any combination 
of relaxin, PGF2 <*, and oestradiol with regard to cervical ripening 
and/or the initiation of parturition.
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12.2 INTRODUCTION
Intrayaginal prostaglandin F2a (PGF2a) (MacLennan & Green 1979 
(Appendix 1)), oestradiol (Gordon & Calder 1977) and purified porcine 
relaxin (MacLennan et al 1980 (Chapter 11)) have been used individual­
ly to ripen the cervix and, with variable success, to initiate labour. 
No clinical trials have been reported of the effects of combinations 
of hormonal cervical ripening agents. The present trial was designed 
to examine empirically whether there is any clinical advantage to the 
use of these hormones in combination and to study any apparent 
relationships between their modes of action when given in these 
circums tances.
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12.3 PATIENTS AND METHODS
Relaxin was obtained from the ovaries of pregnant sows and was 
purified by the method of Sherwood and QfByrne (1974) with minor mod­
ifications as described by Kwok et al (1980). The relaxin used in 
this study had a biopotency of 1500 guinea-pig units (GPU) /mg relat­
ive to the reference preparation NIH-R-PI (potency 442 GPU/mg). The 
purified relaxin used was equivalent to the CM-a* peak described by 
Sherwood and 0TByrne (1974) and is the same as that used for the 
analysis of the primary structure and sequence studies of porcine 
relaxin (James et al 1977).
Permission for the clinical trials was obtained from the research 
and ethics committee of The Queen Victoria Hospital, Adelaide. As 
only a limited supply (140 mg) of relaxin was available, a preliminary 
double blind randomised pilot study was set up involving 4 groups of 
10 patients . The patients in each group received 2 mg relaxin and 10 
mg oestradiol-178; 10 mg oestradiol-178 and 25 mg PGF2a ; 2 mg relaxin 
and 25 mg PGF2a; or 2 mg relaxin, 25 mg PGF201 and 10 mg oestradiol-178. 
It was proposed that the remaining 80 mg relaxin be used to examine in 
greater numbers the combination that appeared most effective. Thus, 
at the end of the double blind randomised study, an additional 40 
patients were given the combination containing 2 mg relaxin and 25 mg 
PGF2a. Close matching of the 4 groups in the initial randomised trial 
was apparent by the end of the study (Table 15). The patients from 
similar pretreatment trials (Chapter 11 and Appendix 2), shown for 
comparison in Table 16, also had clinical characteristics comparable 
to those of the overall total of 50 patients given the relaxin/PGF2a 
combination.
Criteria for inclusion in the study were singleton pregnancy, 
cephalic presentation, unscarred uterus, maternal height over 150 cm,
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no history of asthma, and informed patient consent. The hormonal 
combinations were made up to 10 ml with distilled water and mixed with 
700 mg of water-soluble cellulose (Tylose) granules (Hoechst) to make 
a viscous gel. One of the authors (AHM), unaware of the treatment 
allocation, assessed the cervical score (modified Bishop score)
(Calder, Embrey & Tait 1977) at 5.00 p.m. on the evening before the 
proposed induction of labour. The gel was then placed in the poster­
ior vaginal fornix by means of a soft latex catheter and a syringe, No 
attempt was made in this trial to stretch the cervix or sweep the 
fetal membranes. The patient was asked to remain in bed for an hour. 
The next morning at 8.00 a.m. the cervical score was reassessed by the 
same author. Thereafter, the labour was managed by obstetricians un­
aware of the constituents of the vaginal gel. Statistical analysis of 
the results was done with the Student one-tailed t test, the Fisher 
exact test and the x2 test.
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12.4 RESULTS
The outcome of the pilot study is shown in Table 17. The mean 
cervical score improved after treatment in each group, the greatest 
improvement occurring in the group receiving the relaxin/PGF2 0t combin­
ation. This combination was also associated with the highest incid­
ence of labour. However, the differences between the results from 
each group were not statistically significant for the numbers studied.
As the relaxin/PGF2 0t combination was associated with the greatest 
clinical effect in the pilot trial, an additional 40 patients were 
given this combination to examine more thoroughly any enhancement of 
these hormones* individual actions. The results of all 50 patients 
given therelaxin/PGF2 0t combination are shown in Table 16, in which 
they are compared with previously reported trials (Chapter 11 and 
Appendix 2) of cervical pretreatment with a placebo, 2 mg relaxin, or 
25 mg PGF2 0t alone. The combination of relaxin and PGF201 given to 50 
patients was not associated with a greater mean improvement in 
cervical score or a higher incidence of labour than pretreatment with 
either relaxin or PGF201 alone.
There was no statistical difference in the outcome of labour 
between any of the treatment groups in this trial with respect to 
length of labour, analgesic requirements, mode of delivery, or Apgar 
scores. No maternal or neonatal side effects were detected during the 
study.
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12.5 DISCUSSION
The pilot study suggested no major enhancement of the individual 
effects (Gordon & Calder 1977; MacLennan et al 1980; MacLennan &
Green 1980) of these hormones when used in combination, with the 
possible exception of relaxin and PGF2a» The limited quantity of 
purified relaxin available for this trial curtailed the study of large 
numbers in each group in the pilot study. The study of the influence 
of exogenous hormones on parturition in patients close to their 
expected date of delivery is open to error when the number of patients 
studied is small. There can be biologicalvariation in the response to 
these hormones when they are given via this route (MacLennan & Green 
1979; Gordon & Calder 1977; MacLennan et al 1980), and there is a 
small chance of spontaneous labour in any 15 h period near term 
(Control Group, Appendix 1). The empiricism of the model is further 
compounded by the lack of information on different rates of absorption 
of the different classes of hormones, prostaglandins, steroids and 
peptides, from the gel by the tissues, such that absorption may be 
sequential. It was important to study the relaxin/PGF2 a combination 
in greater numbers to allow better analysis of the possibility of an 
additive or synergistic effect of these hormones in combination.
After treatment of 50 patients with relaxin and PGF2 C1 in combination, 
it was clear that there was no such enhancement of these hormones1 
individual effects. However, future administration of these hormones 
in a known time sequence, rather than in apparent combination, may be 
more physiologic if, for example, prior oestrogen or prostaglandins 
stimulate an increase in relaxin receptor sites. Oestrogen admin­
istration has been shown to induce relaxin receptors in the uterus of 
ovariectomized rats but not in the cervices of ovariectomized, 
oestrogen treated sows (unpublished observations). In the rat, prost-
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aglandin synthetase inhibitors block the cervical ripening effect of 
relaxin, suggesting that prostaglandins may mediate the effect of 
relaxin on the cervix (Kennedy 1976). However, in this study PGF2 CC 
did not enhance the effect of relaxin when given at the same time as 
relaxin, and therefore, if PGF2 C1 does mediate the response of the 
human cervix to relaxin, it may require administration before the 
treatment with exogenous relaxin.
The 3 hormones studied did not induce separate or complimentary 
detectable cervical changes when given in combination. The possibil­
ity that they may act in sequence through the same pathway to produce 
the same effect remains to be examined. Thus, there would appear to 
be no clinical advantage to using these hormones in combination in the 
circumstances described, but their future use in sequence might prove more 
effective and give further insight into their relationships at the 
onset of parturition.
C H A P T E R  1 3
RIPENING OF THE HUMAN CERVIX AND INDUCTION OF LABOUR 
WITH INTRACERVICAL PURIFIED PORCINE RELAXIN
164,
13.1 SUMMARY
In a randomised double blind placebo controlled trial involving 
54 patients, a viscous gel containing either distilled water or 1 or 2 
mg pure porcine relaxin was instilled in the cervical canal on the 
evening prior to the surgical induction of labour. Seven of the 36 
patients receiving relaxin laboured overnight. Of the control 
patients none went into labour. Both the 1 mg dose and the 2 mg dose
significantly improved the mean cervical scores compared to the
placebo treatment. The favourability of the cervix at the time of the 
initial treatment did not influence the effect of the 2 mg dose but
when the results were analysed by parity the 2 mg dose was more
effective in the primiparous patients and the 1 mg dose was more 
effective in the multiparous patients. Compared to the results of 
previous trials the intracervical application of porcine relaxin is no 
more effective than its intravaginal application in effecting cervical 
ripening or inducing labour. This trial confirms the responsiveness 
of the human term cervix to exogenous relaxin and supports the suggest­
ion that endogenous relaxin may play a similar role in facilitating 
cervical ripening and parturition.
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13.2 INTRODUCTION
In most species studied there is a surge in serum relaxin approx­
imately 24 h prior to the onset of parturition. In association with 
this increase in relaxin there is a shortening, softening and opening 
of the cervix which is known as cervical ripening. It is postulated 
that in the human one of the main roles of the polypeptide hormone 
relaxin is to facilitate connective tissue remodelling during reprod­
uction such as occurs during the cervical ripening process (Chapter 1). 
Human relaxin is not yet available for in vitro or in vivo trials but 
porcine relaxin has recently been purified in sufficient quantities 
for clinical trials. To date, there have been three clinical trials 
with pure porcine relaxin (MacLennan et al 1980 (Chapter 11); MacLennan 
et al 1981 (Chapter 12); Evans et al 1983). The first two showed that 
2 mg of vaginally applied porcine relaxin in a tylose gel promoted 
cervical ripening in over 80 percent of patients near term and 
apparently initiated labour in approximately one-third of the treat­
ment groups. The third trial confirmed the efficiency of porcine 
relaxin as a cervical ripening agent when applied to the cervix in 
Carbowax pessaries containing either 2 or 4 mg of relaxin. Vaginally 
applied prostaglandins and relaxin appear to work in sequence to 
produce the same clinical (Chapter 12) and histological (Chapter 14) 
changes in the cervix. When given intracervically rather than 
vaginally prostaglandin-containing gels appear to be more effective as 
cervical ripening agents and can be given in smaller doses to induce 
labour (Wingerup, Anderson & Ulmsten 1979; Ekman et al 1983).
This study examines for the first time the efficacy of pure 
porcine relaxin as a cervical ripening agent when applied intracerv­
ically in a viscous gel in two differing doses.
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13.3 PATIENTS AND METHODS
Permission for the clinical trials was obtained from the research 
and ethics committee of The Queen Victoria Hospital, Adelaide and from 
the Australian Department of Health. A randomised placebo controlled 
double blind trial was designed involving 54 patients who were schedul­
ed for surgical induction near term. Criteria for inclusion in the 
trial were singleton pregnancy, cephalic presentation, unscarred 
uterus, maternal height over 150 cm, a pretreatment cervical score of 
6 or less (modified Bishop score) (Calder, Embrey & Tait 1977) and 
informed patient consent. The patients were randomly allocated to 
receive either a placebo (2 ml sterile water), 1 mg or 2 mg of 
purified porcine relaxin, the allocated constituent being mixed with 
150 mg tylose granules (Hoechst) to make a viscous gel. Close match­
ing of the groups was apparent by the end of the trial (Table 18). The 
mean parity of the placebo group was higher than the treatment groups 
but this did not reach statistical significance.
Relaxin was obtained from the ovaries of pregnant sows and was
purified by the method of Sherwood and 0*Byrne (1974) with the modif­
ications of Walsh and Niall (1980). The relaxin used in this study 
had a biopotency of 1500 guinea-pig units (GPU) /mg relative to the 
reference prepapartion NIH-R-PI (potency 442 GPU/mg). The purified
relaxin used was equivalent to the CM-a1 peak described by Sherwood
and 0'Byrne (1974) and is the same as that used for the analysis of the 
primary structure and sequence studies of porcine relaxin (James et al 
1977).
A.H.M.:, unaware of the treatment allocation, assessed the 
cervical score at 5 p.m. on the evening before the proposed induction 
of labour. The gel was then applied from the top of the cervical 
canal by means of a thin plastic cannula which was gradually withdrawn
VARIABLE PLACEBO 
(n = 18)
1 mg RELAXIN 
(n = 18)
2 mg RELAXIN 
(n = 18)
Mean maternal age (yr) 25.1 28.4 25.8
Mean gestation (wk) 40.0 39.7 39.9
Mean parity 1.1 0.8 0.6
Mean birth weight (kg) 3.6 3.3 3.4
Mean cervical score 
at priming 3.7 3.7 3.4
TABLE 18 Comparison of treatment and control groups in the intra- 
cervical relaxin pretreatment trial
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so that the 2 ml of gel was completely expelled into the cervical 
canal before removal of the cannula from the external os. No attempt 
was made in this trial to stretch the cervix or sweep the membranes.
The patient was asked to remain in bed for 1 h. Next morning at 8 
a.m. the cervical score was reassessed by A.H.M. Thereafter, the 
labour was managed by obstetricians unaware of the constituents of the 
vaginal gel.
Statistical analysis of the results was performed using Student’s 
(one tailed) t test and Fisher's exact test.
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13.4 RESULTS
The effect of the placebo gel and the relaxin gels 15 h after 
intracervical application is shown in Table 19L No patients in the 
placebo group laboured overnight but 7 of the 36 patients receiving 
relaxin became established in labour 'during this time (p<0.05,
Fisher's exact test). One patient in each of the relaxin treated 
groups had spontaneous rupture of the membranes overnight in associat­
ion with the onset of labour. The mean improvement in the cervical 
score was 1.1 for the placebo group. Compared to this group the mean 
improvement of 2.2 in the cervical score of patients treated with 1 mg 
relaxin was significant (p<0.05, Student's t test) as was the mean 
improvement of 3.0 following treatment with 2 mg relaxin (p<0.025).
The difference in the results between the 1 and 2 mg groups was not 
statistically significant. The cervical score improved regardless of 
the initial cervical score in the 2 mg relaxin treated groups (p<0.05, 
Student's t test) but the improvement seen in the 1 mg relaxin treated 
groups as analysed by the initial cervical score did not reach stat­
istical significance for the numbers studied (Table 20). When analys­
ed by parity a statistically significant improvement in the cervical 
score was seen only in the primiparous patients receiving 2 mg 
relaxin and the multiparous patients receiving 1 mg relaxin (p<0.05, 
Student's t test) (Table 21). There was no statistical difference in 
the outcome of the labours (Table 22). No apparent side effects to 
the relaxin treatment were detected in the mothers or the babies and 
the indication given for each of the 5 caesarean sections was "failure 
to progress".
OUTCOME PLACEBO 1 mg RELAXIN 2 mg RELAXIN
(n = 18) (n = 18) (n = 18)
Delivered at 15 h .0 II 0
Established in labour 0 2 4
Mean change in cervical
score 1.1 2.2 3.0
No. with no change 7 5 4
TABLE 19 
relaxin.
Outcome of pretreatment with intracervical placebo or
INITIAL SCORE MEAN IMPROVEMENT IN CERVICAL SCORE
PLACEBO 1 mg RELAXIN 2 mg RELAXIN
0 - 3  1.2 (7) 2.9 (9) 3.4 (8)
4 - 6  1.1 (11) 1.7 (9) 2.7 (10)
TABLE 20 Analysis of results of intracervical relaxin pretreatment 
by initial cervical score.
No. of patients in parentheses
PARITY MEAN IMPROVEMENT IN CERVICAL SCORE
PLACEBO 1 mg RELAXIN 2 mg RELAXIN
Primiparous 0.7 (6) 1.6 (11) 3.8 (11)
Multiparous 1.4 (12) 3.3 (7) 1.7 (7)
TABLE 21 Analysis of results of intracervical pretreatment by parity 
No. of patients in parentheses
OUTCOME PLACEBO 1 mg RELAXIN
(n = 18) (n = 18)
2 mg RELAXIN 
(n = 18)
Augmented with oxytocin 14 13 12
Mean, length of labour (hr) 7.1 6.2 7.3
Caesarean section 1 2 2
Instrumental delivery 2 3 3
Mean Apgar score at 1 min. 7.6 7.9 7.5
Mean Apgar score at 5 min. 8.8 9.1 9.1
TABLE 22„ Outcome of labour in intracervical pretreatment trial
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13.5 DISCUSSION
The results of this trial confirm the findings of the first 
clinical trials using purified porcine relaxin in showing that exo­
genous porcine relaxin has a cervical ripening effect on the human 
cervix near term. In the first published randomised double blind 
trial (MacLennan et al 1980) the relaxin treated group had a slight 
bias towards being more favourable at the time of the application of 
the gel. In this trial the placebo and treatment groups were well 
matched although the placebo group had a higher but not statistically 
significant different mean parity. There were 12 multiparous patients 
in the placebo group but only 7 in each of the treatment groups.
This may account for the 7.1 h mean length of labour in the placebo 
group with is 1-2 h shorter than comparable placebo groups of lower 
mean parity in the other trials (Chapters 11 & 12) and, thus, explain 
why, unlike the previous trials, a significant reduction in the 
length of labour was not apparent in the relaxin treated group 
compared to the control group. The mean length of labour of 6.7 h in 
the relaxin treated groups is similar to the significantly reduced 
mean length of labour (6.6 h) of relaxin treated patients in the 
previous trials described in this thesis.
The improvement in cervical score and the incidence of subsequent 
labour in this trial of intracervical relaxin gel are no better than 
the results obtained following the iritravaginal application of 
relaxin (Chapter 11). Although both methods were not compared in the 
same trial the similarity of the trials and the close matching of the 
patients studied in both trials suggests that there is no advantage in 
the intracervical application of relaxin compared to its vaginal 
application in a viscous gel. In the first trial (Chapter 11), 2 mg 
of purified porcine relaxin given intravaginally in tylose gel gave a
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mean improved cervical score of 3.4 points and 33 percent of the 
patients laboured during the next 15 h. In this trial of intracervic- 
ally applied relaxin the 2 mg group improved its mean cervical score 
3.0 points and 20 percent of the patients laboured.
In this trial, only 2 mg of intracervical relaxin proved to be 
statistically better than the placebo in producing cervical ripening 
in the primiparous patients and 1 mg of relaxin was the only statistic­
ally significant effective dose in the multiparous patients. The 
favourability of the cervix at the time of the application did not 
appear to inhibit or enhance the action of the exogenous relaxin's 
cervical ripening effect. Evans et al (1983) did not analyse their 
patients by parity or initial cervical favourability but their results 
suggested that 2 mg of vaginally applied porcine relaxin was more 
effective than 4 mg. The greater efficacy of the smaller dose could 
not be explained although a down-regulation effect of "overdosing" was 
hypothesised. The same phenomenon may have occurred in the multi­
parous patients in this trial.
It is likely that at intracervical application of the gel some of 
the gel may have entered the neighbouring extraamniotic space and 
would have been in close contact with the fetal membranes. It is of 
interest to note that over the next 15 h only 2 out of the 36 
patients receiving relaxin gel had spontaneous rupture of the fetal 
membranes. It has been hypothesised that relaxin may facilitate 
membrane rupture as collagenase and plasminogen activator secretion 
are stimulated by porcine relaxin in human amnion and chorion cells 
cultured in vitro (Koay et al 1983). However, this in vitro effect 
was described after an incubation period of 32 h and therefore 15 h 
may have been too short a time to study the effect of exogenous 
porcine relaxin on human fetal membranes in vivo.
Finally, this study provides further evidence that the human
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cervix will recognise and respond to pure porcine relaxin despite 
there being only an approximate 50 percent homology in the amino acid 
structure between porcine and human relaxin (Hudson et al 1983). 
Paradoxically, human myometrial contractility is not inhibited by 
porcine relaxin (Chapter 10) but human cervical smooth muscle contract­
ility is inhibited by porcine relaxin (Norstrom et al 1984). It is 
yet to be proven that human myometrium has relaxin receptors and that 
human relaxin will inhibit human myometrial activity. However, given 
that this is likely, the different response of the myometrium and the 
cervix in the human to porcine relaxin suggests that human relaxin 
receptors may be modulated in different ways in different target 
organs and thus allow the uterine body and the uterine cervix to 
function independently of each other and still be under the influence 
of the same hormone at different times during pregnancy.
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C H A P T E R  1 4
THE MORPHOLOGY OF CERVICAL RIPENING INDUCED BY THE 
HORMONES RELAXIN AND PROSTAGLANDIN F2o IN A RABBIT MODEL
17 8,
14.1 SUMMARY
In previous studies both purified porcine relaxin and prostaglan­
din F2 a have been applied vaginally in the human to promote cervical 
ripening near term. In this study the histological changes in the 
cervix induced by these locally applied hormones are described in a 
rabbit model. Similar histological changes occurred following treat­
ment with relaxin or prostaglandin F201 and these changes were compar­
able with those seen in the cervix following the spontaneous onset of 
labour in control rabbits. The main histological features were a dis­
solution of the collagen bundles and an apparent increase in the 
ground substance. However, a unique giant cell infiltrate was seen in 
the relaxin treated and spontaneously labouring control rabbits. The 
nature and possible function of these giant, cells are discussed. The 
similarity of the general morphological changes in the cervix induced 
by relaxin and prostaglandin F201 supports the concept that these 
hormones may act either in sequence or separately to activate the same 
collagenolytic system to produce the same effect in cervical connect­
ive tissue rather than acting in parallel to produce separate or 
complementary structural changes.-
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14.2 INTRODUCTION
In most mammals, prior to parturition, there are structural 
changes in the connective tissue of the cervix that lead to its alter­
ed distensibility, dilatation and softening that are collectively 
known as cervical ripening. In the human, several hormonal agents 
(Steiner & Creasy 1983) including vaginally applied purified porcine 
relaxin (Chapter 11) and prostaglandin F2 « (Appendix 1) have been 
given prior to the induction of labour to induce such changes in the 
cervix. These two hormones individually applied appear to produce a 
similar clinical effect and when given in combination there does not 
appear to be any additive effect (Chapter 12). This suggests that 
these hormones may act in sequence or separately, to produce the same 
effect rather than working in parallel to produce different or comple­
mentary changes in the cervix.
No study of the histological changes in the cervix following 
administration of pure porcine relaxin or prostaglandin F2 0  has been 
published. This study examines and compares the histological changes 
induced by these hormones. For ethical reasons adequate material for 
the study could not be collected from the human. Therefore, the 
rabbit was chosen as it has been shown that this animal is a good 
model for the investigation of the mechanical behaviour of the cervix 
and, the rabbit cervix appears to be comparable to the human cervix in 
its physiologic responses (Conrad & Hoover 1982; Danforth, Buckingham 
& Roddick 1960).
14.3 MATERIALS AND METHODS
Twelve mature female New Zealand White rabbits weighing 4.5-5.8 
Kg were studied. Six of these served as untreated controls. Two of 
the control rabbits were not pregnant, two were sacrificed on day 28 
of pregnancy, one was sacrificed in labour on day 29 of gestation and 
one 12 h postpartum on day 30 of gestation. Of the other six rabbits, 
two were treated with either 4 mg prostaglandin F201 and four with 0.3 
mg purified porcine relaxin. Both hormones were mixed in a tylose gel 
and administered vaginally by means of a syringe and catheter on day 
27 of pregnancy. Fifteen hours later on day 28 of pregnancy the 
treated animals were sacrificed. The uterus was removed after 
sacrifice and the cervix and lower uterine segment fixed for histolog­
ical examination. Paraffin sections of each cervix were cut in a 
sagittal plane and were stained with either haematoxylin and eosin, 
Masson's trichrome to highlight collagen or Alcian Blue - Periodic 
Acid Schiff (P.A.S.) which stains the mucopolysaccharides of the 
ground substance blue.
Tissues for electron microscopy were fixed in a 5% paraformalde­
hyde and 3% gluteraldehyde in cacodylate buffer, post fixed in 1.5% 
osmic acid, dehydrated in a series of ethanolic solutions, transferred 
to propylene oxide and then embedded in Epon. Sections were examined 
on grids with AE1801 electron microscope at initial magnifications of 
1,700 to 40,000.
The doses of prostaglandin F2 C1 and porcine relaxin chosen were in 
proportion to body weight to the clinically effective dose of these 
hormones which produce cervical ripening when administered vaginally 
in the human (Chapter 11). The porcine relaxin used was purified as 
in Chapter 2.
4 RESULTS
14.4.1 Control Rabbits (Figure 27)
The non-pregnant rabbit cervix is a relatively small firm 
structure and the histology reflects this appearance in that the 
collagen, staining dark blue on Masson's stain, is densely packed 
around the small muscle bundles, which stain pink (Figure 27A). 
There is little ground substance between the collagen fibres and 
the collagen bundles run in relative unison around the cervical 
muscle.
In late pregnancy (day 28) the rabbit cervix is a larger 
softer structure than the non-pregnant cervix, being about twice 
its previous size. The collagen bundles are not so densely packed 
and this results in a lighter blue staining of these fibres 
(Figure 27B). The collagen bundles still run together in a 
uniform fashion around the muscle fibres and there is an apparent 
slight increase in the ground substance.
In labour (Figure 27C) the rabbit cervix is even softer and 
longer than in late gestation. There is marked submucosal oedema 
and separation of the.collagen fibres deeper in the cervix. The 
collagen fibres seem to be in disarray with little uniformity in 
their direction. There is an apparent large increase in the 
ground substance and the blood vessels are more prominent. Giant 
cells which are described in detail below, appear for the first 
time. They are seen more commonly around the blood vessels and in 
the subepithelial layer, although they can be found throughout 
the depth of the cervix and extend into the lower uterine segment.
Twelve hours pospartum the rabbit cervix is still macroscop- 
ically large (approximately three times the non-pregnant size) 
but firmer in consistency than during labour. The muscle bundles
Figure27 Cervical tissue from control rabbits.
Masson's trichrome stain (x80)
A. Non pregnant B. Day 29 pregnancy
C. During labour D. 12 hours postpartum
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are more prominent and a large number of blood vessels are appar­
ent (Figure 27D). The collagen fibres between the muscle bundles 
are more densely packed than during labour and are beginning to 
regain their uniformity of direction. There appears to be a 
corresponding reduction of ground substance and the giant cells 
seen in the cervix during labour could only occasionally be found.
14.4.2 Prostaglandin and Relaxin Treated Rabbits (Figure 28) 
With the exception of the more frequent presence of giant
cells in the relaxin treated cervices the histological changes 
induced by the two hormonal treatments are similar to each other 
and comparable to the changes seen in the cervix of the control 
rabbit in labour. All hormonally treated cervices responded in 
similar fashion. Macroscopically the cervices were large and 
soft. Histologically there is submucosal oedema and deeper in 
the cervical tissue there is an apparent marked increase in the 
ground substance, as demonstrated with Alcian Blue - P.A.S. stain. 
The collagen fibres do not run in uniform bundles but are gener­
ally widely separated without concurrence in their orientation.
The blood vessles are more prominent in number and size suggest­
ing an increase in vascularity. Only an occasional giant cell 
was seen in one of the prostaglandin treated cervices whilst 
numerous giant cells were seen in three of the four relaxin 
treated cervices.. They are similar in morphology and general 
position to those seen in the cervices of labouring and post­
partum control rabbits.
14.4.3 Giant Cells (Figures 29 and 30)
These cells do not conform to a precise description of any 
previously recorded cells and could not be positively classified
■Figure 28 Cervical tissue from treated rabbits at day 28 
of pregnancy.
Mason's trichrome stain
A. Prostaglandin F 2a treated (x80)
B. Relaxin treated (x80)
C. Prostaglandin F 2a treated (x200)
D. Relaxin treated (x200)
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by any of four senior pathologists to whom they were shown. In 
this report we have simply called them giant cells because of 
their size (50-100 my in'diameter) rather?thandefinitively 
classifying them in any family of cells. There was some similar­
ity in their appearance to ganglion cells and to decidual cells 
but neither neuronal nor uterine origin could be confirmed. They 
stain basophilic on haematoxolyin and eosin staining and are 
P.A.S. positive. They are multinucleated with large areas of 
vacuolation in the cytoplasm (Figure 29A, B). Ultrastruetural 
examination showed these cells to be densely packed with ribo­
somes, mitochondria and rough-surfaced endoplasmic reticulum 
(Figures 30 and 31). Numerous small vesicles were seen through­
out the cytoplasm but Golgi apparatus was not prominent and there 
were very few lysosomes. Multiple microvilli cover the surface 
of the cell and vesicles near the cell membrane suggest active 
pinocytosis. In some cells the nucleolus is relatively amorphous 
and in others the nucleolonema stands out clearly from the pars 
amorpha. Overall the ultrastructural picture is of a very active 
cell possibly involved in chemical or hormonal production and 
secretion.
These cells were seen frequently in the relaxin treated 
cervices and in the control cervix during labour. Only very 
occasional giant cells were seen in one of the prostaglandin 
treated cervices and in the postpartum control cervix. They 
were not seen in any of the non-pregnant or 28 day pregnant 
control rabbits. When present, these cells could be found 
throughout the connective tissue of the cervix but they appeared 
to be more prominent around blood vessels and in the submucosal 
layer. These cells were also found to extend into the lower 
uterine segments of the relaxin treated and labouring rabbits.
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Figure29 Giant cells in rabbit cervical tissue (x200).
A. Control rabbits in spontaneous labour 
(H. and E. stain).
B. Relaxin treated rabbit (Mason's trichrome stain).
Figure30 The ultrastructure of a giant cell in the cervical
tissue of a pregnant rabbit treated with relaxin on 
day 28 of gestation (x7,500).
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Figure31 The ultrastructure of a giant cell in the cervical
tissue of a pregnant rabbit treated with relaxin on 
day 28 of gestation (xl8,900).
In these latter sections, the giant cells were1 found predominant 
ly in th.e deeper layers of the decidua and between the muscle 
fibres of the inner myometrium.
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14.5 DISCUSSION
This study shows that vaginally applied porcine relaxin and pros­
taglandin F2 <* separately induce similar histological changes in the 
rabbit cervix. In clinical trials where porcine relaxin and prosta­
glandin F 2<x were used in combination to induce cervical ripening, no 
additive clinical effect nor apparent synergism in their action was 
found (Chapter 12). This histological study supports the suggestion 
made in these clinical trials that relaxin and prostaglandin F2a may 
act to produce the same structural changes in the term cervix rather 
than acting in parallel to produce separate or complementary cervical 
connective tissue changes. Whilst it is possible that relaxin and 
prostaglandins may act in sequence to produce this similar effect it 
is also possible that these hormones may separately stimulate the same 
collagenolytic process in cervical tissue near term. It has recently 
been shown that both prostaglandin (Norstrom & Wiqvist 1984) and 
relaxin (Norstrom et al 1983) increase cyclic adenosine $  , 51-mono­
phosphate (cAMP) in human cervical tissue at the end of pregnancy and 
it has been suggested that the effects of these hormones on cervical 
connective tissue metabolism are mediated by cAMP. Thus, this histol­
ogical study and previous clinical studies suggest that relaxin and 
prostaglandin F2a may have similar morphological effects on the term 
cervix, even though the link or sequence of action between them is yet 
to be established.
The treatment-induced histological changes in the rabbit cervix 
were similar to those observed in the rabbit cervix during spontaneous 
labour , suggesting that relaxin and prostaglandin F2® can induce the 
normal structural changes in the cervix associated with spontaneous 
cervical ripening and parturition. The hormonally induced changes 
described in this paper are comparable to the morphological changes in
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needle biopsies of the human cervix in early pregnancy, following 
treatment with prostaglandin E2 .(Uldbjerg et al 1981). However, there 
have been no histological reports of the changes in the human cervix 
at term after treatment with prostaglandin F2a or relaxin, presumably 
because of the difficulty in obtaining adequate cervical tissue at 
this time. As the rabbit has been shown to be a suitable model for 
studying cervical ripening (Conrad & Hoover 1982) it is suggested that 
the connective tissue changes induced by these hormones in the rabbit 
cervix, as described in this paper, are likely to reflect the morph­
ological changes that occur in the human cervix after vaginal 
application of prostaglandin F2a or relaxin.
The nature and function of the giant cell infiltrate is of some 
interest. These cells were mostly confined to the cervical and lower 
uterine segment sections from the rabbit in labour and three of the 
four rabbits treated with relaxin. Although these particular cells do 
not seem to have been described before in such a situation, different 
types of cells have been seen to invade the cervix during parturition 
in several species. Leukocytic infiltration has been described in the 
ovind cervix during parturition (Parry & Ellwood 1981). These cells 
are mostly neutrophils, but plasma cells, eosinophils and lymphocytes 
are also seen. In the guinea-pig and the human there is a leukocytic 
invasion of the cervix prior to parturition with a significant 
increase in the number of eosinophils (Liggins 1981). Janqueira et al 
(1980) hypothesise that the neutrophilic polymorphonuclear leukocytic 
invasion of the human cervix around the time of parturition contributes 
to the widespread collagenolysis occuring in the cervix at that time. 
They suggest that this action is mediated through the release of 
collagenase either from the leukocytes or indirectly from other 
cervical cells producing enzymes capable of digesting the extracellul­
ar matrix proteins. Other studies (Jones & Scott-Burden 1979) show
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that macrophages are another potential source of such enzymes and 
that macrophage plasminogen activator promotes digestion of the extra­
cellular matrix. Whether the giant cells described in the rabbit 
cervix near parturition are involved in collagenolysis cannot be 
determined from this study.
i  sa
C H A P T E R  1 5
THE ABSORPTION OF PORCINE RELAXIN FROM 
THE HUMAN VAGINA AND CERVICAL CANAL
15.1 SUMMARY
The systemic absorption of porcine relaxin administered in a 
tylose gel either vaginally or into the cervical canal to induce 
cervical ripening was measured by a homologous porcine relaxin radio­
immunoassay. Peripheral serum samples were taken before and after 
treatment for up to 6 hours. A marked rise in serum relaxin levels 
was seen in 6 of the 12 patients treated with relaxin. The degree of 
cervical ripening associated with the relaxin treatment appeared to 
correlate with the absorption of the hormone. This is the first 
description of the absorption of a polypeptide hormone from the lower 
genital tract and suggests that relaxin's cervical ripening effect may 
be mediated either systemically or by direct action at the site of 
local application.
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15.2 INTRODUCTION
The vagina is permeable to a wide variety of both organic and 
inorganic compounds and in the human has been used as a route of 
administration for steroid hormones and prostaglandins (Benziger & 
Edelson 1983). The vaginal absorption of a polypeptide hormone has 
not been documented in the human. The polypeptide hormone relaxin has 
recently been purified from porcine sources and has been tested in 
clinical trials as a cervical ripening agent when applied vaginally 
and intracervically. In doses of 2 mg mixed in a tylose gel it 
produces a significant degree of cervical ripening in approximately 85 
percent of patients (Chapters 11 and 13). The aim of this study was 
to see if systemic absorption of porcine relaxin occurred from both 
the vagina and cervical canal and if so, to measure its rate of 
absorption as reflected by peripheral serum porcine relaxin levels 
when meausured in a homologous porcine relaxin radioimmunoassay.
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15.3 PATIENTS AND METHODS
The absorption of porcine relaxin was measured in a total of 14 
patients. Two mg of relaxin were instilled vaginally in a 5 ml tylose 
solution in 6 patients, 6 further patients were given the same dose of 
relaxin into the cervical canal in a 2 ml tylose solution and 2 
patients received only a placebo (distilled water) in tylose gel (one 
by each route).
The systemic absorption of the porcine relaxin was measured by 
taking peripheral blood samples before treatment and hourly for up to 
6 hours after application of the relaxin gel. Serum porcine relaxin 
was measured in the radioimmunoassay described in Chapter 4 which in 
this case was homologous for porcine relaxin. All samples in this 
study were run in the same assay.
The cervical score (modified Bishop’s score (Calder et al 1977)) 
was assessed by the same observer both before treatment and 6 hours 
later.
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15.4 RESULTS
No rise in baseline levels of serum relaxin occurred in either 
control patient receiving the placebo. Five of the 6 patients given 
porcine relaxin by the intracervical route showed a marked rise in 
their serum relaxin levels from 1 h after treatment and this rise 
persisted in some cases until the end of sampling (Figure 32). 
Improvement in the cervical score was noted in each patient when 
assessed again 6 h after treatment.
Only 1 of the 6 patients given relaxin by the vaginal route 
showed a definite rise in serum relaxin concentration following 
treatment (Figure 33). The cervical score of this patient improved 2 
points in 6 h. Little or no improvement was seen over a 6 h period 
in the cervical scores of the remaining 5 patients. None of the 14 
patients in this study commenced in labour during the 15 h following 
application of the gel.
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FIGURE 32 Serum relaxin concentrations as measured in a porcine radio­
immunoassay following the intracervical application of 2 mg porcine 
relaxin. The figures in red indicate the improvement in the cervical 
score 6 hours after treatment.
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FIGURE 33 Serum relaxin concentrations as measured in a porcine radio­
immunoassay following the vaginal application of 2 mg porcine relaxin.
The figures in red indicate the improvement in the cervical score 6 hours 
after treatment.
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15.5 DISCUSSION
This is the first study to show the absorption of a polypeptide 
hormone from the lower reproductive tract. It would appear from the 
small numbers in this study that absorption of porcine relaxin occurr­
ed more readily from the cervical canal than from the vagina. However, 
it should be noted that the cervical ripening effect was unusually 
poor in 5 patients given relaxin by the vaginal route. These patients 
showed an improvement of only 0-1 points in the cervical score whereas 
the mean improvement in larger studies using this route is 3.4 points 
(Chapter 11). Thus, these patients, may be atypical and further 
studies of peripheral serum levels are required (and are in progress) 
in patients who show a normal and significant degree of cervical 
ripening following the intravaginal instillation of porcine relaxin.
Nevertheless,* a major rise in peripheral serum relaxin levels was 
seen in 6 of the 12 patients treated with porcine relaxin soon (1 h) 
after its application. The levels at 1 h were well above the normal 
range of relaxin in late pregnancy (Chapter 5) using the same assay 
and in this case, as the assay measures porcine relaxin, the increase 
is most likely to be due to the systemic absorption of the exogenous 
relaxin. No rise in endogenous relaxin was seen after application of 
the placebo gels.
This study suggests that the cervical ripening action of exogen­
ously applied relaxin may be mediated either through its systemic 
circulation and/or its local absorption directly into the cervical 
tissues. However, clearly the absorption of relaxin, especially 
possibly the vaginal route, is variable and more research is required 
to ascertain the best route of administration and in particular the 
best carrier of the relaxin. Many new gels and pessaries for vaginal 
and intracervical prostaglandins are currently being tested through­
out the world and present studies in the author*s laboratory are 
aimed at testing the in vitro and in vivo release rates of relaxin 
from water based gels and a hydrogel pessary.
C H A P T E R  1 6
FOLLOW-UP STUDIES ON PATIENTS INVOLVED 
IN CLINICAL TRIALS OF PORCINE RELAXIN
16.1 SUMMARY
Whilst no short term side effects have been detected in the 
clinical trials reported in this thesis or elsewhere (Evans et al 
1983), long term follow-up of patients treated with porcine relaxin is 
still underway. In particular, no involuntary infertility has yet 
been detected. Twenty-five patients have been sampled 3 to 12 months 
after treatment and no porcine relaxin antibodies have been detected 
in their serum. Screening for antibody formation is continuing.
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16.2 INTRODUCTION
A concern of the candidate, the hospital's ethics committee and 
the Australian Department of Health was the possibility of any clinical 
side effects in the human trials. Permission for the clinical trials 
described in this thesis was only granted by the Australian Department 
of Health, the Australian National Biological Standards Laboratory, 
the Australian National Health and Medical Research Council and The 
Queen Victoria Hospital, Adelaide, Research and Ethics Committee, 
after considerable chemical, pharmacological and animal data had been 
presented and evaluated concerning the purification and clinical use 
of porcine relaxin. The strict quality control measures for the 
purification of porcine relaxin described in Chapter 2 have had to be 
maintained throughout the trials. (In 1982, the National Institutes 
of Health (U.S.A.) also gave permission for clinical trials with pure 
porcine relaxin and no side effects were reported in the first U.S. 
trial reported by Evans et al (1983)).
Patients in the cervical ripening and embryo transfer trials were 
carefully monitored, as previously described, during treatment, labour 
and their period of hospitalisation. No short term maternal or neo­
natal side effects were noted. However, a register of patients who 
have received porcine relaxin has been kept and long term follow-up is 
underway. Many patients who were in the first two cervical ripening 
trials have now conceived again and several have delivered a second 
child since the trial. No involuntary infertility has been reported 
or detected to date in patients who have received porcine relaxin.
The risks of side effects of any hormone are difficult to estim­
ate when used in the human for the first time. However, the extensive 
use of very impure preparations of relaxin in the 1950's and 1960's 
when given parenterally had not been associated with apparent side
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effects and a similarity could be drawn to the use of porcine;dnsulin 
for many years until the recent introduction of human insulin. After 
repeated injections of porcine insulin antibodies to porcine insulin 
do occur in a small percentage of diabetics. As there is a greater 
similarity in the amino acid structure of porcine and human insulin 
than porcine and human relaxin it is considered important to check 
whether the single vaginal or intracervical administration of 2 mg 
porcine relaxin induces antibody formation in the human. To date 25 
patients have volunteered to give serum samples for these checks 3 to 
12 months after receiving porcine relaxin. Much larger numbers are 
currently being sampled.
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16.3 METHODS
The radioimmunoassay described in Chapter 4 was modified as below. 
Serum samples were stored frozen at -80°C until used. 0.1 ml was 
incubated with 50 pg 125I-labelled porcine relaxin at 4°C for 48 h. 
Anti-human gamma globulin (non gamma chain specific, precipitating 
antibody purchased from Antibodies Inc., California) was added, in two 
series in doses of 0.1 ml or 0.05 ml, to the serum with the labelled 
relaxin incubate. This was further incubated overnight at 4°C. These 
mixtures were then spun at 3000 rpm for 20 minutes on a Sorvall RC-2 
centrifuge. The supernatant was decanted and a 0.4 ml cold barbitone 
buffer (pH 8.6, 0.05 M) was added to each tube and the precipitate 
resuspended. They were then recentrifuged as before and the super­
natant decanted,,the tubes wiped with cotton-tip and decanted. This 
avoided "trapping" of i25I-relaxin in the precipitation matrix.
Counts of the study and control samples in triplicate were performed 
as in Chapter 4.
16.4 RESULTS
None of the 25 study serum samples showed evidence of anti- 
porcine relaxin antibodies. The results are shown in Table 23.
PATIENT NUMBER ANTIHUMAN GAMMAGLOBULIN 
% bound ■125I-relaxin 
0.1 ml 0.05 ml
1 5.2 1.4
2 4.8 3.9
3 6.9 4.1
4 5.6 2.1
5 2.5 2.6
6 6.2 2.3
7 4.6 2.0
8 4.4 1.6
9 7.1 1.9
10 9.5 2.7
11 7.3 1.8
12 9.7 2.2
13 7.5 0.77
14 9.4 0.61
15 8.3 2.9
16 9.0 1.1
17 4.6 1.2
18 10.1 1.5
19 2.3 2.2
20 4.3 2.3
21 5.3 1.9
22 3.8 3.7
23 7.8 2.2
24 3.8 2.2
25 3.7 1.5
Controls:
A 8.3 4.0
B 10.9 4.9
C 4.5 3.1
control patients being investigated for formation of porcine anti­
bodies for two concentrations of precipitating antihuman gamma­
globulin.
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16.5 DISCUSSION
Although no patients have yet produced antibodies to porcine 
relaxin it is considered important to continue to check for this 
possibility. It is also unwise to assume that even if porcine relaxin 
antibodies are produced that they would not interfere with the role of 
human relaxin and thus the monitoring for long term side effects will 
be continued. Such surveillance is not simple and it is hard to 
comprehensively follow these patients when blood sampling and access 
for follow-up surveys is voluntary.
The use of porcine relaxin in clinical trials is relevant only to 
facilitate the study of human relaxin when it becomes available for 
clinical trials later this decade. The areas in which porcine relaxin 
has been successfully applied, the doses, carriers and routes used 
will all allow the quicker assessment of human relaxinfs role in the 
human and therapeutic potential. Thus, when human rdlaxin is event­
ually available in sufficient amounts for clinical use it will perhaps 
be unnecessary to use pure porcine relaxin.
C H A P T E R  1 7
FINAL DISCUSSION
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17.1 GENERAL
Detailed discussion of each of the 12 studies presented in this 
thesis has been presented at the end of the relevant Chapter (Chapters 
5-16). The candidate chose four main areas to study relaxing possible 
role in human reproduction, namely peripheral serum relaxin levels 
during pregnancy, implantation of the blastocyst, myometrial contract­
ility and cervical ripening prior to parturition. In a single thesis 
it has not been possible to comprehensively investigate all the possible 
roles of relaxin both before and during pregnancy. However, studies in 
the candidate*s laboratories have also confirmed the data of Essig et 
al (1982) that porcine relaxin appears to enhance washed human sperm 
motility, both in vitro and in columns of human cervical mucus, and our 
preliminary data also suggests that pure porcine relaxin enhances the 
penetration of mouse ova by human sperm. Studies are in progress on the 
influence of relaxin on uterine stromal growth and uterine accommodation 
during pregnancy in the rat and on the possible role of relaxin in 
involution of the uterus during the puerperium. Studies in other 
laboratories (not the candidate's) involve investigation of relaxin's 
role in ovulation, fetal membrane rupture, breast development and 
lactation.
The possible roles of relaxin in the human are diverse but, so far, 
the areas being investigated are centred around its two main mechanisms 
of action which are (1) its probable influence on connective tissue 
remodelling in target tissues, and (2) its influence on cellular cyclic 
AMP, e.g. in the inhibition of myometrial contractility. The possible 
biological roles of relaxin have been summaries in Table 1, Chapter 1.
In this thesis peripheral serum relaxin-like immunoactivity, as 
measured in a porcine relaxin radioimmunoassay, has been shown for the
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first time to decline steadily throughout the second half of pregnancy 
rather than remain stable as had been suggested in the few previous 
reports published. This decline is compatible with a waning role of 
relaxin in maintaining uterine quiescence. Even lower levels are 
reported in patients post term and in patients in premature labour. 
Whether such low levels contribute to the onset of parturition 
deserves much more study and is the subject of further project grant 
requests by the candidate in 1985. For the first time in the human 
statistically significantly higher levels of relaxin have been found in 
early labour compared to late pregnancy. Whilst this data needs to be 
confirmed by sequential studies, the suggestion is that the human is 
like all other animals so far investigated and has a peak of relaxin 
release and/or production near the onset of parturition. Such a peak 
may not contradict its postulated role in inhibiting myometrial 
contractility earlier in pregnancy if, as suggested in detail in the 
hypothesis below, the myometrium is responsive to oxytocin only at 
term and relaxin does not effectively inhibit oxytocin driven myomet­
rial contractions. The rise in relaxin at parturition, however, 
allows the connective tissue changes in the cervix known as cervical 
ripening and this facilitates labour by decreasing the force needed by 
the oxytocin driven myometrial contractions to expel the fetus.
The radioimmunoassay data also suggests that the source of 
relaxin is maternal and that little or no relaxin crosses into the 
fetal circulation. Unusually high levels of maternal serum relaxin 
may be associated with excessive pelvic joint pain and laxity. This 
is. the first report of an association between relaxin and such pelvic 
effects and warrants further investigation. In this study such high 
levels of relaxin in these patients were not associated with post­
maturity supporting the hypothesis that myometrial contractility is 
not inhibited by high or low relaxin concentrations at term when the
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myometrium comes under the influence of oxytocin.
The human studies in this thesis could not substantiate any role 
for relaxin in implantation. However, as discussed in Chapter 9, 
there were many possibilities why porcine relaxin by this route, dose 
and timing might have been inappropriate. Certainly in the rat exo­
genous relaxin influences implantation as described in Chapter 8 and 
relaxin levels are high in the human in early pregnancy. These early 
high levels in parallel and in conjunction with serum progesterone 
may on the other hand reflect its possible role in maintaining uterine 
quiescence by inhibiting myometrial contractility. However, this 
hypothesis awaits testing with human relaxin.
The most convincing data for a role for relaxin in the human was 
seen in the studies of cervical ripening and the initiation of part­
urition. Here both endogenous (Chapter 5) and exogenous (Chapter 15) 
relaxin levels rose in association with cervical ripening. In 
particular, exogenous porcine relaxin had a significant cervical 
ripening effect in most patients near term and initiated labour in up 
to one-third of these cases (Chapters 11 and 13). The similarity of 
the clinical outcome (Appendices 1, 2 and 3) and the similarity in the 
morphologically induced changes (Chapter 14) of prostaglandin F2a and 
purified porcine relaxin suggests that there is a close link between 
these hormones in their mechanism of action and it seems likely that 
they may act either in sequence or separately to activate the same 
collagenolytic system to produce the same effect in cervical 
connective tissue. In an attempt to integrate what is known of 
relaxin's action in the human and in other animals with its postulated 
roles of (1) maintaining uterine quiescence to term, arid (2) facilitat­
ing parturition, the following hypothesis is presented.
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17.2 HYPOTHESIS
Relaxin1s role in the prevention and initiation of labour (Figure 
34)
At the time of writing (1984) the precise mechanisms involv­
ed in the initiation of human parturition remain an enigma. How­
ever, in animals. such as the sheep which have the placental 
enzyme 17a - hydroxylase, progesterone under the influence of
fetal cortisol can be metabolised to 17a, 20a-dihydroxy proges­
terone. The increase in availability of 17a- hydroxylated C2 1  
steroids in the placenta contributes to the sharp rise in uncon­
jugated oestrogen concentrations in maternal blood prior to part­
urition. This increase in the oestrogen/progesterone ratio near 
term is thought to induce oestrogen receptors in the uterus and 
so increase cellular oestrogen in that organ. Although such a 
change in the serum oestrogen/progesterone ratio does not appear 
to occur in the human a change in the oestrogen/progesterone 
receptor status has not been excluded and a rise in cellular 
oestrogen in the uterine tissues near term is still possible.
However, in the huma^ Liggins (1984) postulates that an 
alteration in the balance between prostaglandin synthesis 
stimulators and inhibitors, probably initiated by the fetus, 
promotes an increase in the synthesis of prostaglandins from 
stores of arachidonic acid in the decidua and fetal membranes. 
Whether prostaglandins stimulate relaxin production or vice versa 
is not known but the work of Liggins (1984) and the data describ­
ed in this thesis suggest they interact to stimulate the same 
collagenolytic mechanism in the cervix producing the connective 
tissue changes of cervical ripening.
Relaxin receptors appear to be induced in target tissues by
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increasing levels of oestrogen. Thus, cervical stromal and muscle 
cells may become responsive to relaxin especially when the levels of 
both oestrogen and relaxin increase prior to parturition. Oestrogen 
also induces oxytocin receptors and in the human the myometrium 
becomes increasingly responsive to oxytocin towards term (Challis and 
Mitchell 1981).
The centre of this hypothesis (see Fig. 34) depends on whether 
human myometrium will respond to human relaxin as rat myometrium 
responds to rat or porcine relaxin, i.e. in the rat relaxin can inhibit 
spontaneous and prostaglandin driven myometrial contractility but not 
oxytocin driven myometrial contractility (Porter 1979a). Thus, at 
term, when either oestrogen or prostaglandins (depending on the animal, 
Fig. 34) initiate a rise in oxytocin receptors and the.myometrium 
becomes responsive to oxytocin, relaxin cannot now inhibit uterine 
contractility and in conjunction with the cervical ripening effect of 
high levels of prostaglandin and relaxin, labour begins.
The candidate is aware, as partly discussed in Chapter 10, of 
other complex interactions of calcium, calmodulin and cyclic AMP 
together with the possible influence of myometrial cell gap junctions. 
However, the simplified hypothesis above is compatible with the known 
changes in these other factors (Challis & Mitchell 1981). Neverthe­
less, much has still to be learnt about the initiation of both pre­
mature and term labour in the human and I present this hypothesis to 
allow its testing in future projects (s$e below).
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FIGURE 34 Relaxin's possible role in the prevention and initiation of 
labour. A hypothetical scheme of the relationship of relaxin to other 
hormones involved in parturition.
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17.3 FUTURE RELAXIN RESEARCH
The production and availability of genetically engineered bio­
active human relaxin for in vitro, animal and clinical trials will 
greatly help our understanding of the specific roles that relaxin 
plays in human reproduction. It is clear from many of the studies in 
this thesis that species specific relaxin will be necessary to confirm 
the roles suggested by the animal and in vitro studies using porcine
s
relaxin. As detailed in Chapter 1 two relaxin genes have been 
identified in the human and the amino acid sequence of both of these 
has been deduced by the biochemists of the Florey Institute, Melbourne. 
Orily one of these relaxins is thought to be biologically active (Dr.
G. Tregear, personal communication). Small amounts of the potentially 
bioactive human relaxin have been synthesised and attempts are current­
ly underway in the U.S.A. to synthesise large quantities of human 
relaxin using recombinant DNA technology.
With respect to the areas covered in this thesis human relaxin 
will be most valuable* Firstly if antibodies to human relaxin can be 
successfully raised a homologous human relaxin radioimmunoassay can be 
set up. Potentially this would be more sensitive than the porcine 
assay for human samples and hopefully specific for human relaxin 
allowing better correlation of relaxin levels in normal and abnormal 
pregnancy. Perhaps even more important than the estimation of peri­
pheral serum levels will be the estimation of tissue levels of human 
relaxin, as relaxin may act as a local hormone. Access to human 
relaxin will also facilitate the development of a human relaxin recep­
tor assay. More knowledge of relaxin receptors should greatly enhance 
our understanding of the mechanisms controlling relaxin.
The role of human relaxin in sperm motility, ovum penetration and 
implantation can also be helped by the use of species specific relaxin
2lP,
and there may be merit in repeating the clinical trial described in 
Chapter 9 with human relaxin once safety and quality control studies 
on the genetically engineered relaxin have been conducted.
The hypothesis described earlier in this chapter concerning human 
relaxin1s role in maintaining uterine quiescence until late pregnancy 
cannot be tested until human relaxin is available. Thereafter the in 
vitro experiments described in Chapter 10 would be valuable in quickly 
establishing whether human relaxin plays such a role. Lastly human 
relaxin should be used in vitro and in vivo studies to determine its 
effect on human cervical ripening and parturition. Experience gained 
in the porcine relaxin studies described in this thesis with regards 
routes of administration, carriers, doses, protocols, etc., will 
facilitate the studies with human relaxin. Once again safety studies 
and long term follow up of patients treated with human relaxin will be 
necessary.
The true role of human relaxin in human reproduction and any 
potential therapeutic application of it will have to be established by 
carefully conducted clinical trials. Clinical trials with human 
relaxin will have to be conducted slowly and critically. Small numbers 
of patients in such trials may give misleading results and generally 
only one of many clinical variables can be tested at one time. So it 
is important that commercial investors in this 'new* hormone do not 
demand quick results or make dubious claims before the hormone has 
been comprehensively investigated. For if relaxin is marketed as it 
was in the 1950's before its role was understood and before it had 
been fully investigated, then relaxin could undeservedly fall again 
into clinical disrepute. Nevertheless, relaxin appears to be involved 
in many important areas of human reproduction as described in this 
thesis and the! long term therapeutic potential in understanding its 
potential roles in the human is very exciting.
A P P E N D I X  1
CERVICAL RIPENING AND INDUCTION OF LABOUR 
WITH INTRAVAGINAL PROSTAGLANDIN F2<*
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Al. 1 SUMMARY
A randomised double blind trial was done to determine the effect 
on cervical ripening of 50 mg intravaginal prostaglandin F2 C1 (PGF201) 
in a methyl cellulose gel given on the evening before surgical induct­
ion of labour. Patients were given either placebo or PGF201 and in 
both groups cervical stretching and sweeping of the fetal membranes 
was attempted. Of the 40 control patients, 3 had gone into labour and 
the mean improvement in the cervical score was 1.6 before surgical 
induction the next morning. However, 20 of the 40 patients receiving 
PGF2 CI went into labour before the proposed induction and the mean 
change in cervical score (5.1) was significantly greater than that in 
the placebo group. Of the 40 patients pretreated with PGF2 C1, 37 had 
improved cervical scores and significantly fewer required agumentation 
in labour with intravenous oxytocin than in the control group. No 
side effects were experienced and the patients found the treatment 
acceptable.
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Al.2 INTRODUCTION
Surgical induction of labour in the presence of a long, closed, 
firm and posteriorly facing cervix when the presenting fetal part is 
high in the pelvis is usually associated with a high complication rate 
and a high intervention rate during labour, despite subsequent augmen­
tation with intravenous oxytocin or prostaglandins. Fewer complicat­
ions result when the cervix is favourable at the time of induction 
(Calder & Embrey 1973). Attempts to penetrate and locally pretreat 
the unfavourable cervix with laminaria tents (Cross & Pitkin 1978), 
oestradiol (Gordon & Calder 1977) and extraamniotic prostaglandin E2  
(Calder, Embrey & Tait 1977) before the induction of labour have met 
with some success. More impressive results were obtained when 
prostaglandin E2 was given in a vaginal gel (McKenzie & Embrey 1977).
Induction of labour may lead to further intervention. Thus, 
efforts to decrease the trauma of induction and avoid subsequent 
intervention seems appropriate. The place of prostaglandin F2a 
(PGF2a) in the ripening of the cervix before induction of labour is 
not known. We have compared the effect of the application of exogenous 
PGF2a with that of cervical stretching and stripping of the fetal 
membranes which itself causes a rapid rise in endogenous PGF2Ct (Mitchell, 
Flint & Bibby 1977) and has often been claimed to be a method of improv­
ing cervical favourability or in some instances of precipitating labour.
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A1.3 PATIENTS AND METHODS
A randomised double blind trial involving 80 patients was set up 
with the permission of The Queen Victoria Hopsital's research and 
ethics committee. Criteria for inclusion in the trial were: singleton 
pregnancy, cephalic presentation, an unscarred uterus, maternal height 
over 150 cm and informed consent from the patient. The patients were 
randomly allocated to two groups which received either 50 mg PGF2a 
C’Prostin F2a') or a placebo (sterile water), the allocated constituent 
being mixed in 10 ml of a sterile solution of 8% methyl cellulose gel. 
In both groups stretching of the cervix and sweeping of the fetal 
membranes was attempted.
Random allocation was achieved by having a random list of two 
numbers. The numbers were sealed in envelopes by a third party and 
one of us (R.G.) confirmed the patient's eligibility for the trial 
before opening the envelopes in the randomised order to discover the 
treatment allocation. Close matching of the two groups was apparent 
by the end of the trial (Table Al).
A.H.M., unaware of the treatment allocation, assessed the cervical 
score (modified Bishop score (Calder et al 1977)) at 5 p.m. on the 
evening before proposed induction of labour. The viscous gel was then 
placed in the posterior vaginal fornix by means of a soft latex 
catheter and a syringe. The patient was asked to remain in bed for 1 h. 
Next morning at 8 a.m. the cervical score was reassessed by A.H.M. 
Thereafter, the labour was managed by obstetricians who were unaware 
of the constituents of the vaginal gel.
Statistical analysis of the results was carried out by means of 
the following tests, the Fisher exact test, the Mann-Whitney test and 
the X2 test.
VARIABLE PLACEBO GROUP 
(n = 40)
PROSTAGLANDIN GROUP 
(n = 40)
Mean maternal age (yr) 27.0 27.2
Mean gestation (wk) 40.1 40.1
Mean parity 1.0 1.1
Mean birth weight (kg) 3.5 3.6
Mean cervical score at priming 5.2 4.7
TABLE Al Patient matching in treatment and control groups
A1.4 RESULTS
Cervical stretch and sweep alone (i.e. the placebo gel group) 
resulted in the onset of labour in 3 out of 40 patients in that group 
(Table A2), whereas 20 of the 40 patients receiving prostaglandin F2 C1 
with a cervical stretch and sweep started labour without further 
stimulation (p<0.00002, Fisher exact test). The average improvement 
in cervical score of the placebo gel group was 1.6, and in the 
prostaglandin group it was 5.1 (p<0.00005, Mann-Whitney test). The 
improvement in the cervical score was still significant even when the 
patients who had already delivered by 8 a.m. on the day of the propos­
ed induction were excluded (p<0.0001, Mann-Whitney test). The cervical 
score remained unchanged in 20 of the control group whereas only 3 of 
the prostaglandin treated group showed no evidence of improvement (p< 
0.00005, Mann-Whitney test).
Significantly fewer women in the group pretreated with prosta­
glandin needed intravenous oxytocin to augment their labour (p<0.01 
test). There were 26 normal deliveries in the group given the placebo. 
This result did not reach statistical significance. There was no 
significant difference in the average length of labours but there were 
more short labours in the prostaglandin treated group (Table A3). Three 
patients (all in the prostaglandin group) had labour® lasting more 
than 12 h. The amount of analgesia required in labour, the incidence 
of fetal .distress, the Apgar scores and the incidence of neonatal 
jaundice were not significantly different in the two groups. No side 
effects were noted in the group receiving vaginal PGF2 C1.
There was an improvement in the cervical score in the PGF2 CX group 
whatever the gestation (Table A4), parity (Table A5), or initial cervical 
score (Table A6). An analysis of the patients who actually went into 
labour after the PGF201 pretreatment showed that onset of labour was not
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related to the patient's parity, gestation, or the favourability of the 
cervix at the time of priming. 5.1 (range 1-9) was the mean priming 
score of thoseowho went into labour in the prostaglandin treated group 
without further stimulation and in those who did not go into labour 
after PGF201 the mean priming score was 4.8 (range 1-9).
An analysis of all patients not in labour at the proposed time of 
surgical induction showed that those with a cervical score of 5 or less 
had a mean length of labour of 8 h and 40% had a normal delivery.
Those with a cervical score of 6 or more had a mean length of labour 
of 6.4 h and spontaneous vaginal delivery in 63% of cases.
In both the treatment and the placebo gel groups some patients 
were aware of mild tightenings for up to 3 h after cervical stretching 
and application of the vaginal gel. Those experiencing contractions 
for more than 3 h after pretreatment generally proved to be in labour. 
At postnatal interview all the patients found this method of treatment 
acceptable.
OUTCOME PLACEBO GROUP
(n = 40)
PROSTAGLANDIN GROUP 
(n = 40)
Delivered at 15 h 3 13
Established in labour 0 7
Average change in cervical
score 1.6 5.1
Average change in those
undelivered 1.1 3.2
No. with no change 20 3
No. needing augmentation 26 10
TABLE A2 Outcome of cervical pretreatment on the morning of 
proposed surgical induction
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OUTCOME PLACEBO GROUP 
(n = 40)
PROSTAGLANDIN GROUP 
(n = 40)
Caesarean section 3 2
Instrumental delivery 16 12
JL
Mean length labour (hr) 6.5 6.75
Labour under 6 hr 12 19
Pethidine given (mean dose) 21 (116 mg) 25 (112 mg)
Epidural block (mean dose) 15 (20 ml) 12 (30 ml)
Apgar at 1 min. 7.9 7.8
Apgar at 5 min. 9.0 9.0
TABLE A3 Outcome of labour in control and prostaglandin treated 
groups
*
Excluding Caesarean, section
GESTATION (wk) MEAN IMPROVEMENT IN CERVICAL SCORE
PLACEBO PROSTAGLANDIN
35 - 38+ 0.4 (5) 7.0 (4)
39 - 41 1.3 (26) 4.9 (28)
41+ 1.7 (9) 4.9 (8)
TABLE A4 Gestation and mean change in cervical score 15 h after pre­
treatment.
No. of patients in parentheses
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PARITY MEAN IMPROVEMENT IN CERVICAL SCORE
PLACEBO PROSTAGLANDIN
0 1.1 (17) 5.2 (17)
1 1.4 (14) 5.9 (10)
2+ 2.3 (9) 4.2 (13)
TABLE A5 Parity and mean change in cervical score 15 h after pre­
treatment .
No. of patients in parentheses
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INITIAL SCORE MEAN IMPROVEMENT IN CERVICAL SCORE
PLACEBO PROSTAGLANDIN
0 - 3 2.1 (11) 6.7 (12)
■p. I 1.0 (18) 5.0 (18)
7 - 9 1.9 (11) 3.5 (10)
TABLE A6 Initial cervical score and mean change in cervical score
15 h after pretreatment.
No. of patients in parentheses
A1.5 DISCUSSION
Cervical stretching and sweeping of the membranes led to only a 
small improvement in the mean cervical score and only 3 out of 40 
patients went into labour. Spontaneous labour might be expected in 
this proportion of women since most patients had reached their expect­
ed date of delivery. However, vaginal examination and stripping of 
the fetal membranes rapidly doubles the plasma concentrations of 
prostaglandin F2a (Mitchell et al 1977). This manipulation may have 
been associated with the small improvement in the mean cervical score 
of the placebo group and may have potentiated the effect of the exo­
genous PGF2a in the treatment group.
The trial was designed to compare the combined effect of exogen­
ous and endogenous PGF2a with the effect of stimulating a rise in 
endogenous prostaglandin concentrations alone. The addition of exo­
genous PGF2a (50 mg) is apparently much more effective than cervical 
stretching and sweeping alone. The effect of vaginal prostaglandin
gel without stripping of the fetal membranes is being investigated.
In 92% of the prostaglandin treated patients the cervical score
improved and in 50% labour was initiated. These results are better 
than those reported when laminaria tents (Cross & Pitkin 1978), extra- 
amniotic oestradiol (Gordon & Calder 1977) and extraamniotic prosta­
glandin E2 (Calder et al 1977) were used for cervical ripening. How­
ever, a success rate similar to the one reported here was obtained 
with intravaginal prostaglandin E2 (McKenzie & Embrey 1977).
The results of this study are in accord with the findings of sev­
eral other groups (Calder & Embrey 1973; Turnbull & Anderson 1968) who 
demonstrated that patients with unfavourable cervical scores at 
surgical induction have longer labours with a lower spontaneous 
delivery rate than patients with more favourable cervical scores at
induction. However, in those patients given PGF2 0C there was no correl­
ation between cervical favourability, gestation or parity and the 
initiation of labour that evening. Thus, we cannot yet define a group 
in which vaginal PGF2a without other intervention will result in 
labour.
There were more spontenaeous deliveries and more labours of short 
duration in the prostaglandin treated group than in the controls. 
Although these differences were not statistically significant, 
significantly fewer women in the PG group required intravenous oxy­
tocin. Ambulation during labour is claimed to reduce the amount of 
analgesia required during labour, fetal distress and the operative 
delivery rate (Flynn, Kelly & Hollins 1978). During the present trial 
ambulation was not encouraged, to remove any effect that this might 
create. However, augmentation of labour with vaginal prostaglandin in 
a high-viscosity gel does not preclude ambulation in labour after an 
initial brief period of recumbancy to allow absorption. A combination 
of vaginal prostaglandin, radiotelemetry and ambulation allows induced, 
monitored but apparently "natural" labour to occur with a lower 
incidence of subsequent intervention than previously experienced when 
intravenous oxytocin was used to induce labour. Vaginal prostaglan­
dins seem to make the induction of labour more simple, especially in 
the presence of an unfavourable cervix, but careful selection of 
patients is still necessary.
A P P E N D I X 2
A DOUBLE BLIND DOSE TRIAL OF INTRAVAGINAL PROSTAGLANDIN 
F2a FOR CERVICAL RIPENING AND THE INDUCTION OF LABOUR
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A2.1 SUMMARY
A randomised double blind trial involving 90 patients was set up 
to compare the efficacy of 25 mg PGF2 0t, 50 mg PGF2 CX and a placebo on 
cervical ripening when given in a vaginal tylose gel on the evening 
before surgical induction of labour. Preliminary stretching of the 
cervix and sweeping of the fetal membranes was not undertaken. In the 
30 control patients, labour was not initiated and the mean improvement 
in the cervical score before surgical induction the next morning was 
0.86. In the group of 30 patients receiving 25 mg PGF2 01, labour 
commenced during the night in 9 patients and the mean improvement in 
the cervical score was 3.76 (p<0.0005); the corresponding figures for 
the 30 patients receiving 50 mg of PGF2 <* were 10 patients coming into 
labour and cervical score improvement of 4.63 (p<0.0005). The differ­
ence in the mean improvement of the cervical score between the two 
prostaglandin groups was not significant. Significantly fewer prosta­
glandin treated patients needed augmentation during labour with intra­
venous oxytocin (p<0.025) and there was a significant increase in the 
spontaneous delivery rate in the combined prostaglandin treated group 
(p<0.025). There was no statistical difference in the outcome of 
labour between the two prostaglandin groups. It was not possible to 
predict the patients whose cervices would not respond to PGF2 0C pre­
treatment (15%) or those in whom labour would be initiated (30%). No 
side effects were experienced.
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A2.2 INTRODUCTION
Intravaginal prostaglandin E2 (PGE2 ) and prostaglandin (F2 C1) have 
been used successfully to ripen the unfavourable cervix with a 
subsequent reduction in intrapartum complications (MacKenzie & Embrey 
1977; MacLennan & Green 1979). Pretreatment with intravaginal prost­
aglandins is beneficial even in the presence of a favourable cervix 
(Mellows et al 1977; MacKenzie & Embrey 1978).
In Australia only PGF201 is available and there is little document­
ation of the efficacy of different doses of this prostaglandin when 
given in vaginal gel before surgical induction of labour. In a 
previous trial (MacLennan & Green 1979) we reported that 50 mg intra­
vaginal PGF201 initiated labour in 50 percent of the patients studied 
and that 92 percent of the patients showed signs of cervical ripening 
following the pretreatment. In that trial, however, stretching of the 
cervix and sweeping of the fetal membranes was attempted in each 
patient and it was not determined whether this potentiated the effect 
of the exogenous prostaglandin.
Thus, a randomised dose trial has been set up to compare the 
effects of 50 mg PGF2 01, 25 mg PGF201 and a placebo gel given intra- 
vaginally, and to study their effectiveness in the absence of any 
additional manipulation of the cervix.
A2.3 PATIENTS AND METHODS
A randomised double blind trial involving 90 patients was set up 
with the permission of The Queen Victoria Hospital's research and 
ethics committee. Criteria for inclusion in the trial were singleton 
pregnancy, cephalic presentation, an unscarred uterus, maternal height 
over 150 cm, informed consent from the patient and an absence of any 
history of asthma (as theoretically, PGF2a given vaginally may 
exacerbate this condition). The patients were randomly allocated to 
3 groups receiving either 25 mg PGF2a (Prostin F2a, Upjohn), 50 mg 
PGF2ot or a  placebo (10 ml sterile water), the allocated constituent 
being made up to 10 ml with sterile water and mixed with 700 mg tylose 
granules (Hoechst) to make a viscous gel. Random allocation was 
achieved by having a random list of 3 numbers. The numbers were 
sealed in enveloped by a third party and one of us (R.G.) confirmed 
the patient's eligibility for the trial before opening the envelopes 
in the randomised order to discover the treatment allocation. Close 
matching of the 3 groups in all respects was apparent by the end of 
the trial (Table A7).
A.H.M., unaware of the treatment allocation, assessed the cervic­
al score (modified Bishop score (Calder et al 1977)) at 5 p.m. on the 
evening before the proposed induction of labour. The viscous gel was 
then placed in the posterior vaginal fornix by means of a soft latex 
catheter and syringe. The patient was asked to remain in bed for 1 h. 
Next morning at 8 a.m. the cervical score was reassessed by A.H.M. 
Thereafter, the labour was managed by obstetricians unaware of the 
composition of the vaginal gel.
Statistical analysis of the results was carried out using 
Student's t test, the Fisher exact test and the X2 test.
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VARIABLE PLACEBO 25 mg PGF2 OC 50 mg PGF201
Maternal age (yr) 26.1 26.0 26.2
Gestation (wk) 40.0 40.2 40.1
Parity 0.6 0.8 0.8
Birth weight (kg) 3.4 3.4 3.5
Initial cervical score 4.3 4.2 4.1
TABLE A7 Patient matching in control and pretreatment groups
Mean figures
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A2.4 RESULTS
The effect of the 3 gels 15 h after vaginal application is shown 
in Table A8. Labour did not supervene in any of the patients pretreat­
ed with placebo, whereas 9 patients given 25 mg PGF 2 a (p<0.001) and 10 
patients given 50 mg PGF2 a (p<0.0005) laboured. The mean improvement 
in the cervical score was 0.86 for the placebo group compared with 
3.76 foi the 25 mg PGF201 group (p<0.0005) and 4.63 for the group receiv­
ing 50 mg PGF2 <* (p<0.0005). There was no statistical difference 
between the 2 prostaglandin groups as regards the initiation of labour 
or the improvement in the cervical score.
Significantly fewer patients needed augmentation with intravenous 
oxytocin after pretreatment with 50 mg PGF2 a (p<0.0025) and with 25 mg 
PGF2 <* (p<0.025) than the placebo group (Table A9). There was an 
increased number of normal deliveries in both of the prostaglandin 
treated groups. The increased incidence of normal deliveries for the 
prostaglandin groups taken together was statistically significant 
(p<0.025). There was no statistical difference between any of the 
groups as regards the length of labour, analgesic requirements and 
Apgar scores.
A similar degree of cervical ripening was found for both prosta­
glandin doses when the results were grouped according to the initial 
cervical score (Table A10, parity (Table All) and gestation (Table A12). 
The onset of labour was not related to cervical favourability, parity 
or gestation. On the other hand, there was no correlation of these 
factors with the patients who showed no signs of cervical ripening 
after prostaglandin pretreatment. However, it was our clinical 
impression that where the presenting part was high, cervical ripen­
ing following prostaglandin application was poor. There was a high 
incidence of surgical delivery and malposition of the fetal head in
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labour among patients whose cervices did not respond to pretreatment.
No maternal or fetal side effects were recorded in either of the 
groups treated with PGF201.. There was one neonatal death due to 
multiple major congenital anomalies in the 50 mg PGF201 group. The 
indications for the caesarean sections in the prostaglandin groups 
were fetal distress (2) and cephalopelvic disproportion, and in the 
placebo group the indications were cervical dystocia, failure to 
progress and fetal distress.
OUTCOME PLACEBO 25 mg PGF 2a 50 mg PGF 2a
(n = ;30) (n = 30) (n = 30)
Delivered withiri 15 h 0 6 5
Established in labour 0 3 5
Mean change in cervical 
score 0.86 3.76 4.63
Mean change where labour 
did not supervene 0.86 1.93 2.65
No. with no change 18 6 3
TABLE A8 Outcome of cervical pretreatment
OUTCOME PLACEBO 25 nig PGF2a 50 mg PGF2a
(n = 30) (n = 30) (n = 30)
No. augmented with oxytocin 
Mean length of labour* (hr) 
(+ S.D.)
Caesarean section 
Instrumental delivery 
Pethidine given (mean dose) 
Epidural block (mean dose) 
No analgesic in labour 
Apgar at 1 min.
Apgar at 5 min.
23 15 12
8.2 (+ 3.2) 7.8 (+ 3.8) 7.3 (+ 3.7)
3 1 2
15 9 10
13 (115 mg) 17 (96 mg) 18 (97 mg)
15 (31 ml) 13 (20 ml) 8 (28 ml)
4 6 8
8.1 7.8 8.1
9.0 9.1 9.1
TABLE A9 Outcome of labour in control and treatment groups
*Excluding Caesarean section
INITIAL SCORE MEAN IMPROVEMENT IN CERVICAL SCORE
PLACEBO 25 mg PGF2a 50 mg PGF2ct
0 - 3  0.9 (14) 3.7 (15) 5.6 (14)
4 - 6  0.9 (12) 4.5 (11) 3.8 (11)
7 - 9  0.5 (4) 2.6 (4) 3.4 (5)
TABLE A10 Initial and post-treatment cervical scores
No; of patients in parentheses
PARITY MEAN IMPROVEMENT IN CERVICAL SCORE
PLACEBO 25 mg PGF2a 50 mg PGF2a
0 0.9 (16) 3.2 (13) 4.4 (15)
1 0.7 (11) 4.5 (12) 5.0 (9)
2+ 1.3 (3) 3.4 (5) 4.9 (6)
TABLE All Parity and mean change in cervical score 
No. of patients in parentheses
GESTATION (wk) MEAN IMPROVEMENT IN CERVICAL SCORE
38 - 
40 - 
41+
PLACEBO 25 mg PGF2a 50 mg PGF2a
39+ 0.8 (13) 6.1 (5) 3.0 (9)
41 1.0 (12) 3.2 (17) 6.1 (14)
0.6 (5) 3.1 (7) 4.1 (7)
TABLE A12 Gestation and mean change in cervical score 
No. of patients in parentheses
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A2.5 DISCUSSION
This trial confirms our preliminary report (MacLennan & Green 
1979) of the efficacy of intravaginal PGF2ct as a  cervical ripening 
agent. In the first trial, stretching and sweeping of the cervix, 
followed by 50 mg PGF2oi given intravaginally, initiated labour in 
half the patients and the mean improvement in the cervical score was 
5.1. In comparison, in this trial where no cervical manipulation was 
attempted, one third of the prostaglandin pretreated patients labour­
ed and the mean improvement in the cervical score was 4.6. Although 
the difference is not statistically significant (0.5 <p<0.1) for the 
numbers involved in these trials, cervical manipulation may be 
responsible for the apparent small enhanced effect of the exogenous 
PGF2a by further increasing endogenous prostaglandin. In the first 
trial, the placebo group also underwent cervical stretching and sweep­
ing of the membranes and 3 of the 40 patients laboured with a mean 
cervical improvement of 1.6 compared to none of the 30 patients given 
placebo in the present trial and a mean cervical improvement of 0.9. 
Thus, such cervical manipulation at the time of pretreatment may 
potentiate to a small degree the effect of intravaginal PGF2a.
As regards the comparative effectiveness of the 25 mg and 50 mg 
PGF2a, there appears to be little difference in their effect on 
cervical ripening, the initiation of labour and reducing subsequent 
intervention in labour. The 25 mg dose appeared to be more effective 
than described by MacKenzie & Embrey (1979) in their trial of 16 
patients, where 2 patients laboured after treatment and the mean 
improvement in the cervical score was 2.2.
Despite the general effectiveness of intravaginal PGF2 Gt, there 
was still a small group (15 percent) in whom there was no apparent 
effect. This group had a higher incidence of labour complications and
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required surgical intervention more often. It is possible that failure 
of the cervix to ripen after prostaglandin pretreatment may indicate 
the presence of a malposition or disproportion.
As noted in our first trial (MacLennan & Green 1979), it was not 
possible to predict those patients who would labour after vaginal 
application of the prostaglandin. A subsequent trial (MacLennan &
Green 1980) suggests that where the cervix is favourable for surgical 
induction of labour, augmentation with vaginal prostaglandin after 
rupture of the membranes, rather than before, is more effective than 
conventional augmentation with intravenous oxytocin. If predictabil­
ity of delivery and timing of labour is required, then in this favour­
able group, vaginal PGF2a after surgical induction may be more 
appropriate than pretreatment the evening before surgical induction. 
However, where the cervix is not favourable and induction of labour is 
necessary, PGF2a pretreatment appears to be beneficial in most 
instances.
A P P E N D I X  3
THE EFFECT OF INTRAVAGINAL PROSTAGLANDIN F2a ON LABOUR 
AFTER SPONTANEOUS AND ARTIFICIAL RUPTURE OF THE MEMBRANES
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A3.1 SUMMARY
The effect on labour of 50 mg intravaginal PGF201 or a standard 
intravenous oxytocin regimen was compared in 2 randomised trials 
involving a total of 83 patients, 23 of whom had experienced spontan­
eous rupture of the'.membranes (S.R.O.M.) and 60 of whom had artificial 
rupture of the membranes (A.R.M.) to induce labour. In each trial, 
labour had not been initiated by membrane rupture alone. In both 
trials only 20 percent of the patients receiving PGF2 CI required 
further augmentation of labour with intravenous oxytocin. The mean 
length of labour in patients receiving PGF2 C1 was 2.5 h shorter in the 
A.R.M. trial and 3.0 h shorter in the S.R.O.M. trial than the mean 
length of labour in patients receiving intravenous oxytocin (p<0.01). 
In the A.R.M. trial, the PGF2 OC treated group had significantly less 
analgesic requirements (p<0.001). Although more normal deliveries 
occurred in the patients treated with PGF201 than oxytocin in both 
trials, the numbers did not reach statistical significance.
No side effects occurred in the PGF201 treated patients or their 
babies and this method was much preferred by patients and nursing 
staff alike.
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A3.2 INTRODUCTION
Intravaginal prostaglandin E2 (PGE2 ) and prostaglandin F201 (PGF 
2 a) have been used successfully as cervical ripening agents (MacKenzie 
& Embrey 1977; MacLennan & Green 1979). However, there are no 
published trials on the use of intravaginal prostaglandins to induce 
labour following either spontaneous rupture of the membranes (S.R.O.M.) 
or artificial rupture of the membranes (A.R.M.). Randomised trials 
were threfore designed to compare the efficiency of 50 mg intravaginal 
PGF2 CX with intravenous oxytocin in patients where rupture of the 
membranes alone had not initiated labour. Patients whose membranes 
rupture spontaneously before the onset of labour are more prone to 
intrapartum complications, e.g. fetal malposition, prolonged labour 
and infection. Thus, as the outcome of labour in these patients might 
be different from those having a surgical induction of labour, 
separate randomisation of the treatments has been carried out for 
spontaneous and artificial rupture of the membranes.
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A3.3 PATIENTS AND METHODS
Eighty-three patients not in labour, 23 after S.R.O.M. and 60 
following A.R.M. were randomly allocated to groups receiving either 
intravenous oxytocin or 50 mg intravaginal PGF2a mixed with 700 mg 
sterile tylose granules (Hoechst) to make a viscous gel. Random 
allocation was achieved by having 2 random lists of 2 numbers. A 
separate list was used for each mode of onset of membrane rupture.
The numbers were sealed in envelopes by a third party and the 
patient's eligibility for the trial was confirmed before the envelopes 
were opened in the randomised order to discover the treatment 
allocation. The cervical score (modified Bishop score (Calder et al 
1977)) was assessed by the same observor (R.G.) in each patient.
Close matching in the A.R.M. group occurred by the end of the trial 
and to a lesser extent in the S.R.O.M. group (Table A13).
Criteria for inclusion in the trial were singleton, pregnancy, 
cephalic presentation, an unscarred uterus, maternal height over 150 
cm, no history of asthma, informed consent from the patient, and an 
absence of signs of labour. The timing of and necessity for stimulat­
ion of labour was left to the discretion of the obstetrician in charge 
who made this decision before the random selection of the method was 
made.
The same intravenous, oxytocin regimen was used in each patient 
allocated this treatment, the infusion commencing at 3.33 my/minute 
and increasing every 15 minutes until labour was established or to a 
maximum of 40.0 my/minute. Patients were given intravaginal PGF2a by 
means of a soft latex catheter placed in the posterior vaginal fornix. 
No attempt was made in this trial to stretch the cervix and strip the 
fetal membranes. The patients receiving PGF^a were asked to remain in 
bed for 1 h, but thereafter were allowed to ambulate if they wished,
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fetal heart monitoring being carried' out by radiotelemetry. The mean 
length of ambulation in the prostaglandin group was 1 h. If labour 
was not satisfactorily established 4 h after application of the PGF2a 
intravenous oxytocin was commenced. Statistical analysis of the 
results was carried out using Student's t test, the Fisher exact test 
and the X2 test.
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A3.4 RESULTS
The outcome of labour after intravaginal PGF201 and intravenous 
oxytocin following A.R.M. is shown in Table A14 and that following 
S.R.O.M. is shown in Table A1S In the A.R.M. group there is a stat­
istically significant improvement in the outcome of the PGF2 a-treated 
patients with respect to the length of labour and their analgesic 
requirements during labour. In the S .R.O.M. group only the length of 
labour was significantly reduced. When the A.R.M. and the S.R.O.M. 
groups are added together, the reduction in the mean length of labour 
of the PGF2 «-treated patients becomes highly significant (p<0.01) 
compared with the oxytocin group, but the increase in spontaneous 
vaginal deliveries amongst the PGF2 a-treated patients did not quite 
reach statistical significance (0.05 <p<0.1, X2 test). Nine babies in 
the oxytocin groups required phototherapy for the treatment of neo­
natal jaundice, whilst only 3 babies in the PGF2 d-treated group 
required this treatment; however, this difference was not significant.
No side effects were recorded in either treatment group and in 
particular there was no difference in the incidence of puerperal 
pyrexia. There was a marked patient preference for vaginal gel rather 
than the intravenous drip. No caesarean sections were performed on 
patients given PGF2 01, whereas this procedure was necessary in 4 
patients who were treated with intravenous oxytocin. The reasons 
given for the sections were: failure to progress (2), cephalopelvic
disproportion (1), and fetal distress (1).
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A3.5 DISCUSSION
The results of this study suggest that intravaginal PGF201 is an 
effective method of stimulation of labour. Only 8 of the 40 prosta­
glandin treated patients were deemed by the obstetrician to need 
further augmentation with intravenous oxytocin. Few of these patients 
required intravenous therapy for ketosis or dehydration and thus the 
inconvenience and discomfort of intravenous therapy during labour_was 
generally avoided. The vaginal gel was clearly the more popular method 
amongst the patients and the nursing staff involved in the trial.
In both :the A.R.M. and the S.R.O.M. groups, labour was signific­
antly shorter in those given PGF2a and yet this did not seem to be at 
the expense of a stronger and more painful labour, since in the A.R.M. 
trial, the analgesic requirements were significantly reduced. Although 
the prostaglandin-treated patients were free to ambulate during their 
labour, this aspect of their management was not mandatory and the 
average length of ambulation was only 1 h. However Flynn & Kelly 
(1978) have shown that labour is shortened in the ambulant patient, 
there is less analgesic requirement and there are more normal deliver­
ies. Thus, ambulation may have been a factor in the improved outcome 
of the prostaglandin-treated groups.
The tendency in the prostaglandin-treated groups towards an 
increase in spontaneous vaginal deliveries compared with the control 
group is similar to the findings in 2 other randomised trials we have 
reported, where intravaginal prostaglandins were given prior to A.R.M. 
(Appendices 1 and 2). All our trials were randomised in the same 
fashion and when the figures in each trial are totalled, 94 of 140 
patients (67%) given vaginal PGF2a had a normal vaginal delivery 
compared with 58 of 113 patients (51%) given intravenous oxytocin 
after membrane rupture (p<0.025).
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The apparent extra cost of PGF2 « in direct comparison to oxytocin 
is more than offset when an account is made of the associated costs in 
intravenous oxytocin, e.g. I.V. fluids, giving sets, intravenous 
cannulae, drip counters, pumps and riursing time. Further large cost 
benefits can be claimed for PGF201 therapy from the point of view of 
shorter labours, decreased analgesic requirements, and the apparent 
increase in the normal delivery rate. Larger trials will be necessary 
to show whether neonatal jaundice is significantly reduced after 
induction of labour with PGF2 CI compared with intravenous oxytocin.
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